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Prologue	  	  	  
If	  you	  can	  keep	  your	  head	  when	  all	  about	  you	  
Are	  losing	  theirs	  and	  blaming	  it	  on	  you;	  
If	  you	  can	  trust	  yourself	  when	  all	  men	  doubt	  you,	  
But	  make	  allowance	  for	  their	  doubting	  too:	  
	  
If	  you	  can	  wait	  and	  not	  be	  tired	  by	  waiting,	  
Or	  being	  lied	  about,	  don’t	  deal	  in	  lies,	  
Or	  being	  hated	  don’t	  give	  way	  to	  hating,	  
And	  yet	  don’t	  look	  too	  good,	  nor	  talk	  too	  wise;	  
	  
If	  you	  can	  dream—and	  not	  make	  dreams	  your	  master;	  
If	  you	  can	  think—and	  not	  make	  thoughts	  your	  aim,	  
If	  you	  can	  meet	  with	  Triumph	  and	  Disaster	  
And	  treat	  those	  two	  impostors	  just	  the	  same	  
	  
If	  you	  can	  bear	  to	  hear	  the	  truth	  you’ve	  spoken	  
Twisted	  by	  knaves	  to	  make	  a	  trap	  for	  fools,	  
Or	  watch	  the	  things	  you	  gave	  your	  life	  to,	  broken,	  
And	  stoop	  and	  build	  ’em	  up	  with	  worn-­‐out	  tools;	  
	  
If	  you	  can	  make	  one	  heap	  of	  all	  your	  winnings	  
And	  risk	  it	  on	  one	  turn	  of	  pitch-­‐and-­‐toss,	  
And	  lose,	  and	  start	  again	  at	  your	  beginnings	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If	  you	  can	  force	  your	  heart	  and	  nerve	  and	  sinew	  
To	  serve	  your	  turn	  long	  after	  they	  are	  gone,	  
And	  so	  hold	  on	  when	  there	  is	  nothing	  in	  you	  
Except	  the	  Will	  which	  says	  to	  them:	  ‘Hold	  on!’	  
	  
If	  you	  can	  talk	  with	  crowds	  and	  keep	  your	  virtue,	  
Or	  walk	  with	  Kings—nor	  lose	  the	  common	  touch,	  
If	  neither	  foes	  nor	  loving	  friends	  can	  hurt	  you,	  
If	  all	  men	  count	  with	  you,	  but	  none	  too	  much:	  
	  
If	  you	  can	  fill	  the	  unforgiving	  minute	  
With	  sixty	  seconds’	  worth	  of	  distance	  run,	  
Yours	  is	  the	  Earth	  and	  everything	  that’s	  in	  it,	  
And—which	  is	  more—you’ll	  be	  a	  Man,	  my	  son!	  
	  
	  
	  R.	  Kipling.	  Rewards	  and	  Fairies.	  1910.	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Abstract	  /	  Resumen	  	  
OBJETIVOS	  
	  
Hasta	  el	  momento	  actual	  no	  se	  ha	  descrito	  ninguna	  herramienta	  clínica	  para	  
la	  toma	  de	  decisiones	  preoperatoria	  en	  la	  cirugía	  valvular	  aórtica	  de	  alto	  riesgo,	  con	  
vistas	   a	  poder	  dirigir	   al	   paciente	  hacia	   el	   recambio	   valvular	   transcatéter	  o	  hacia	   la	  
cirugía	   convencional.	   Esto	   origina	   una	   disparidad	   en	   los	   criterios	   de	   selección	   de	  
pacientes	   entre	   los	   diferentes	   estudios	   publicados	   en	   la	   literatura	  médica,	   que	   se	  
basan	   fundamentalmente	   en	   consensos	   de	   expertos	   o	   recomendaciones	  
comerciales.	  
	  
	  El	   presente	  estudio	  esta	  basado	  en	   la	  hipótesis	  de	  que	  existen	   factores	  de	  
riesgo	   preoperatorios	   con	   que	   influyen	   de	   manera	   diferente	   en	   la	   mortalidad	  
perioperatoria	   en	   la	   cirugía	   valvular	   aórtica	   de	   alto	   riesgo	   en	   función	   del	   tipo	   de	  
procedimiento	   (recambio	   valvular	   aórtico	   convencional	   o	   transcatéter)	   que	   se	  
realice.	  Pretende	  identificar	  estos	  factores	  así	  como	  cuantificar	  su	  impacto	  potencial	  
en	   la	   mortalidad,	   con	   la	   finalidad	   de	   poder	   evaluar	   y	   discriminar	   mejor	   a	   futuros	  





Se	   recogen	   de	  manera	   retrospectiva	   los	   datos	   de	   una	   serie	   consecutiva	   de	  
pacientes	  que	  recibieron	  un	  recambio	  o	   implante	  valvular	  aórtico	   (asociado	  o	  no	  a	  
revascularización	   coronaria)	   en	   un	   solo	   centro	   (Consorcio	   Hospital	   General	  
Universitario,	   Valencia,	   España)	   entre	   2007	   y	   2012.	   Las	   cohortes	   recogidas	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Se	  realizó	  un	  emparejamiento	  estadístico	  por	  técnicas	  de	  regresión	  logística	  y	  
nivelación	   del	   grado	   de	   propensión	   (propensity	   score	   matching)	   considerando	   las	  
principales	   variables	   de	   riesgo	   preoperatorio	   y	   comorbilidad	   para	   identificar	   67	  
controles	   adecuados	   dentro	   del	   grupo	   de	   recambio	   valvular	   convencional	   frente	   a	  
los	  53	  casos	  del	  grupo	  transcatéter.	  Se	  realizó	  un	  análisis	  estadístico	  entre	  los	  casos	  y	  
los	   controles	   emparejados	   para	   variables	   descriptivas,	   mortalidad	   y	   morbilidad	  
mayor	   perioperatoria,	   duración	   de	   la	   estancia	   hospitalaria	   así	   como	   un	   análisis	  
univariante	   y	  multivariante	   para	  mortalidad	   perioperatoria	   y	   el	   evento	   compuesto	  
de	   mortalidad	   perioperatoria	   o	   complicaciones	   mayores	   neuro	   o	   cardiovasculares	  
(MACCE)	  y	  un	  estudio	  de	  supervivencia	  a	  largo	  plazo.	  	  
	  
Los	  análisis	  principales	   se	  basaron	  en	  el	  diseño	  de	  un	   índice	   	  estadístico	  de	  
clasificación	   y	   discriminación	   hacia	   la	   técnica	   transcatéter	   o	   la	   convencional	   en	  
pacientes	   de	   alto	   riesgo,	   basándose	   en	   la	  mortalidad	   perioperatoria	   observada	   en	  
casos	   y	   controles	   emparejados,	   y	   en	   las	   variables	   identificadas	   como	   predictores	  
independientes	  de	  mortalidad	  en	  el	  análisis	  multivariante	  de	  regresión	  logística.	  Del	  
mismo	   modo	   se	   realizó	   un	   análisis	   comparativo	   de	   resultados	   quirúrgicos	  
(mortalidad	  y	  morbilidad	  mayor)	  entre	  ambos	  grupos.	  Como	  análisis	  secundarios	  se	  
consideraron	  los	  análisis	  de	  subgrupos	  entre	  los	  abordajes	  transapical	  y	  transfemoral	  
dentro	   del	   grupo	   de	   implante	   transcatéter;	   y	   entre	   los	   grupos	   de	   bajo	   riesgo	  
quirúrgico	  frente	  a	  los	  de	  alto	  riesgo	  quirúrgico	  en	  la	  serie	  global.	  También	  se	  realizó	  





	   Arteropatía	   extracardiaca,	   hipertensión	   pulmonar	   severa	   y	   disfunción	   del	  
ventrículo	   izquierdo	  fueron	  factores	   identificados	  como	  predictores	   independientes	  
de	  mortalidad	  en	  el	  análisis	  multivariante	  de	  regresión	  logística	  (con	  coeficientes	  de	  
regresión	   B	   de	   2.080,	   1.662	   y	   1.083	   respectivamente).	   Cada	   paciente	   se	   clasificó	  
como	   “Perfil	   Bajo”	   o	   “Perfil	   Alto”	   en	   función	   de	   la	   presencia	   o	   ausencia	   de	   estos	  
factores	  para	  posteriormente	  construir	  un	  Árbol	  de	  Regresión	  y	  Regresión	  (CRT)	  y	  así	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discriminar	  entre	  los	  procedimientos	  transcatéter	  o	  convencional	  para	  la	  mortalidad	  
perioperatoria	   en	   función	   del	   perfil	   asignado.	   La	   curva	   operador-­‐receptor	   (COR)	  
obtuvo	  un	  área	  bajo	  la	  curva	  de	  0.835	  (0.38-­‐1.000).	  
	  
No	  se	  hallaron	  diferencias	   relevantes	  en	   relación	  a	  variables	  preoperatorias	  
de	   riego	   o	   comorbilidades,	   así	   como	   en	   la	   mortalidad	   perioperatoria	   ni	   en	   la	  
supervivencia	  a	   largo	  plazo	  entre	  los	  casos	  de	  implante	  transcatéter	  y	   los	  controles	  
emparejados	   de	   recambio	   convencional.	   El	   evento	   compuesto	   MACCE	   fue	  
significativamente	  mayor	  en	  el	  grupo	  transcatéter	  (17,0%	  vs.	  4,5%,	  p<0.05)	  que	  en	  el	  
control,	   así	   como	   la	   tasa	   de	   ritmo	   de	   marcapasos	   al	   alta	   (20,8%	   respecto	   a	   0%,	  
p<0,001).	  También	  se	  apreciaron	  resultados	  significativos	  en	  cuanto	  a	  la	  duración	  de	  
la	   estancia	   en	   la	   unidad	   de	   cuidados	   intensivos	   en	   el	   grupo	   transcatéter	   (2,03	   +/-­‐	  
2,58	  días)	   respecto	  al	   grupo	   control	   (3.33	  +/-­‐	  1.80	  días	   ),	   aunque	  estas	  diferencias	  
desaparecieron	  en	  el	  análisis	  de	  subgrupos	  al	  utilizar	  un	  valor	  de	  EuroSCORE	  logístico	  





La	   aparición	   de	   las	   técnicas	   de	   implante	   valvular	   aórtico	   transcatéter	   han	  
supuesto	  un	  hito	  en	  el	  tratamiento	  de	  la	  estenosis	  aórtica	  calcificada	  degenerativa,	  y	  
probablemente	  el	  mayor	  avance	  tecnológico	  en	  el	  campo	  de	  la	  cirugía	  cardiaca	  de	  la	  
última	  década.	  Ha	  transformado	  la	  visión	  general	  y	   la	  aproximación	  quirúrgica	   	  a	   la	  
enfermedad	   cardiaca	   valvular,	   obligando	   a	   cirujanos,	   cardiólogos	   clínicos	   e	  
intervencionistas	  a	  colaborar	  estrechamente	  en	  pro	  del	  beneficio	  del	  paciente.	  	  
	  
La	   perspectiva	   actual	   en	   el	   estudio	   de	   las	   técnicas	   transcatéter	   pretende	  
aportar	   guías	   clínicas	   a	   cirujanos	   y	   cardiólogos	   involucrados	   en	   esta	   terapia	   hacia	  
identificar	   aquellos	   subgrupos	   de	   pacientes	   en	   los	   que	   este	   procedimiento	   puede	  
aportar	   mayores	   o	   menores	   beneficios,	   o	   incluso	   suponer	   un	   riesgo	   adicional.	   En	  
nuestro	   estudio	   se	   identificaron	   factores	   preoperatorios	   que	   actúan	   como	  
predictores	   independientes	  de	  mortalidad	  en	   la	   serie	  estudiada,	  mediante	   técnicas	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estadísticas	   de	   regresión	   logística	   multivariante:	   arteropatía	   extracardiaca,	  
hipertensión	  pulmonar	  severa	  	  disfunción	  del	  ventrículo	  izquierdo.	  Se	  demostró	  que	  
estos	  factores	  no	  solo	  juegan	  un	  papel	   importante	  en	  la	  mortalidad	  perioperatoria,	  
sino	   que	   también	   que	   su	   impacto	   relativo	   para	   cada	   técnica	   (trancatéter	   o	  
convencional)	   es	   diferente.	   De	   este	   modo,	   el	   nuevo	   índice	   de	   clasificación	   actúa	  
como	  una	  herramienta	  de	   fácil	  uso	  en	   la	  valoración	  preoperatoria	  de	   los	  pacientes	  
candidatos	  a	  cirugía	  valvular	  aórtica	  de	  alto	  riesgo,	  con	  capacidad	  de	  discriminación	  
entre	   ambos	   procedimientos.	   Mediante	   la	   clasificación	   de	   los	   pacientes	   como	   un	  
índice	   de	   “Perfil	   Bajo”	   o	   “	   Perfil	   Alto”	   resulta	   sencillo	   elegir	   entre	   la	   técnica	   más	  
adecuada.	   Sin	   embargo,	   la	   validación	   externa	   de	   estos	   resultados	   es	   una	   cuestión	  
todavía	  pendiente	  de	  valoración	  en	  futuros	  análisis.	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1.	  Natural	  history	  of	  aortic	  stenosis	  in	  adults	  
	  
	  
The	   most	   common	   cause	   of	   valvular	   aortic	   stenosis	   (AS)	   in	   adults	   is	  
calcification	   of	   a	   normal	   trileaflet	   or	   congenital	   bicuspid	   valve	   (1).	   Calcific	   AS	   is	  
characterized	  by	  lipid	  accumulation,	  inflammation,	  fibrosis,	  and	  calcification	  (2)	  and	  
is	  the	  most	  frequent	  heart	  valve	  disease	  in	  Europe	  and	  the	  United	  States.	  It	  typically	  
presents	   in	   older	   individuals	   (i.e.	   >75	   years)	   in	   contrast	   to	   bicuspid	   AS,	   which	  
presents	  a	  decade	  or	  more	  earlier.	  Rheumatic	  AS,	  uncommon	  in	  the	  Western	  world,	  
occurs	  due	  to	  fusion	  of	  the	  commissures	  with	  scarring	  and	  calcification	  of	  the	  cusps,	  
and	   retraction	   of	   the	   leaflets	   resulting	   in	   the	   valve	   being	   both	   regurgitant	   and	  
stenotic.	  
	  
In	   individuals	  with	  normal	  aortic	  valves,	   the	  effective	  area	  of	  valve	  opening	  
equals	   the	  cross-­‐sectional	  area	  of	   the	   left	  ventricular	  outflow	   tract,	  which	   is	  about	  
3.0	   to	   4.0	   cm2	  in	   adults.	   As	   aortic	   stenosis	   develops,	   a	   minimal	   valve	   gradient	   is	  
present	  until	  the	  orifice	  area	  becomes	  less	  than	  one-­‐half	  normal.	  The	  natural	  history	  
of	  aortic	  stenosis	  therefore	  begins	  with	  a	  prolonged	  asymptomatic	  period	  associated	  
with	  minimal	  mortality.	  
	  
In	  adults	  with	  valvular	  AS,	  the	  obstruction	  develops	  gradually,	   typically	  over	  
many	   years	   during	   which	   the	   left	   ventricle	   (LV)	   adapts	   to	   the	   systolic	   pressure	  
overload	   with	   progressive	   concentric	   hypertrophy	   that	   results	   in	   diastolic	  
dysfunction	  (3),	  reduced	  coronary	  reserve	  (4),	  myocardial	   ischemia,	  and	  eventually,	  
depressed	   contractility	   resulting	   in	   LV	   systolic	   dysfunction	   (5).	   Ultimately,	   in	   some	  
patients,	  heart	  failure	  or	  sudden	  death	  occurs.	  
Typically,	   patients	   with	   AS	   are	   free	   from	   cardiovascular	   symptoms	   (i.e.,	  
angina,	  syncope,	  and	  heart	  failure)	  until	  late	  in	  the	  course	  of	  the	  disease.	  However,	  
once	  symptoms	  manifest,	  the	  prognosis	  is	  poor,	  with	  the	  interval	  from	  the	  onset	  of	  
symptoms	  to	  the	  time	  of	  death	  being	  approximately	  2	  years	   in	  patients	  with	  heart	  
failure,	  3	  years	  in	  those	  with	  syncope,	  and	  5	  years	  in	  those	  with	  angina.	  Gardin	  et	  al.	  
reported	   that	   among	   symptomatic	   patients	   with	   moderate-­‐to-­‐severe	   AS	   treated	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medically,	  mortality	  rates	  after	  the	  onset	  of	  symptoms	  were	  approximately	  25%	  at	  1	  
year	  and	  50%	  at	  2	  years	  (6),	  with	  approximately	  50%	  of	  deaths	  being	  sudden.	  In	  the	  
elderly	  high-­‐risk	  patients	  in	  the	  PARTNER	  (Placement	  of	  Aortic	  Transcatheter	  Valve)	  
trial	  who	  were	  treated	  medically	  (Cohort	  B),	  the	  survival	  at	  1	  year	  was	  only	  50%	  (7).	  
	  
Serial	   hemodynamic	   examinations	   over	   periods	   ranging	   from	   two	   to	   nine	  
years	   reveal	   significant	   and	   initially	   silent	   progression	   in	  most	  but	  not	   all	   patients.	  
This	  progression	  is	  manifested	  by	  a	  reduction	  in	  the	  aortic	  valve	  area	  and	  an	  increase	  
in	  the	  transvalvular	  systolic	  pressure	  gradient.	  The	  development	  of	  symptoms	  is	  an	  
indication	   for	   valve	   replacement	   since	   the	   prognosis	   in	   untreated	   symptomatic	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Estimation	  of	  aortic	  valve	  area,	  aortic	  jet	  velocity,	  and	  transvalvular	  gradient	  
by	  echocardiography	  or,	   less	  often,	  cardiac	  catheterization	  has	  been	  used	  to	  define	  
patients	  as	  having	  mild,	  moderate,	  or	   severe	  aortic	   stenosis	   (table	  1).	   Severe	  AS	   is	  
said	   to	   be	   present	   when	   the	   calculated	   effective	   valve	   area	   is	   less	   than	   1.0	   cm2.	  
Critical	  aortic	  stenosis	  is	  said	  to	  be	  present	  when	  the	  calculated	  effective	  valve	  area	  
is	  less	  than	  0.75	  cm2	  or	  the	  Doppler	  aortic	  jet	  velocity	  is	  over	  5	  m/sec	  (13)	  (discussed	  
later	  in	  this	  section).	  	  
	  
Table	  1.	  Severity	  of	  aortic	  stenosis	  in	  adults	  
	  
	  
Aortic	  jet	  velocity,	  m/sec	   Mean	  gradient,	  mmHg	   Valve	  area,	  cm2	  
Normal	   ≤2.0	   <5	   3.0-­‐4.0	  
Mild	   <3.0	   <25	   >1.5	  
Moderate	   3.0-­‐4.0	   25-­‐40	   1.0-­‐1.5	  
Severe	   >4.0	   >40	   <1.0*	  
	  
	  
Schematic	  representation	  of	  the	  natural	  history	  of	  aortic	  stenosis	  and	  of	  the	  major	  
impact	   of	   aortic	   valve	   replacement.	   Survival	   is	   excellent	   during	   the	   prolonged	  
asymptomatic	   phase.	   After	   the	   development	   of	   symptoms,	   however,	   mortality	  
exceeds	   90	   %	   within	   a	   few	   years.	   Aortic	   valve	   replacement	   prevents	   this	   rapid	  
downhill	  course.	  
Critical	  aortic	   stenosis	  has	  been	  defined	  hemodynamically	  as	  a	   valve	  area	  <0.75	  
cm2	   (<0.6	   cm2/m2)	   and/or	   an	   aortic	   jet	   velocity	   >5.0	   m/sec.	   However,	   the	  
decision	  about	  valve	   replacement	   is	  not	  based	  solely	  on	  hemodynamics	  as	  some	  
patients	  who	  meet	  these	  criteria	  are	  asymptomatic,	  while	  others	  with	  less	  severe	  
measurements	  are	  symptomatic.	   In	  patients	  with	  severe	  aortic	  stenosis	  who	  also	  
have	  a	  low	  cardiac	  output	  state	  the	  aortic	  jet	  velocity	  and	  mean	  gradient	  may	  be	  
lower	  than	  indicated	  above	  (low-­‐gradient	  aortic	  stenosis).	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Some	   consideration	   of	   body	   size	   should	   be	   included	   in	   any	   estimation	   of	  
valve	   area	   (14).	   However,	   simply	   normalizing	   for	   body	   surface	   area	   can	   lead	   to	  
misleading	  conclusions,	  especially	  in	  obese	  patients.	  	  
	  
The	   term	   “symptomatic	   AS”	   refers	   to	   AS	   that	   is	   causing	   cardiac	   symptoms	  
such	  as	  heart	   failure,	  anginal	  chest	  discomfort,	  or	  syncope.	  Nevertheless,	   the	  most	  
common	  symptoms	  in	  patients	  who	  are	  followed	  prospectively	  are	  nonspecific	   (eg,	  
decreased	  exercise	  tolerance	  and	  dyspnea	  on	  exertion)(11).	  Care	  should	  be	  taken	  to	  
avoid	   attributing	   noncardiac	   symptoms	   to	   aortic	   stenosis:	   dyspnea	  may	   be	   due	   to	  
deconditioning	   or	   lung	   disease,	   ankle	   edema	   has	   many	   causes	   other	   than	   heart	  
failure,	  and	  nonanginal	  chest	  or	  shoulder	  pain	  is	  not	  a	  symptom	  of	  AS.	  	  
	  
Symptoms	  in	  patients	  with	  aortic	  stenosis	  and	  normal	  left	  ventricular	  systolic	  
function	  rarely	  occur	  until	   the	  valve	  area	   is	  <1.0	  cm2,	  the	  aortic	   jet	  velocity	   is	  over	  
4.0	   m/sec,	   and/or	   the	   mean	   transvalvular	   gradient	   exceeds	   40	   mmHg.	   However,	  
many	  patients	  do	  not	  develop	  symptoms	  until	  even	  more	  severe	  valve	  obstruction	  is	  
present,	   while	   some	   patients	   have	   symptoms	   when	   the	   stenosis	   is	   less	   severe,	  
particularly	  if	  there	  is	  coexisting	  aortic	  regurgitation	  or	  systemic	  atrial	  hypertension.	  	  
	  
Studies	   of	   patients	   undergoing	   serial	   cardiac	   catheterization	   have	   identified	  
subgroups	  of	  patients	  with	  aortic	  stenosis	  with	  distinctly	  different	  progression	  rates	  
(15,16).	  Serial	  echocardiography	  studies	  have	  provided	  data	  similar	  to	  that	  obtained	  
in	   cardiac	   catheterization	   studies,	   although	   the	   time	   intervals	   between	   follow	   up	  
have	  been	   shorter	   and	   these	   studies	   are	   less	   prone	   to	   selection	   bias	   (17–24).	   The	  
average	   rate	   of	   progression	   has	   been	   similar	   in	   numerous	   studies,	   but	   the	   rate	   of	  
progression	  varies	  widely	  among	  individual	  patients	  (17).	  
	  
• The	  average	  rate	  of	  increase	  in	  the	  mean	  systolic	  gradient	  is	  4	  to	  7	  mmHg	  per	  
year,	  but	  some	  patients	  show	  an	  increase	  of	  as	  much	  as	  15	  to	  19	  mmHg	  per	  
year.	  
• Valve	  area	  declines	  at	  an	  average	  rate	  of	  0.1	  cm2	  per	  year	  but	  some	  patients	  
have	  little	  or	  no	  progression	  and	  others	  progress	  more	  rapidly.	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   23	  
• Aortic	  jet	  velocity	  increases	  by	  an	  average	  of	  0.3	  m/sec	  per	  year.	  
	  
Patients	  with	  mild	  disease	  (ie,	  aortic	  jet	  velocity	  less	  than	  3.0	  m/sec)	  are	  unlikely	  
to	   develop	   symptoms	   due	   to	   aortic	   stenosis	   over	   the	   ensuing	   five	   years.	   A	  
substantial	  number	  of	  patients	  with	  severe	  aortic	  stenosis	  are	  not	  yet	  symptomatic	  
but	  these	  patients	  have	  low	  event	  free	  survival	  rates	  (56	  to	  63	  %	  at	  two	  years	  and	  25	  
to	  33	  %	  at	  four	  to	  five	  years)	  (17-­‐24).	  	  
	  
Data	   from	   observational	   studies	   of	   patients	  with	   asymptomatic	   aortic	   stenosis	  
suggest	  that	  peak	  aortic	  velocity	  and/or	  rate	  of	  progression	  of	  peak	  aortic	  velocity	  is	  
associated	  with	  risk	  of	  death	  or	  aortic	  valve	  replacement.	  Studies	  at	  three	  different	  
sites	  illustrate	  the	  range	  of	  predictive	  factors	  and	  rates	  of	  progression:	  
	  
1. University	   of	   Washington	  —	  The	   importance	   of	   hemodynamic	   factors	   was	  
demonstrated	   in	  a	  prospective	   study	  of	  123	  patients	  with	  aortic	   stenosis	   in	  
whom	   yearly	   echocardiography	   and	   exercise	   testing	   were	   performed	   for	   a	  
mean	   of	   2.5	   years	   (18).	   Entry	   criteria	   included	   an	   aortic	   jet	   velocity	   ≥2.5	  
m/sec	   and	   the	   absence	   of	   symptoms	  due	   to	   aortic	   stenosis.	   The	   end	   point	  
was	  defined	  as	  death	  or	  aortic	  valve	  surgery.	  
	  
• Event-­‐free	   survival	   at	   one,	   three,	   and	   five	   years	   was	   93,	   62,	   and	   26	   %,	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• The	   aortic	   jet	   velocity	   increased	   by	   0.32±0.34	   m/sec	   per	   year,	   the	   mean	  
gradient	   by	   7±7	   mmHg	   per	   year,	   and	   the	   aortic	   valve	   area	   decreased	   by	  
0.12±0.19	  cm2	  per	  year.	  Multivariate	  predictors	  of	  outcome	  were	  jet	  velocity	  
at	   baseline,	   the	   rate	   of	   change	   of	   aortic	   jet	   velocity,	   and	   functional	   status	  
score.	  Factors	  such	  as	  age,	  sex,	  or	  cause	  of	  aortic	  stenosis	  were	  not	  predictive	  
of	  outcome.	  
	  
• The	  likelihood	  of	  remaining	  alive	  and	  free	  of	  valve	  surgery	  at	  two	  years	  varied	  
inversely	   with	   disease	   severity	   as	   estimated	   from	   the	   baseline	   aortic	   jet	  
velocity:	   the	   respective	   values	   were	   84,	   66,	   and	   21	   %	   when	   the	   baseline	  
aortic	   jet	  velocity	  was	  <3.0,	  3.0	   to	  4.0,	  and	  >4.0	  m/sec,	   respectively	   (figure	  3).	   These	   values	   defined	   patients	   with	   mild,	   moderate,	   and	   severe	   aortic	  
stenosis.	  
	  
Kaplan-­‐Meier	  analysis	  shows	  survival	  without	  valve	  replacement	  for	  123	  patients	  
with	  valvular	  aortic	  stenosis	  who	  were	  initially	  asymptomatic.	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2. Medical	   University	   of	   Vienna	  —	  A	   prospective	   study	   evaluated	   126	  
asymptomatic	   patients	  with	   severe	   aortic	   stenosis,	   defined	   as	   an	   aortic	   jet	  
velocity	  ≥4	  m/sec,	  who	  were	  followed	  for	  a	  mean	  of	  22	  months	  (19).	  
	  
• Event-­‐free	   survival	   (with	   end	   point	   defined	   as	   death	   or	   aortic	   valve	  
replacement	  for	  symptoms)	  was	  67	  %	  at	  one	  year,	  56	  %	  at	  two	  years,	  and	  33	  
%	  at	  four	  years.	  
• Only	  the	  extent	  of	  aortic	  valve	  calcification	  was	  an	  independent	  predictor	  of	  
outcome.	  Patients	  with	  no	  or	  mild	  valvular	  calcification,	  compared	   to	   those	  
with	  moderate	  or	  severe	  calcification,	  had	  significantly	  higher	  rates	  of	  event-­‐
free	   survival	   at	   one	   and	   four	   years	   (92	   versus	   60	   %	   and	   75	   versus	   20	   %,	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Event	  free	  survival	  in	  patients	  with	  aortic	  stenosis	  who	  are	  initially	  asymptomatic	  
is	   related	   to	   the	   aortic	   jet	   velocity	   (Vmax)	   at	   entry.	   Aortic	   jet	   velocity	   varies	  
inversely	  with	  valve	  area.	  	  
In	  a	  study	  of	  126	  patients	  with	  asymptomatic	  severe	  aortic	  stenosis	  followed	  for	  a	  
mean	  of	  22	  months,	  Kaplan-­‐Meier	  analysis	  shows	  that	  event-­‐free	  survival	  (death	  
or	  aortic	   valve	   replacement)	   is	   related	   to	   the	  degree	  of	  aortic	   valve	  calcification	  
observed	  on	  echocardiography.	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• Patients	  who	  had	  events	  had	  a	  higher	  rate	  of	  progression	  of	  stenosis.	  Among	  
patients	   with	   moderate	   to	   severe	   calcification	   with	   increase	   in	   aortic	   jet	  
velocity	  of	  ≥0.3	  m/sec	  within	  one	  year,	  the	  cardiac	  event	  rate	  was	  79	  %	  (20).	  
• Event-­‐free	  survival	  (with	  the	  end	  points	  of	  death	  or	  indication	  for	  aortic	  valve	  
replacement	   including	   symptoms,	   left	   ventricular	   systolic	   dysfunction,	   or	  
rapid	   hemodynamic	   progression)	   was	   64,	   36,	   25,	   12	   and	   3	   %	   at	   one,	   two,	  
three,	  four,	  and	  six	  years.	  
• Peak	   aortic	   valve	   velocity,	   but	   not	   aortic	   valve	   area,	   was	   an	   independent	  
predictor	   of	   event-­‐free	   survival.	   Patients	   with	   a	   peak	   aortic	   valve	   velocity	  
≥5.5	  m/s	  had	  event-­‐free	  survivals	  of	  44,	  25,	  11,	  and	  4	  %	  at	  one,	  two,	  three,	  
and	   four	   years	   compared	  with	   76,	   43,	   33,	   and	  17	  %	   for	   patients	  with	  peak	  
aortic	  velocities	  between	  5.0	  and	  5.5	  m/s.	  
• All	  but	  seven	  patients	  had	  moderate	  to	  severe	  aortic	  valve	  calcification.	  Valve	  
calcification	  was	  not	  associated	  with	  event-­‐free	  survival.	  
	  
	  
3. Mayo	  Clinic	  —	  A	  large	  retrospective	  study	  included	  622	  patients	  with	  severe,	  
asymptomatic	   aortic	   stenosis	   (peak	   aortic	   jet	   velocity	   ≥4	   m/sec	   and	   mean	  
aortic	  valve	  area	  0.9	  cm2)	  (25).	  
	  
• The	   probability	   of	   remaining	   free	   of	   cardiac	   death	   and	   aortic	   valve	  
replacement	  was	   80,	   63,	   and	  25	  %	  at	   one,	   two,	   and	   five	   years;	   the	   rate	  of	  
remaining	  free	  of	  cardiac	  symptoms	  and	  unoperated	  was	  82,	  67,	  and	  33	  %	  at	  
the	  same	  time	  points.	  
• Patients	  with	  peak	   aortic	   jet	   velocity	   ≥4.5	  m/sec	  had	   increased	  event	   rates	  
(relative	  risk	  1.34	  for	  symptoms	  and	  1.48	  for	  valve	  replacement	  or	  death).	  
• The	  rate	  of	  sudden	  death	  while	  still	  asymptomatic	  and	  without	  surgery	  was	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The	  rate	  of	  progression	  of	  the	  stenotic	  lesion	  and	  the	  time	  to	  onset	  of	  symptoms	  
varies	   significantly	   among	   patients.	   Whether	   patients	   at	   high	   risk	   for	   rapid	  
progression	  can	  be	  successfully	  identified	  remains	  controversial.	  Several	  prospective	  
series	   have	   attempted	   to	   identify	   risk	   factors	   for	   progression	   in	   asymptomatic	  
patients	  (with	  symptomatic	  patients	  being	  treated	  surgically)	  (21,25–27).	  Among	  the	  
factors	  that	  may	  be	  important	  are:	  
	  
• Aortic	  jet	  velocity	  and	  valve	  area	  
• Degree	  of	  valve	  calcification	  
• Response	  to	  exercise	  testing	  
• Cause	  of	  aortic	  stenosis	  
• Hypercholesterolemia	  




Serial	  hemodynamic	  measurements	  alone	  have	  not	  been	  proven	  clinically	  useful	  
in	   asymptomatic	   patients	   since	   the	   absolute	   valve	   area	   or	   transvalvular	   pressure	  
gradient	  does	  not	  determine	  the	  onset	  of	  symptoms	  and	  the	  optimal	  time	  for	  valve	  
replacement.	   As	   many	   as	   one-­‐third	   patients	   with	   symptomatic	   AS	   do	   not	   have	  
critical	  AS	  (valve	  area	  less	  than	  0.75	  cm2).	  However,	  serial	  echocardiography,	  which	  
also	  provides	  information	  about	  left	  ventricular	  function	  and	  associated	  lesions,	  is	  an	  
important	  part	  of	  an	  integrated	  approach	  that	   includes	  a	  detailed	  history,	  a	  careful	  
physical	  examination,	  and	  evaluation	  of	  exercise	  tolerance	  
	  
Concerning	   ethiologies,	   there	   are	   three	   primary	   causes	   of	   valvular	   AS:	   a	  
congenitally	  bicuspid	  valve	  with	   superimposed	  calcification	   (unicuspid	  or	  bicuspid);	  
degenerative	   calcific	   disease	   of	   a	   trileaflet	   valve;	   and,	   much	   less	   common	   in	  
developed	  countries,	  rheumatic	  valve	  disease.	  	  
	  
Among	   patients	   with	   congenital	   or	   degenerative	   disease,	   progression	   to	   valve	  
replacement	  occurs	  earliest	  with	  a	  unicuspid	  valve,	   later	  with	  a	  bicuspid	  valve,	  and	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latest	  with	  a	   tricuspid	   valve.	   These	   relationships	  were	   illustrated	   in	   a	   study	  of	  932	  
adults	   who	   underwent	   surgery	   for	   isolated	   AS	   (1).	   Patients	   with	   mitral	   valve	  
replacement	  or	  mitral	  stenosis	  were	  excluded	  to	  ensure	  that	  patients	  with	  rheumatic	  
valve	  disease	  were	  not	  included.	  Also	  excluded	  were	  patients	  with	  a	  previous	  aortic	  
valvotomy,	  indicating	  severe	  valve	  obstruction	  due	  to	  congenital	  disease.	  
	  
An	  anatomically	  abnormal	  valve	  was	  present	  in	  54	  %:	  49	  %	  had	  a	  bicuspid	  valve	  
and	  4	  %	  had	  a	  unicuspid	  valve,	  but	  the	  frequency	  varied	  importantly	  with	  age:	  
	  
• Among	   the	   7	   %	   of	   patients	   who	   underwent	   surgery	   at	   ≤50	   years	   of	   age,	  
approximately	  two-­‐thirds	  had	  a	  bicuspid	  valve	  and	  one-­‐third	  had	  a	  unicuspid	  
valve	  
• Among	  the	  40	  %	  of	  patients	  who	  underwent	  surgery	  between	  the	  ages	  of	  50	  
and	   70,	   approximately	   two-­‐thirds	   had	   a	   bicuspid	   valve	   and	   one-­‐third	   a	  
tricuspid	  valve;	  only	  rare	  patients	  had	  a	  unicuspid	  valve.	  
• Among	   the	   remaining	   patients	   over	   age	   70,	   approximately	   60	   %	   had	   a	  




A	  different	  aspect	  regards	  aortic	  valve	  thickening	  (sclerosis)	  without	  stenosis,	  
which	  is	  common	  in	  elderly	  adults.	  It	  is	  typically	  detected	  either	  as	  a	  systolic	  murmur	  
on	   physical	   examination	   or	   by	   echocardiography,	   and	   is	   associated	  with	   increased	  
cardiovascular	  mortality	  
	  
Aortic	  sclerosis	  may	  progress	  to	  significant	  aortic	  stenosis.	  In	  a	  review	  of	  2131	  
patients	  with	  aortic	  valve	  thickening	  detected	  on	  echocardiography,	  aortic	  stenosis	  
developed	  in	  338	  (16	  %)	  after	  seven	  years	  (28).	  The	  stenosis	  was	  mild	  to	  moderate	  in	  
84	   %	   of	   these	   patients	   and	   severe	   in	   16	   %.	   Only	   mitral	   annular	   calcification	   was	  
significantly	  associated	  with	  progression	  in	  multivariable	  analysis.	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Patients	  with	  symptomatic	  severe	  AS	  who	  do	  not	  undergo	  valve	  replacement	  
have	  a	  poor	  prognosis	  (figure	  1).	  Mortality	  in	  patients	  with	  AS	  dramatically	  increases	  
after	   the	   development	   of	   the	   cardiac	   symptoms.	   As	   a	   result,	   prompt	   valve	  
replacement	  is	  recommended	  in	  such	  patients.	  The	  high	  mortality	  rates	  observed	  in	  
symptomatic	  patients	  who	  do	  not	  undergo	  valve	  replacement	  may	  be	  in	  part	  due	  to	  
comorbidities	   that	  preclude	  surgery.	  The	   following	  examples	  demonstrate	   the	  high	  
mortality	  rate	  associated	  with	  severe	  symptomatic	  AS:	  
	  
• A	  review	  of	  studies	  performed	  during	  1913	  to	  1970	  found	  that	  mean	  survival	  
after	   onset	   of	   heart	   failure	   ranged	   from	   0.5	   to	   2.8	   years,	   after	   onset	   of	  
syncope	  ranged	  from	  0.8	  to	  3.8	  years,	  and	  after	  onset	  of	  angina	  ranged	  from	  
2	  to	  4.7	  years	  (29).	  Studies	  performed	  during	  1967	  to	  1982	  reported	  two-­‐year	  
actuarial	   mortality	   rates	   of	   24	   to	   69	   %	   in	   patients	   with	   New	   York	   Heart	  
Association	  functional	  class	  III	  to	  IV	  symptoms.	  	  
• In	  the	  PARTNER	  trial,	  179	  patients	  with	  AS	  with	  heart	  failure	  symptoms	  were	  
assigned	   to	   the	   standard	   therapy	   arm	   (7).	   The	   majority	   of	   these	   patients	  
received	  balloon	  aortic	  valvuloplasty	  (64	  %	  during	  the	  first	  30	  days	  and	  20	  %	  
later).	  The	  mortality	  rate	  at	  one	  year	  was	  51	  %	  in	  this	  group.	  	  
• In	   an	   observational	   study	   of	   symptomatic	   AS	   patients	   not	   eligible	   for	   a	  
transcatheter	   aortic	   valve	   implantation	   trial,	   274	   patients	   received	  medical	  
treatment	  (including	  balloon	  aortic	  valvuloplasty	  in	  65	  %)	  (12).	  Mortality	  was	  
32	  %	  during	  median	  follow-­‐up	  of	  one	  year.	  
	  
	  
To	   end	  with,	   pulmonary	   hypertension	   (pulmonary	   artery	   pressure	   >30	  mmHg)	  
commonly	  occurs	  in	  symptomatic	  patients	  with	  aortic	  stenosis	  and	  is	  associated	  with	  
a	  more	  severe	  clinical	  picture	  and	  a	  poor	  prognosis	  after	  aortic	  valve	  replacement.	  	  
	  
These	  relationships	  were	  illustrated	  in	  a	  study	  of	  388	  symptomatic	  patients	  with	  
isolated	   aortic	   stenosis	   who	   underwent	   cardiac	   catheterization;	   pulmonary	  
hypertension	   was	   absent	   in	   35	   %,	   mild	   to	   moderate	   pulmonary	   hypertension	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(defined	  as	  pulmonary	  artery	  systolic	  pressure	  31	  to	  50	  mmHg)	  was	  present	  in	  50	  %	  
and	   severe	  pulmonary	  hypertension	   in	  15	  %	   (30).	   The	  only	   factors	  associated	  with	  
severe	  pulmonary	  hypertension	  were	  overt	  heart	  failure	  and	  elevated	  left	  ventricular	  
end-­‐diastolic	  pressure;	  neither	  the	  aortic	  valve	  area	  nor	  the	  left	  ventricular	  ejection	  
fraction	  was	  related	  to	  the	  pulmonary	  artery	  pressure.	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2.	  Diagnosis	  of	  aortic	  stenosis	  
	  
	  
2.1.	  	   ECHOCARDIOGRAPHY	  VERSUS	  CATHETERIZATION.	  	  
	  
Although	   invasive	   cardiac	   catheterization	  has	  historically	  been	   the	   standard	  
for	  quantification	  of	  AS,	  this	  function	  has	  been	  largely	  replaced	  by	  echocardiography	  
(31,32).	  
	  
Echocardiographic	  diagnosis	   is	  made	  by	   the	  observation	  of	   a	   calcified	   valve	  
with	   restricted	   leaflet	   opening	   by	   two-­‐dimensional	   (2D)	   echocardiography	   with	  
quantification	   of	   the	   peak	   and	  mean	  AV	   gradient	  made	   by	   applying	   the	   simplified	  
Bernoulli	   equation	   (Δp=4v2)	   to	   the	   maximal	   velocity	   recorded	   through	   the	   aortic	  
valve	  by	  continuous-­‐wave	  Doppler.	  Multiple	  imaging	  windows	  (apical	  4-­‐chamber	  and	  
long-­‐axis,	   right	   parasternal,	   suprasternal	   notch,	   and	   subcostal	   views)	   should	   be	  
obtained	   to	   assure	   acquisition	   of	   the	  maximal	   velocity	   and	   to	   avoid	   angle-­‐related	  
errors.	  Although	  aortic	  valve	  area	  (AVA)	  can	  be	  measured	  by	  planimetry,	   it	   is	  more	  
accu-­‐	   rately	   assessed	  by	   application	  of	   the	   continuity	   equation,	   using	   pulsed-­‐wave	  
Doppler	   in	   the	   left	   ventricular	   outflow	   tract	   (LVOT)	   and	   continuous-­‐wave	   Doppler	  
across	  the	  valve.	  	  
	  
Severe	   stenosis	   is	   defined	   in	   the	   guidelines	   (13,14)	   as	   a	   peak	   velocity	   >4.0	  
m/s,	  a	  mean	  gradient	  >40	  mm	  Hg,	  OR	  valve	  area	  <1.0	  cm2	  when	  LV	  systolic	  function	  
is	  normal.	  To	  account	  for	  patient	  size,	  the	  valve	  area	  is	  often	  indexed	  to	  body	  surface	  
area,	  with	  0.6	  cm2/m2	  considered	  to	  be	  the	  threshold	  for	  severe	  AS.	  An	  important	  
exception	   is	   when	   the	   gradient	   suggests	   less	   severe	   stenosis	   than	   the	   valve	   area,	  
most	   commonly	   due	   to	   low	   stroke	   volume,	   either	   in	   dilated	   ventricles	   with	   low	  
ejection	  fraction	  (EF)	  or	  small	  ventricles	  with	  normal	  EF.	  In	  this	  setting,	  a	  dobutamine	  
stress	  study,	  may	  be	  helpful.	   If	   the	  maximum	  jet	  velocity	  rises	  over	  4	  m/s	  with	  the	  
dobutamine-­‐induced	  increase	   in	  stroke	  volume	  whereas	  the	  AVA	  remains	   less	  than	  
1.0	  cm2,	  then	  the	  valve	  is	  truly	  severely	  stenotic.	  On	  the	  other	  hand,	  if	  stroke	  volume	  
increases	   with	   little	   rise	   in	   gradient	   (causing	   valve	   area	   to	   increase	   substantially),	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then	   the	  AS	   is	  only	  mild	   to	  moderate	   in	   severity,	  and	   the	  LV	  dysfunction	   is	  due	   to	  
causes	  other	  than	  AS	  (33–35).	  
	  
Occasionally,	   the	   AVA	   appears	   larger	   than	   the	   elevated	   gradient	   would	  
suggest,	   usually	   due	   to	   elevated	   stroke	   volume	   from	   aortic	   regurgitation	   (AR),	  
anemia,	  fever,	  or	  hyperthyroidism.	  Sometimes,	  though,	  it	  reflects	  a	  technical	  error	  in	  
applying	  the	  continuity	  equation,	  when	  the	  blood	  accelerates	  within	  the	  LVOT	  due	  to	  
an	  upper	  septal	  bulge,	  which	  may	  result	  in	  an	  overestimation	  of	  valve	  area.	  To	  avoid	  
this,	  one	  can	  try	  to	  measure	  the	  LVOT	  area	  at	  the	  point	  of	  maximal	  velocity,	  though	  
the	  geometry	  is	  often	  quite	  distorted	  in	  this	  region,	  making	  estimation	  of	  the	  LVOT	  
area	  difficult.	  	  
	  
Alternatively,	   one	   can	   use	   the	   LV	   stroke	   volume	   (from	   2D	   or	   three-­‐
dimensional	   [3D]	  measurements	   of	   the	   LV,	   ideally	   with	   contrast	   infusion)	   or	   right	  
ventricular	   (RV)	   stroke	   volume	   (from	   RV	   outflow	   tract)	   as	   the	   input	   into	   the	  
continuity	  equation.	  Dividing	  this	  stroke	  volume	  by	  the	  time	  velocity	  integral	  of	  the	  
AV	  continuous-­‐wave	  Doppler	  will	  also	  yield	  the	  AVA,	   independent	  of	  any	  distortion	  
in	  the	  LVOT.	  
	  
Despite	   the	   convenience	   and	   widespread	   applicability	   of	   transthoracic	  
echocardiography	   (TTE),	   there	   are	   occasions	   when	   invasive	   measurements	   are	  
needed,	   such	   as	   in	   patients	   with	   a	   discrepancy	   between	   clinical	   and	  
echocardiographic	   assessments.	   In	   such	   cases,	   catheterization	   should	   generally	   be	  
performed	  with	  dual	  catheters,	  1	  placed	  in	  the	  LV,	  the	  other	  in	  the	  proximal	  aorta	  to	  
obtain	   simultaneous	   pressure	   measurements	   and	   obtain	   the	   most	   accurate	  
assessment	  of	   the	  gradient.	   Infusion	  of	  dobutamine	  may	  allow	  assessment	  of	   low-­‐
output,	   low-­‐gradient	   AS	   in	   the	   catheterization	   laboratory	   (36).	   Other	   adjunctive	  
testing	  used	  in	  quantifying	  AS	  includes	  transesophageal	  echocardiography	  (TEE)	  (37),	  
computed	  tomography	  scanning	  (dynamic	  or	  gated	  during	  systole)	  (38),	  and	  cardiac	  
magnetic	  resonance	  imaging	  (39).	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2.2.	  	   STRESS	  TESTING.	  
	  
	  	   The	  presence	  or	  absence	  of	  symptoms	  should	  guide	  the	  management	  of	  AS	  
patients,	  yet	  in	  many	  cases,	  this	  important	  clinical	  benchmark	  is	  difficult	  to	  establish,	  
owing	   to	   the	   subjective	  nature	  of	   the	   symptoms	   and	   comorbid	   conditions	   such	   as	  
chronic	   lung	   disease	   in	   this	   patient	   population.	   In	   general,	   stress	   testing	   is	  
contraindicated	   when	   symptoms	   are	   present	   because	   of	   the	   potential	   for	  
complications	   in	   these	   patients.	   However,	   in	   patients	   with	   equivocal	   symptoms,	  
stress	   testing,	   and	   in	   particular	   stress	   echocardiography,	   can	   be	   very	   helpful	   (40).	  
Simple	   determination	   of	   functional	   capacity	  may	   help	   show	   limitations	   of	  which	   a	  
patient	  may	  be	  unaware.	   Isolated	  echocardiographic	  changes	  during	  the	  stress	  test	  
without	   symptoms	   or	   change	   in	   blood	   pressure	   should	   not	   be	   interpreted	   as	   a	  
positive	  indicator	  of	  severe	  AS.	  Other	  potential	  markers	  for	  AS	  severity	  include	  signs	  




2.3	  	   SPECIAL	  CONSIDERATIONS	  
	  
2.3.1.	   SYMPTOM	  STATUS.	  
	  
	  	   With	   severe,	   symptomatic,	   calcific	   AS,	   AVR	   is	   the	   only	   effective	   treatment	  
that	   improves	   symptoms	   and	   prolongs	   survival	   (41,42).	   These	   results	   are	   partly	  
dependent	   on	   LV	   function.	   In	   the	   setting	   of	   LV	   dysfunction	   caused	   by	   afterload	  
mismatch,	   survival	   is	   still	   improved,	   although	   improvement	   in	   LV	   function	   and	  
resolution	  of	  symptoms	  might	  be	  incomplete	  after	  AVR.	  Age	  itself	  is	  a	  risk	  factor	  for	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2.3.2.	   ASSOCIATED	  CORONARY	  ARTERY	  DISEASE.	  
	  
	  In	   patients	  with	  moderate	  AS,	  who	   are	   undergoing	   coronary	   artery	   bypass	  
graft	   surgery	   (CABG),	   AVR	   should	   be	   performed	   at	   the	   time	   of	   revascularization	  
irrespective	   of	   symptoms	   related	   to	   moderate	   AS	   (45,46).	   There	   are	   no	   data	   to	  
support	   performing	   AVR	   for	   mild	   AS	   at	   the	   time	   of	   CABG.	   Patients	   undergoing	  
surgical	   AVR	   with	   significant	   stenoses	   (>50%	   to	   70%	   stenosis)	   in	   major	   coronary	  
arteries	   should	   be	   treated	   with	   concomitant	   CABG.	   Options	   in	   patients	   with	  
combined	  AS	  and	  CAD	  continue	  to	  grow	  with	  the	  use	  of	  hybrid	  procedures	  where	  PCI	  
is	  followed	  by	  valve	  surgery.	  It	  is	  possible	  that	  such	  a	  strategy	  could	  be	  performed	  in	  
the	  setting	  of	  TAVR	  (45,46).	  
	  
	  
2.3.3.	   ASSOCIATED	   LESIONS	   —	   AORTIC	   REGURGITATION,	   MITRAL	  
REGURGITATION,	   PULMONARY	   HYPERTENSION,	   TRICUSPID	  
REGURGITATION.	  	  
	  
Patients	  with	  severe	  AS	  often	  have	  additional	  associated	  significant	  valvular	  
heart	   disease.	   Treatment	   of	   these	   lesions	   in	   patients	   undergoing	   AVR	   should	   be	  
under-­‐	   taken	   using	   standard	   criteria.	   However,	   treatment	   of	   associated	   valvular	  
lesions	  may	  increase	  the	  risk	  of	  AVR	  (47).	  A	  special	  circumstance	  is	  that	  of	  pulmonary	  
hypertension	   (PH)	  either	  primary	  or	   secondary	   (reactive	  or	   related	   to	   increased	  LV	  
end-­‐diastolic	  pressure).	  Both	  conditions	  may	   increase	   the	   risk	  of	  AVR	  and	  must	  be	  
taken	  into	  consideration	  in	  the	  risk/benefit	  ratio.	  
	  
PH	  can	  be	  present	  in	  patients	  with	  severe	  AS,	  either	  from	  the	  transmission	  of	  
increased	   LV	   diastolic	   and/or	   left	   atrial	   pressures,	   associated	   mitral	   regurgitation	  
(MR),	  or	   from	  a	  secondary	   increase	   in	  pulmonary	  vascular	   tone.	  The	  prevalence	  of	  
PH	   in	  patients	  with	  AS	   is	  undefined,	  varying	  widely	  on	   the	  definition	  used	  and	   the	  
population	  studied	  (48,49).	  Clinically,	  PH	  associated	  with	  critical	  AS	  portends	  a	  poor	  
prognosis	  and	  is	  associated	  with	  an	  increased	  risk	  of	  sudden	  cardiac	  death	  (50).	  The	  
presence	  of	  PH	  makes	  patients	  more	  susceptible	  to	  any	  hemodynamic	  and	  electrical	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instability	   related	   to	   the	   procedure	   and	   may	   increase	   the	   risk	   of	   postprocedural	  
complications.	   In	  addition,	  PH	  may	  result	   in	  right	  heart	   failure	  and	  severe	  tricuspid	  
regurgitation	  (TR),	  both	  of	  which	  complicate	  management	  and	  increase	  risks.	  
	  
In	   the	   setting	   of	   severe	   AS	   and	   PH	   several	   treatment	   strategies	   have	   been	  
used	  (51).	  Persistently	  elevated	  left-­‐sided	  cardiac	  filling	  pressures	  increase	  the	  risk	  of	  
pulmonary	   edema	   when	   challenged	   with	   a	   pulmonary	   vasodilator.	   Pulmonary	  
vasodilators,	  such	  as	  nitric	  oxide,	  prostacylin,	  and	  sildenafil,	  have	  been	  administered	  
during	   and	   following	   cardiac	   surgery	   with	   improved	   hemodynamic	   effects	   (52).	  
However,	   their	   overall	   clinical	   utility	   in	   improving	   late	   survival	   in	   the	   surgical	  
population	  remains	  unclear.	  	  
	  
	  
2.3.4.	   LOW	  GRADIENT–LOW	  EJECTION	  FRACTION.	  	  
	  
As	   mentioned,	   the	   combination	   of	   overt	   congestive	   heart	   failure	   and	   low	  
aortic	  valve	  gradient	  is	  relatively	  common.	  This	  may	  be	  a	  consequence	  of	  excessive	  
afterload	  (despite	  left	  ventricular	  hypertrophy	  [LVH])	  or	  reduced	  contractile	  function	  
likely	  due	  to	  increased	  myocardial	  fibrosis	  (53).	  When	  there	  is	  overt	  heart	  failure	  due	  
to	   low	  forward	   flow	  and	  a	   low	  transvalvular	  gradient	   (mean	  gradient	  <30	  mm	  Hg),	  
both	   mechanisms	   may	   be	   present.	   Because	   of	   reduced	   contractility	   in	   the	   low-­‐
flow/low-­‐gradient	  AS	  patient,	  prognosis	  with	  surgical	  AVR	  is	  adversely	  affected	  with	  
operative	  mortality	  as	  high	  as	  20%.	  However	  the	  5-­‐year	  survival	  is	  still	  reported	  to	  be	  
better	   in	  patients	   treated	   surgically	   (54,55).	  When	   the	  primary	   reason	   for	  poor	   LV	  
performance	   is	   excessive	   afterload,	   the	   prognosis	   following	   surgical	   AVR	   is	   usually	  
good	  (5).	  In	  general,	  patients	  with	  low	  gradient,	  low	  EF	  who	  have	  the	  best	  prognosis	  
are	   those	   with	   inotropic	   reserve	   (shown	   by	   an	   increase	   in	   stroke	   volume	   with	  
dobutamine	  infusion),	  who	  have	  limited	  coronary	  disease	  and	  a	  mean	  gradient	  that	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2.3.5.	   BASAL	  SEPTAL	  HYPERTROPHY—OUTFLOW	  TRACT	  GRADIENTS.	  	  
	  
Although	   infrequent,	   proximal	   septal	   bulging	   with	   LVOT	   obstruction	   may	  
present	   unique	   issues	   in	   the	   presence	   of	   AS.	  While	   this	   can	   be	   readily	   addressed	  
during	   AVR	   via	   myomectomy,	   such	   an	   approach	   would	   not	   be	   possible	   with	  
transcatheter	  procedures.	  Thus,	   careful	  preprocedural	  echocardiographic	   screening	  
is	   recommended	  to	  specifically	  avoid	   this	  scenario	   in	  patients	  being	  considered	   for	  
transcatheter	  aortic	  valve	  replacement.	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3.	  Indications	  for	  valve	  replacement	  in	  aortic	  stenosis	  
	  
	  
In	   individuals	  with	  normal	  aortic	  valves,	  the	  valve	  area	   is	  3.0	  to	  4.0	  cm2.	  As	  
aortic	   stenosis	   (AS)	   develops,	   a	  minimal	   valve	   gradient	   is	   present	   until	   the	   orifice	  
area	  falls	  by	  more	  than	  50	  %.	  In	  general,	  symptoms	  in	  patients	  with	  AS	  and	  normal	  
left	  ventricular	  systolic	  function	  rarely	  occur	  until	  aortic	  stenosis	  is	  severe	  (generally	  
defined	  as	  a	  valve	  area	  <1.0	  cm2,	  usually	  accompanied	  by	  an	  aortic	  jet	  velocity	  >4.0	  
m/sec	  and/or	  mean	  transvalvular	  gradient	  >40	  mmHg).	  However,	  many	  patients	  do	  
not	  develop	   symptoms	  until	   obstruction	   is	   even	  more	   severe,	  while	   some	  become	  
symptomatic	   with	   lesser	   obstruction,	   particularly	   if	   there	   is	   coexisting	   aortic	  
regurgitation.	  
	  
Surgical	   replacement	   of	   the	   aortic	   valve	   is	   the	   only	   effective	   treatment	   for	  
severe	  AS.	   Although	   there	   is	   some	   lack	   of	   agreement	   about	   the	   optimal	   timing	   of	  
surgery,	   it	   is	   still	   possible	   to	   develop	   rational	   guidelines	   for	   the	   evaluation	   and	  
management	  of	  most	  patients	  (13,14).	  Particular	  consideration	  must	  be	  given	  to	  the	  
natural	  history	  of	  symptomatic	  and	  asymptomatic	  patients	  and	  to	  the	  operative	  risk	  
and	  the	  outcome	  after	  surgery.	  	  
	  
The	   recommendations	   are	   generally	   in	   accord	   with	   the	   2006	   American	  
College	  of	  Cardiology/American	  Heart	  Association	  (ACC/AHA)	  valvular	  heart	  disease	  
guidelines	  with	  2008	   focused	  update	   (table	  2)	  (14).	   Recommendations	   in	   the	  2007	  
European	  Society	  of	  Cardiology	   (ESC)	  guidelines	  are	   similar	  but	  differ	   somewhat	   in	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Table	  2.	  2008	  ACC/AHA	  Guideline	  Summary:	  Indications	  for	  aortic	  valve	  replacement	  
(AVR)	  in	  aortic	  stenosis	  (AS)	  
	  
Class	   I	   -­‐	   There	   is	   evidence	   and/or	   general	   agreement	   that	   AVR	   is	   indicated	   in	  
patients	  with	  AS	  in	  the	  following	  settings	  
•	  Symptomatic	  severe	  AS.	  
•	  Severe	  AS	   in	  patients	  undergoing	  coronary	  artery	  bypass	  graft	  surgery	  or	  surgery	  
on	  the	  aorta	  or	  other	  heart	  valves.	  
•	  Severe	  AS	  with	  a	  left	  ventricular	  ejection	  fraction	  less	  than	  50	  %.	  
Class	  IIa	  -­‐	  The	  weight	  of	  evidence	  or	  opinion	  is	  in	  favor	  of	  the	  usefulness	  of	  AVR	  in	  
patients	  with	  AS	  in	  the	  following	  setting	  
•	   Moderate	   AS	   in	   patients	   undergoing	   coronary	   artery	   bypass	   graft	   surgery	   or	  
surgery	  on	  the	  aorta	  or	  other	  heart	  valves.	  
Class	   IIb	   -­‐	   The	   weight	   of	   evidence	   or	   opinion	   is	   less	   well	   established	   for	   the	  
usefulness	  of	  AVR	  in	  patients	  with	  AS	  in	  the	  following	  settings	  
•	  Severe	  AS	  in	  asymptomatic	  patients	  who	  have	  an	  abnormal	  response	  to	  exercise	  
such	  as	  the	  development	  of	  symptoms	  or	  hypotension.	  
•	  Severe	  AS	   in	  asymptomatic	  patients	  with	  a	  high	   likelihood	  of	   rapid	  progression	  
(as	  determined	  by	  age,	  valve	  calcification,	  and	  coronary	  heart	  disease).	  
•	   Severe	  AS	   in	   asymptomatic	   patients	   in	  whom	   surgery	  might	   be	   delayed	  at	   the	  
time	  of	  symptom	  onset.	  
•	  Mild	   AS	   in	   patients	   undergoing	   coronary	   artery	   bypass	   graft	   surgery	   in	  whom	  
there	  is	  evidence,	  such	  as	  moderate	  to	  severe	  valve	  calcification,	  that	  progression	  
may	  be	  rapid.	  
•	  Extremely	  severe	  AS	  (aortic	  valve	  area	  less	  than	  0.6	  cm2,	  mean	  gradient	  greater	  
than	   60	  mmHg,	   and	   aortic	   jet	   velocity	   greater	   than	   5.0	  m/sec)	   in	   asymptomatic	  
patients	  in	  whom	  the	  expected	  operative	  mortality	  is	  1	  %	  or	  less.	  
Class	  III	  -­‐	  There	  is	  evidence	  and/or	  general	  agreement	  that	  AVR	  for	  AS	  is	  not	  useful	  
in	  in	  the	  following	  settings	  
•	  For	  the	  prevention	  of	  sudden	  cardiac	  death	  in	  asymptomatic	  patients	  who	  have	  
none	  of	  the	  class	  IIa	  or	  IIb	  findings.	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Table	  3.	  2007	  ESC	  Indications	  for	  aortic	  valve	  replacement	  in	  aortic	  stenosis	  
	  
	  	   Class	  
Patients	  with	  severe	  AS	  and	  any	  symptoms	   IB	  
Patients	  with	  severe	  AS	  undergoing	  coronary	  artery	  bypass	  surgery,	  surgery	  
of	  the	  ascending	  aorta,	  or	  on	  another	  valve	  
IC	  
Asymptomatic	  patients	  with	  severe	  AS	  and	  systolic	  LV	  dysfunction	  (LVEF	  <50	  
%)	  unless	  due	  to	  other	  cause	  
IC	  
Asymptomatic	  patients	  with	  severe	  AS	  and	  abnormal	  exercise	  test	  showing	  
symptoms	  on	  exercise	  
IC	  
Asymptomatic	  patients	  with	  severe	  AS	  and	  abnormal	  exercise	  test	  showing	  
fall	  in	  blood	  pressure	  below	  baseline	  
IIaC	  
Patients	   with	   moderate	   AS*	   undergoing	   coronary	   artery	   bypass	   surgery,	  
surgery	  of	  the	  ascending	  aorta	  or	  another	  valve	  
IIaC	  
Asymptomatic	   patients	   with	   severe	   AS	   and	   moderate-­‐to-­‐severe	   valve	  
calcification,	  and	  a	  rate	  of	  peak	  velocity	  progression	  ≥0.3	  m/s	  per	  year	  
IIaC	  
AS	   with	   low	   gradient	   (<40	   mmHg)	   and	   LV	   dysfunction	   with	   contractile	  
reserve	  
IIaC	  
Asymptomatic	  patients	  with	  severe	  AS	  and	  abnormal	  exercise	  test	  showing	  
complex	  ventricular	  arrhythmias	  
IIbC	  
Asymptomatic	   patients	  with	   severe	  AS	  and	  excessive	   LV	  hypertrophy	   (≥15	  
mm)	  unless	  this	  is	  due	  to	  hypertension	  
IIbC	  








Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   41	  
SYMPTOMATIC	  PATIENTS	  
	  
Angina,	  dizziness	  or	  syncope,	  and	  heart	  failure	  (eg,	  dyspnea)	  are	  the	  primary	  
manifestations	  of	  severe	  AS,	  usually	  occurring	  with	  exertion.	  Average	  survival	  after	  
the	  onset	  of	  these	  symptoms	  is	  only	  two	  to	  three	  years,	  with	  a	  high	  risk	  of	  sudden	  
death.	  As	  a	  result,	  symptomatic	  AS	  is	  an	  indication	  for	  valve	  replacement.	  	  
	  
Observational	   studies	   have	   found	   that	   corrective	   surgery	   in	   this	   setting	   is	  
almost	  always	  followed	  by	  symptomatic	   improvement	  and	  a	  substantial	   increase	  in	  
survival	   (56).	   The	   potential	   magnitude	   of	   these	   benefits	   can	   be	   illustrated	   by	   the	  
following	  observations:	  
	  
• In	   a	   retrospective	   review	   of	   99	   elderly	   patients	  with	   AS	   and,	   in	   almost	   all,	  
New	  York	  Heart	  Association	  class	   III	  or	   IV,	   follow-­‐up	  at	  55	  months	   revealed	  
that	  91	  %	  of	  survivors	  were	  in	  NYHA	  class	  I	  or	  II	  (table	  4)	  (57).	  
	  
Table	  4.	  Comparison	  of	  three	  methods	  of	  assessing	  cardiovascular	  disability	  
	  
Class	   New	   York	   Heart	  
Association	  functional	  
classification	  
Canadian	   Cardiovascular	  
Society	   functional	  
classification	  
Specific	  activity	  scale	  
I	   Patients	   with	   cardiac	  
disease	   but	   without	  
resulting	  limitations	  of	  
physical	   activity.	  
Ordinary	   physical	  
activity	   does	   not	  
cause	   undue	   fatigue,	  
palpitation,	   dyspnea,	  
or	  anginal	  pain.	  
Ordinary	   physical	   activity,	  
such	   as	   walking	   and	  
climbing	   stairs,	   does	   not	  
cause	   angina.	  Angina	  with	  
strenuous	   or	   rapid	  
prolonged	  exertion	  at	  work	  
or	  recreation.	  
Patients	   can	   perform	  
to	   completion	   any	  
activity	   requiring	   ≥7	  
metabolic	   equivalents,	  
eg,	   can	   carry	   24	   lb	   up	  
eight	  steps;	  do	  outdoor	  
work	   (shovel	   snow,	  
spade	   soil);	   do	  
recreational	   activities	  
(skiing,	   basketball,	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squash,	   handball,	  
jog/walk	  5	  mph).	  
II	   Patients	   with	   cardiac	  
disease	   resulting	   in	  
slight	   limitation	   of	  
physical	   activity.	   They	  
are	   comfortable	   at	  
rest.	  Ordinary	  physical	  
activity	   results	   in	  
fatigue,	   palpitation,	  
dyspnea,	   or	   anginal	  
pain.	  
Slight	   limitation	   of	  
ordinary	   activity.	   Walking	  
or	   climbing	   stairs	   rapidly,	  
walking	   uphill,	   walking	   or	  
stair	   climbing	   after	   meals,	  
in	   cold,	   in	   wind,	   or	   when	  
under	   emotional	   stress,	   or	  
only	   during	   the	   few	   hours	  
after	   awakening.	   Walking	  
more	   than	   two	   blocks	   on	  
the	   level	   and	   climbing	  
more	   than	   one	   flight	   of	  
ordinary	  stairs	  at	  a	  normal	  
pace	   and	   in	   normal	  
conditions.	  
Patients	   can	   perform	  
to	   completion	   any	  
activity	   requiring	   ≤	   5	  
metabolic	   equivalents,	  
eg,	   have	   sexual	  
intercourse	   without	  
stopping,	  garden,	  rake,	  
weed,	   roller	   skate,	  
dance	  fox	  trot,	  walk	  at	  
4	  mph	  on	  level	  ground,	  
but	   cannot	   and	  do	  not	  
perform	   to	   completion	  
activities	   requiring	   ≥	   7	  
metabolic	  equivalents.	  
III	   Patients	   with	   cardiac	  
disease	   resulting	   in	  
marked	   limitation	   of	  
physical	   activity.	   They	  
are	   comfortable	   at	  
rest.	   Less	   than	  
ordinary	   physical	  
activity	   causes	  
fatigue,	   palpitation,	  
dyspnea,	   or	   anginal	  
pain.	  
Marked	   limitation	   of	  
ordinary	   physical	   activity.	  
Walking	  one	  to	   two	  blocks	  
on	   the	   level	   and	   climbing	  
one	   flight	   in	   normal	  
conditions.	  
Patients	   can	   perform	  
to	   completion	   any	  
activity	   requiring	   ≤	   2	  
metabolic	   equivalents,	  
eg,	   shower	   without	  
stopping,	   strip	   and	  
make	   bed,	   clean	  
windows,	   walk	   2.5	  
mph,	   bowl,	   play	   golf,	  
dress	  without	  stopping,	  
but	   cannot	   and	  do	  not	  
perform	   to	   completion	  
any	   activities	   requiring	  
>	   5	   metabolic	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equivalents.	  
IV	   Patient	   with	   cardiac	  
disease	   resulting	   in	  
inability	   to	   carry	   on	  
any	   physical	   activity	  
without	   discomfort.	  
Symptoms	   of	   cardiac	  
insufficiency	   or	   of	   the	  
anginal	   syndrome	  
may	   be	   present	   even	  
at	  rest.	   If	  any	  physical	  
activity	   is	   undertaken,	  
discomfort	   is	  
increased.	  
Inability	   to	   carry	   on	   any	  
physical	   activity	   without	  
discomfort	   -­‐	   anginal	  
syndrome	   may	   be	   present	  
at	  rest.	  
Patients	   cannot	   or	   do	  
not	   perform	   to	  
completion	   activities	  
requiring	  >	  2	  metabolic	  
equivalents.	   Cannot	  
carry	   out	   activities	  
listed	   above	   (Specific	  
activity	  scale	  III).	  
	  
	  
• In	  a	  retrospective	  study	  of	  144	  symptomatic	  patients,	  survival	  at	  three	  years	  
was	  87	  %	  in	  125	  who	  underwent	  valve	  replacement	  compared	  to	  21	  %	  in	  19	  
nonoperated	  patients	  (10).	  
	  
A	   problem	   with	   such	   retrospective	   observational	   studies	   is	   that	   the	   better	  
outcomes	   with	   surgery	   in	   symptomatic	   AS	   could	   represent	   selection	   bias	   (ie,	  
healthier	   patients	   are	   chosen	   for	   surgery).	   Nevertheless,	   it	   is	   generally	  
recommended	  that	  virtually	  all	  symptomatic	  patients	  with	  severe	  AS	  should	  undergo	  
aortic	  valve	  replacement.	  A	  possible	  exception	  is	  the	  rare	  patient	  with	  end-­‐stage	  left	  
ventricular	  dysfunction	  that	  is	  usually	  due	  to	  coexisting	  coronary	  disease.	  
	  
Operative	   mortality	   (in-­‐hospital	   regardless	   of	   timing	   and	   30-­‐day	   regardless	   of	  
location)	  for	  aortic	  valve	  replacement	  (for	  any	   indication)	  with	  or	  without	  coronary	  
artery	   bypass	   graft	   surgery	   (CABG)	   was	   reported	   for	   2002	   to	   2006	   data	   from	   the	  
Society	  of	  Thoracic	  Surgeons	  (STS)	  National	  Cardiac	  Surgery	  Database	  (58):	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• For	  isolated	  aortic	  valve	  replacement,	  the	  operative	  mortality	  rate	  was	  3.2	  %.	  
Adverse	   event	   rates	   ranged	   from	  1.5	  %	   for	   stroke	   to	   10.9	  %	   for	   prolonged	  
ventilations.	  
• Combined	  aortic	  valve	  replacement	  and	  coronary	  artery	  bypass	  graft	  surgery	  
(CABG)	  is	  associated	  with	  higher	  operative	  mortality	  and	  adverse	  event	  rates	  
than	   isolated	   aortic	   valve	   replacement.	   Mortality	   was	   5.6	   %	   and	   adverse	  
event	  rates	  ranged	  from	  2.7	  %	  for	  stroke	  to	  17.6	  %	  for	  prolonged	  ventilation.	  
	  
A	   variety	  of	   factors	   affect	   survival	   after	   aortic	   valve	   replacement	   for	  AS.	   These	  
include	  patient	  age,	  left	  ventricular	  function	  and	  New	  York	  Heart	  Association	  (NYHA)	  
functional	  class,	  the	  presence	  of	  low	  gradient	  disease,	  and	  the	  volume	  of	  procedures	  
performed	  at	  the	  hospital.	   In	  addition,	  the	  in-­‐hospital	  outcome	  is	  worse	  in	  patients	  






Aortic	  valve	  replacement	  is	  performed	  in	  patients	  with	  a	  wide	  age	  range,	  but	  the	  
proportion	  of	  elderly	  patients	  undergoing	  this	  procedure	   is	   increasing.	  Age	   is	  not	  a	  
critical	   factor	   for	   outcome,	   as	   older	   patients	   generally	   tolerate	   valve	   replacement	  
surgery	  well.	  As	  an	  example,	  a	  retrospective	  review	  of	  1100	  patients	  ≥80	  years	  of	  age	  
reported	   a	   30-­‐day	   and	   all-­‐cause	  mortality	   of	   4.0	   and	   6.6	  %	   (61).	   After	   the	   first	   30	  
postoperative	  days,	  70	  %	  of	  deaths	  were	  due	  to	  noncardiac	  causes.	  Actuarial	  survival	  
at	  one	  and	  five	  years	  was	  89	  and	  69	  %,	  respectively.	  	  
	  
The	   impact	   of	   age	   and	   other	   risk	   factors	   on	   survival	   after	   aortic	   valve	  
replacement	  was	  analyzed	  in	  another	  study	  of	  2359	  patients	  who	  underwent	  a	  first	  
valve	   replacement,	   39	   %	   of	   whom	   had	   concomitant	   coronary	   artery	   bypass	   graft	  
(CABG)	   surgery	   (42).	  Mortality	  within	   30	  days	   of	   surgery	  was	   5.6	  %.	   The	  observed	  
survival	  at	  5,	  10,	  and	  15	  years	  was	  83,	  63,	  and	  46	  %,	  respectively.	  During	  each	  of	  the	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first	   12	   years	   of	   follow-­‐up,	   the	  mortality	  was	   higher	   than	   expected	   in	   a	   reference	  






Factors	   associated	  with	  mortality	   included	   advanced	   NYHA	   functional	   class	  
(III	  or	   IV)	  and	  preoperative	  atrial	   fibrillation.	  Patients	   in	  the	  oldest	  age	  group	  had	  a	  
decreased	  observed	  survival,	  but	  an	  excellent	   relative	   survival,	   suggesting	   that	  age	  






Among	  2227	  patients	  undergoing	  aortic	  valve	  replacement	  who	  survived	  the	  first	  
postoperative	   month,	   the	   observed	   long-­‐term	   mortality	   (open	   blue	   circles)	   is	  
higher	  during	  the	  entire	  follow-­‐up	  period	  when	  compared	  to	  that	  expected	  in	  the	  
general	  population	  (closed	  red	  circles).	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• LEFT	  VENTRICULAR	  FUNCTION	  
	  
The	  outcome	  of	  surgery	  is	  in	  part	  dependent	  upon	  the	  state	  of	  left	  ventricular	  
(LV)	  function,	  as	  both	  systolic	  and	  diastolic	  dysfunction	  are	  independent	  risk	  factors	  
for	   early	   and	   late	   mortality	   (62).	   The	   results	   of	   valve	   replacement	   are	   similar	   in	  
patients	   with	   normal	   ventricular	   function	   and	   those	   with	   modest	   depression	   of	  
contractility	  (ie,	   left	  ventricular	  ejection	  fraction	  [LVEF]	  between	  40	  and	  50	  %).	  The	  
depressed	   ejection	   fraction	   in	   many,	   if	   not	   most,	   patients	   is	   caused	   by	   excessive	  
afterload	  that	  is	  immediately	  corrected	  by	  valve	  replacement.	  Diastolic	  asynchrony	  is	  
normalized	  later	  when	  hypertrophy	  and	  fibrosis	  regress	  (63).	  
	  
In	  comparison,	  patients	  with	  severely	  depressed	  ventricular	  function	  (ie,	  LVEF	  of	  
20	   to	   35	   %)	   may	   not	   experience	   complete	   resolution	   of	   symptoms	   after	   valve	  
replacement.	  However,	  survival	  is	  still	  improved	  in	  this	  setting.	  This	  was	  illustrated	  in	  
a	   report	   of	   154	   patients	   with	   an	   LVEF	   ≤35	   %	   who	   underwent	   aortic	   valve	  
replacement;	  simultaneous	  CABG	  was	  performed	  in	  51	  %.	  The	  following	  results	  were	  
noted	  (41):	  
	  
• Thirty	   day	   mortality	   was	   9	   %;	   multivariate	   analysis	   identified	   significant	  
coronary	  disease	  (≥two	  vessel	  or	  left	  main)	  as	  the	  only	  predictor	  of	  mortality.	  
• Five	   year	   survival	   was	   58	   %;	   multivariate	   analysis	   indicated	   that	   the	   only	  
predictors	   of	   mortality	   were	   significant	   coronary	   disease	   and	   a	   lower	  
preoperative	  cardiac	  output.	  
• NYHA	   functional	   classification	   improved	   by	   at	   least	   one	   class	   in	   88	   %	   of	  
patients	   and	   by	   two	   or	   more	   classes	   in	   66	   %;	   an	   improvement	   in	   LVEF	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• LOW	  GRADIENT	  AORTIC	  STENOSIS	  
	  
Patients	   with	   AS	   and	   left	   ventricular	   dysfunction	   may	   have	   a	   low	  
transvalvular	  pressure	  gradient	  despite	  significant	  valve	  narrowing.	  Such	  patients	  are	  
said	  to	  have	  low	  gradient	  AS,	  which	  is	  defined	  as	  a	  transaortic	  pressure	  gradient	  of	  
less	   than	  30	  mmHg	  and	  a	  calculated	  aortic	  valve	  area	  <1.0	  cm2	  in	  association	  with	  
low	  flow.	  
	  
Some	   patients	   with	   low	   gradient	   AS	   have	   true	   severe	   AS,	   whereas	   others	  
have	   "pseudostenosis,"	   with	   a	   low	   transvalvular	   pressure	   gradient	   because	   of	   the	  
combination	  of	  moderate	  AS	  and	   low	  cardiac	  output.	  The	  distinction	  between	  true	  
stenosis	   and	   pseudostenosis	   is	   made	   by	   evaluation	   of	   characteristic	   changes	   in	  
hemodynamic	   and	   structural	   measurements	   in	   response	   to	   pharmacologic	  
interventions	  that	  augment	  cardiac	  output.	  	  
	  
Patients	   with	   low	   gradient	   true	   AS	   have	   a	   high	   perioperative	   and	  
postoperative	  mortality.	  Nonetheless,	  surgery	  is	  still	  recommended	  in	  most	  patients	  
because	   valve	   replacement	   is	   associated	   with	   better	   outcomes	   than	   continued	  
medical	   therapy	   (45).	   Stress	  echocardiography	   is	   helpful	   in	   risk	   stratifying	   patients	  
with	   severe	   true	   AS	   and	   in	   determining	   the	   appropriate	   therapy.	   Patients	   with	  




ASYMPTOMATIC	  SEVERE	  AORTIC	  STENOSIS	  
	  
With	   infrequent	   exceptions,	   such	   as	   patients	   undergoing	   coronary	   artery	  
bypass	   graft	   surgery	   or	   surgery	   on	   the	   aorta	   or	   other	   heart	   valves,	   the	   2006	  
ACC/AHA	   guidelines	   on	   the	  management	   of	   valvular	   heart	   disease	   concluded	   that	  
valve	   replacement	   should	   not	   be	   routinely	   performed	   for	   isolated	   severe	   AS	   in	  
asymptomatic	  patients	  (13).	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On	   the	   other	   hand,	   careful	   monitoring	   is	   required	   since	   asymptomatic	  
patients	  with	  severe	  AS	  have	  a	  low	  rate	  of	  survival	  free	  from	  valve	  replacement	  (56	  
to	  63	  %	  at	  two	  years	  and	  25	  to	  33	  %	  at	  four	  to	  five	  years	  in	  two	  studies)	  (19,25).	  This	  
is	   associated	   with	   a	   progressive	   reduction	   in	   aortic	   valve	   area	   that	   averages	   0.1	  
cm2/year	   and	   a	   progressive	   increase	   in	   aortic	   jet	   velocity	   that	   averages	   0.3	  m/sec	  
per	   year.	   Risk	   factors	   for	   progression	   include	   small	   valve	   area,	   left	   ventricular	  
hypertrophy,	  and	  moderate	  to	  severe	  valve	  calcification.	  	  
	  
Outcomes	  worsen	  as	  AS	  progresses	  and	  a	  markedly	  elevated	  peak	  aortic	   jet	  
velocity	  (>5.0	  or	  5.5	  m/s)	  is	  an	  independent	  predictor	  of	  cardiac	  mortality	  (20,64).	  	  
	  
	  
• SURGICAL	  VERSUS	  MEDICAL	  THERAPY	  
	  
Consideration	  of	  surgery	  in	  an	  asymptomatic	  patient	  with	  severe	  AS	  requires	  
an	   appreciation	   of	   the	   relative	   risks	   of	   surgical	   and	  medical	   therapy.	   The	   surgical	  
mortality	  of	  aortic	  valve	  replacement	  varies	  widely.	   If	   it	   is	  not	  well	  under	  2	  to	  3	  %,	  
then	  the	  operative	  risk	  clearly	  exceeds	  the	  risk	  of	  sudden	  death	  in	  an	  asymptomatic	  
patient	  who	   does	   not	   undergo	   surgery.	   Furthermore,	   valve	   replacement	   does	   not	  
abolish	   the	   risk	   of	   sudden	   death.	   In	   one	   report	   that	   retrospectively	   analyzed	   the	  
postoperative	  course	  of	  599	  patients,	   the	   late	  annual	  mortality	  was	  3.6	  %;	   sudden	  
death	  accounted	  for	  24	  %	  of	  these	  deaths	  (65).	  
	  
Insertion	   of	   a	   prosthetic	   heart	   valve	   is	   also	   associated	   with	   appreciable	  
morbidity.	   Among	   the	   complications	   of	   prosthetic	   heart	   valves	   are	   prosthesis	  
dysfunction,	  paravalvular	  leak,	  thrombus	  formation,	  arterial	  embolism,	  endocarditis,	  
and	   the	   problems	   associated	   with	   anticoagulation.	   The	   incidence	   of	   serious	  
complications	  depends	  upon	  the	  type	  of	  valve	  and	  a	  number	  of	  clinical	  variables,	  but	  
significant	  complications	  occur	  at	  a	  frequency	  of	  at	  least	  3	  %	  per	  year,	  and	  death	  due	  
directly	  to	  the	  valve	  occurs	  at	  the	  rate	  of	  approximately	  1	  %	  per	  year	  (57,65).	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• VERY	  SEVERE	  AORTIC	  STENOSIS	  
	  
Improved	  outcomes	  with	  aortic	  valve	  replacement	  in	  patients	  with	  asymptomatic	  
very	  severe	  AS	  were	  suggested	  by	  an	  observational	  study	  (64).	  Very	  severe	  AS	  was	  
defined	   as	   an	   aortic	   valve	   area	   of	   ≤0.75	   cm2	  (critical	   AS)	   accompanied	   by	   a	   peak	  
aortic	   jet	   velocity	   ≥4.5	  m/sec	   or	   a	  mean	   transaortic	   pressure	   gradient	   ≥50	  mmHg.	  
Early	  surgery	  was	  performed	  on	  102	  patients	  and	  a	  conventional	  treatment	  strategy	  
(surgery	  for	  symptomatic	  AS)	  was	  followed	  in	  95	  patients.	  
• During	  a	  median	   four	  year	   follow-­‐up,	   the	  operated	  group	  had	  no	  operative	  
mortalities,	   no	   cardiac	   deaths,	   and	   three	   noncardiac	   deaths	   while	   the	  
conventional	  treatment	  group	  had	  18	  cardiac	  and	  10	  noncardiac	  deaths.	  
• For	   57	   propensity	   score-­‐matched	   pairs,	   the	   risk	   of	   all-­‐cause	   mortality	   was	  
significantly	  lower	  in	  the	  operated	  group	  than	  in	  the	  conventional	  treatment	  
group	  (HR,	  0.135,	  95%	  CI,	  0.030	  to	  0.597).	  
	  
The	  results	  suggest	  that	  early	  surgery	  can	  be	  beneficial	  in	  patients	  with	  very	  severe	  
AS	  with	  low	  operative	  risk.	  	  
	  
	  
AORTIC	  VALVE	  REPLACEMENT	  AND	  CORONARY	  ARTERY	  BYPASS	  GRAFT	  
	  
There	   are	   two	   settings	   in	   which	   aortic	   valve	   replacement	   and	   coronary	   artery	  
bypass	  graft	  surgery	  (CABG)	  intersect:	  
• Patients	  who	  are	  candidates	  for	  aortic	  valve	  replacement	  in	  whom	  coronary	  
angiography	  demonstrates	   significant	   coronary	  artery	  disease	   that	   could	  be	  
corrected	  at	  the	  time	  of	  valve	  replacement.	  The	  role	  of	  coronary	  angiography	  
prior	  to	  surgery	  and	  the	  indications	  for	  concurrent	  CABG	  at	  the	  time	  of	  aortic	  
valve	  replacement	  issue	  will	  be	  reviewed	  here.	  
• Patients	   who	   are	   candidates	   for	   CABG	   who	   also	   have	   AS	   that	   might	   be	  
corrected	  at	  the	  same	  surgery.	  This	  issue	  is	  discussed	  separately.	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Despite	   the	   limited	   indications	   for	   cardiac	   catheterization	   to	   assess	   the	   valve	  
disease,	   most	   patients	   require	   coronary	   angiography	   before	   aortic	   valve	  
replacement	  because	  significant	  coronary	  disease	  is	  common	  in	  these	  patients,	  and	  
about	   40	   %	   of	   those	   undergoing	   valve	   replacement	   require	   concurrent	   coronary	  
bypass	  grafting	  (42).	  
	  
Most	  of	  these	  patients	  have	  angina,	  but	  this	  symptom	  can	  also	  be	  induced	  by	  AS	  
alone.	   Thus,	   symptoms	   do	   not	   predict	   the	   presence	   or	   absence	   of	   concurrent	  
coronary	  disease	  and	  the	  ECG	  and	  noninvasive	  stress	  testing	  may	  be	  nondiagnostic.	  
To	  sum	  up,	  the	  likelihood	  of	  coronary	  disease	  increases	  with	  age.	  	  
	  
The	   2006	   ACC/AHA	   and	   the	   2007	   ESC	   guidelines	   on	   the	   management	   of	   valvular	  
heart	   disease	   recommended	   coronary	   angiography	   before	   aortic	   valve	   surgery	   in	  
three	  settings	  if	  they	  are	  not	  severely	  hemodynamically	  unstable	  (table	  5)	  (13):	  
• Patients	  with	  chest	  pain,	  other	  objective	  evidence	  of	  ischemia	  or	  a	  history	  of	  
coronary	  disease.	  
• In	  patients	  at	  risk	  for	  coronary	  disease,	  which	  was	  defined	  as	  men	  ≥35	  years	  
of	   age,	   premenopausal	   women	   ≥35	   years	   of	   age	   who	   have	   coronary	   risk	  
factors,	  and	  postmenopausal	  women.	  
• When	   a	   pulmonary	   autograft	   (Ross	   procedure)	   is	   considered	   in	   patients	   in	  
whom	  the	  origin	  of	   the	  coronary	  arteries	  was	  not	   identified	  by	  noninvasive	  
testing.	  
	  
Table	  5.	  ACC/AHA	  guideline	   summary:	  Coronary	  angiography	   to	  diagnose	   coronary	  
artery	  disease	  in	  patients	  with	  valvular	  disease	  
	  
Class	   I	   -­‐	   There	   is	   evidence	   and/or	   general	   agreement	   that	   coronary	   angiography	  
should	  be	  performed	  in	  patients	  with	  valvular	  disease	  in	  the	  following	  settings	  
•	  	   Before	   valve	   surgery	   (including	   for	   infective	   endocarditis)	   in	   patients	   with	   chest	  
pain	  (although	  angina	   is	  a	  poor	  marker	   for	  coronary	  disease	   in	  patients	  with	  aortic	  
stenosis),	  other	  objective	  evidence	  of	  ischemia,	  or	  a	  history	  of	  coronary	  disease.	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•	  	  Before	  valve	   surgery	   in	  patients	  at	   risk	   for	   coronary	  disease	  defined	  as	  men	  ≥35	  
years	   of	   age,	   premenopausal	   women	   ≥35	   years	   of	   age	   who	   have	   coronary	   risk	  
factors,	  and	  postmenopausal	  women.	  Patients	  undergoing	  mitral	  balloon	  valvotomy	  
do	  not	  require	  coronary	  angiography	  solely	  on	  the	  basis	  of	  coronary	  risk	  factors.	  
•	  	  In	  patients	  with	  apparently	  mild	  to	  moderate	  valve	  disease	  who	  have	  progressive	  
angina,	  objective	  evidence	  of	   ischemia,	  or	  either	  asymptomatic	  or	  symptomatic	   left	  
ventricular	  dysfunction.	  
•	  	  When	  a	  pulmonary	  autograft	  (Ross	  procedure)	  is	  considered	  in	  patients	  with	  aortic	  
stenosis	   or	   in	   adolescents	   or	   young	   adults	   with	   aortic	   regurgitation	   in	   whom	   the	  
origin	  of	  the	  coronary	  arteries	  was	  not	  identified	  by	  noninvasive	  testing.	  
Class	   IIa	  -­‐	  The	  weight	  of	  evidence	  or	  opinion	   is	   in	  favor	  of	  the	  usefulness	  of	  surgery	  
without	  coronary	  angiography	  in	  patients	  with	  valve	  disease	  in	  the	  following	  setting	  
•	  	  Before	  emergency	  valve	  surgery	  for	  acute	  valve	  regurgitation,	  aortic	  root	  disease,	  
or	  infective	  endocarditis.	  
Class	  IIb	  -­‐	  The	  weight	  of	  evidence	  or	  opinion	  is	  less	  well	  established	  for	  the	  usefulness	  
of	  coronary	  angiography	  in	  patients	  with	  valve	  disease	  in	  the	  following	  setting	  
•	  	  Patients	   in	  whom	  cardiac	  catheterization	   is	  performed	   to	  confirm	   the	   severity	  of	  
valve	   lesions	   before	   valve	   surgery	  who	   do	   not	   have	   a	   history	   of	   coronary	   disease,	  
multiple	  coronary	  risk	  factors,	  or	  advanced	  age.	  
Class	  III	  -­‐	  There	  is	  evidence	  and/or	  general	  agreement	  that	  coronary	  angiography	  in	  
patients	  with	  valve	  disease	  is	  NOT	  useful	  in	  in	  the	  following	  settings	  
•	  	   Young	   patients	   undergoing	   nonemergent	   valve	   surgery	   who	   have	   no	   need	   for	  
further	   hemodynamic	   assessment	   by	   cardiac	   catheterization	   who	   do	   not	   have	   a	  
history	  of	  coronary	  disease,	  multiple	  coronary	  risk	  factors,	  or	  advanced	  age.	  
•	  	  Before	  valve	  surgery	  in	  patients	  who	  are	  severely	  hemodynamically	  unstable.	  
	  
	  
On	  the	  other	  hand,	  the	  2006	  ACC/AHA	  guidelines	  reached	  the	  following	  conclusions	  
about	  CABG	  at	  the	  time	  of	  aortic	  valve	  replacement	  (13):	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• CABG	  was	  recommended	   in	  patients	  with	  ≥70	  %	  stenosis	  of	  major	  coronary	  
arteries.	  
• Among	  patients	  undergoing	  CABG,	   the	  weight	  of	  evidence	   favored	  use	  of	  a	  
left	   internal	   mammary	   artery	   graft	   for	   ≥50	   to	   70	   %	   stenosis	   left	   anterior	  
descending	  coronary	  artery.	  
• CABG	   was	   considered	   reasonable	   in	   patients	   with	   50	   to	   70	   %	   stenosis	   of	  
major	  coronary	  arteries.	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4.	  Current	  non-­‐medical	  treatment	  options	  for	  aortic	  stenosis	  
	  
	  
SURGICAL	  AORTIC	  VALVE	  REPLACEMENT	  
	  
Aortic	  valve	  replacement	  (AVR)	   is	   the	  only	  effective	  treatment	  considered	  a	  
Class	   I	   recommendation	   by	   ACCF/AHA	   and	   ESC	   guidelines	   in	   adults	   with	   severe	  
symptomatic	   AS	   (13,14).	   Not	   only	   does	   it	   offer	   symptomatic	   relief,	   the	   operation	  
improves	   long-­‐term	   survival.	   Since	   1960,	   when	   AVR	   was	   first	   introduced,	  
advancement	  in	  prosthetic	  technology	  including	  improved	  hemodynamics,	  durability	  
and	   thromboresistance,	   and	   techniques	   in	   cardiac	   surgery	   such	   as	   cardioplegia,	  
management	   of	   the	   small	   aortic	   root,	   resection	   of	   associated	   subvalvular	   disease,	  
and	   replacement	   of	   associated	   aortic	   aneurysm	   have	   resulted	   in	   improvements	   in	  
both	  operative	  and	  long-­‐term	  results.	  
	  
Current	   AVR	   options	   include	   mechanical,	   bioprosthetic,	   and	   in	   specific	  
situations	   homograft	   and	   autograft	   techniques.	   Each	   has	   their	   advantages	   and	  
drawbacks,	  but	  the	  trend	  in	  some	  centers	  in	  the	  recent	  era	  has	  been	  toward	  tissue	  
valve	  replacement	  in	  a	  majority	  of	  patients	  because	  of	   improved	  durability	  and	  the	  
lack	  of	  requirement	  for	  anticoagulation	  therapy.	  
	  
	  
• MECHANICAL	  VALVES	  
	  
Mechanical	   valves	   are	   now	   extremely	   durable,	   have	   excellent	  
hemodynamics,	   and	   are	   minimally	   thrombogenic	   with	   adequate	   anticoagulation.	  
Current	   anticoagulation	   is	   mostly	   based	   on	   Vitamin	   K	   antagonists.	   Newer	   agents	  
such	  as	  oral	  direct	  thrombin	  inhibitors	  and	  factor	  Xa	  inhibitors	  have	  been	  studied	  in	  
other	   patient	   populations,	   mainly	   atrial	   fibrillation,	   and	   have	   been	   found	   to	   be	  
associated	  with	  decreased	  bleeding	  risk	  and	  minimum	  drug	  or	  food	  interaction	  (43).	  
With	   acenocumarol	   there	   is	   a	   risk	   of	   serious	   thromboembolism	   of	   approximately	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0.5%	  a	  year	  and	  a	  similar	  risk	  of	  major	  hemorrhage	  annually	  (66).	  Mechanical	  valves	  
are	  typically	  preferred	  in	  younger	  patients	  given	  their	  reliable	  long-­‐term	  durability.	  
	  
	  
• BIOPROSTHETIC	  VALVES	  
	  
Compared	   with	   mechanical	   valves,	   bioprosthetic	   valves	   do	   not	   require	  
anticoagulation	   with	   acenocumarol,	   and	   thus	   have	   a	   lower	   risk	   of	   bleeding.	  
However,	   long-­‐term	   durability	   varies	   substantially	   with	   age	   for	   these	   valves.	  
Structural	   valve	   degeneration	   leading	   to	   symptoms	   or	   reoperation,	   commonly	  
associated	  with	  calcification	  of	  the	  biologic	  leaflets,	  occurs	  at	  an	  average	  of	  10	  to	  12	  
years	   in	   younger	   patients	   and	   15	   to	   18	   years	   in	   older	   patients.	   Actuarial	   freedom	  
from	   reoperation	   following	   implant	   of	   a	   modern	   bioprosthetic	   valves	   is	  
approximately	  95%	  at	  5	  years,	  90%	  at	  10	  years,	  but	  drops	  to	  70%	  at	  15	  years	   (67).	  
Thus,	  bioprosthetic	  valves	  are	  generally	  preferred	  in	  older	  patients	  who	  are	  unlikely	  
to	   tolerate	  bleeding	   risk	  associated	  with	  anticoagulation	   treatment	  and	   in	  whom	  a	  
15-­‐year	  durability	  is	  reason-­‐	  able.	  In	  patients	  with	  bioprosthetic	  valves,	  if	  prosthetic	  





Both	   mechanical	   and	   bioprosthetic	   valves	   have	   been	   used	   for	   aortic	   valve	  
replacement	  (AVR).	  Issues	  to	  consider	  when	  choosing	  the	  appropriate	  valve	  include	  
(68):	  
	  
- Mechanical	  valves	  are	  more	  durable.	  
- Mechanical	  valves	  require	  lifelong	  anticoagulation.	  
- Some	   biological	   aortic	   valve	   options	   are	   technically	   more	   challenging	   than	  
others	  (Ross	  procedure	  >	  aortic	  homografts	  >	  stentless	  AVR	  >	  stented	  AVR)	  
- Stented	  tissue	  valves	  are	  associated	  with	  smaller	  effective	  orifice	  areas	  (EOA)	  
than	   stentless	   tissue	   valves,	   due	   to	   the	   space	   occupied	   by	   the	   supporting	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stents.	   This	   can	   be	   particularly	   important	   in	   patients	   with	   a	   small	   aortic	  
annulus	  who	  are	  a	  risk	  for	  patient-­‐prosthesis	  mismatch.	  
- Tissue	   valves	   have	   a	   low	   risk	   for	   thromboembolism,	   and	   do	   not	   require	  
lifelong	  anticoagulation.	  
- Although	   observations	   have	   varied,	   infection	   generally	   occurs	   with	   equal	  
frequency	   on	   mechanical	   and	   bioprosthetic	   devices	   during	   the	   first	  
postoperative	  year	  
- Reoperations	  after	   certain	  biological	   valves	   (eg,	  homografts)	   are	   technically	  
more	  challenging	  than	  after	  implantation	  of	  standard	  bioprosthetic	  valves.	  
	  
The	  2006	  American	  College	  of	  Cardiology/American	  Heart	  Association	  (ACC/AHA)	  
and	  the	  2007	  European	  Society	  of	  Cardiology	  (ESC)	  guidelines	  for	  the	  management	  
of	   valvular	   heart	   disease	   guidelines	  made	   the	   following	   general	   recommendations	  
for	   the	   choice	   of	   aortic	   valve,	   recognizing	   that	   patient	   preference	  may	   also	   play	   a	  
role	  (13,14):	  
	  
- A	   mechanical	   valve	   is	   recommended	   in	   patients	   who	   already	   have	   a	  
mechanical	   valve	   in	   the	  mitral	   or	   tricuspid	   position	   (and	   therefore	   already	  
need	  anticoagulation).	  
- A	   mechanical	   valve	   is	   reasonable	   (a	   weaker	   recommendation)	   in	   patients	  
under	  65	  years	  of	  age	  who	  do	  not	  have	  a	  contraindication	  to	  anticoagulation.	  
- A	  bioprosthesis	   is	  recommended	  in	  patients	  of	  any	  age	  who	  will	  not	  take	  or	  
have	  major	  contraindications	  to	  anticoagulation	  therapy.	  
- A	  bioprosthesis	   is	   reasonable	   in	  patients	  ≥65	  years	  of	  age	  who	  do	  not	  have	  
risk	  factors	  for	  thromboembolism	  and	  in	  patients	  under	  age	  65	  who	  choose	  
this	   approach	   for	   lifestyle	   reasons	   after	   a	   detailed	   review	   of	   the	   risks	   of	  
anticoagulation	  compared	  to	  the	  greater	  likelihood	  of	  a	  second	  valve	  surgery	  
in	  the	  future.	  
- Valve	  re-­‐replacement	  with	  a	  homograft	  is	  reasonable	  in	  patients	  with	  active	  
prosthetic	  valve	  endocarditis.	  
- The	   evidence	   was	   considered	   less	   well	   established	   for	   a	   bioprosthesis	   in	  
women	  of	  childbearing	  age.	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- A	  mechanical	  valve	  may	  be	  recommended	  for	  patients	  with	  small	  aortic	  roots	  
in	  whom	  annular	  enlargement	  is	  high	  risk	  or	  contraindicated.	  
	  
	  
• PATIENTS	  <	  65	  YEARS	  OF	  AGE	  
	  
Given	   the	   similar	   survival	  with	  both	   valve	   types,	   these	   findings	  emphasize	   that	  
valve	  choice	  in	  adults	  <65	  years	  of	  age	  should	  take	  patient	  preferences	  into	  account,	  
specifically	  regarding	  the	  likelihood	  of	  repeat	  valve	  surgery	  versus	  need	  for	  long	  term	  




• ELDERLY	  PATIENTS	  
	  
There	   is	  a	  particular	  preference	  for	  a	  bioprosthetic	  valve	   in	  elderly	  patients,	  
which	   is	   based	   in	   part	   upon	   the	   observation	   that	   the	   longevity	   of	   these	   valves	   is	  
inversely	   related	   to	   age	   (68,69).	   The	   actuarial	   estimate	   of	   the	   rate	   of	   structural	  
deterioration	  of	   bioprosthetic	   aortic	   valves	   at	   15	   years	   varied	   from	  63	  %	  between	  
the	  ages	  of	  40	  and	  49	  (and	  perhaps	  higher	  under	  age	  40)	  to	  10	  %	  over	  age	  70	  (68).	  
The	   lower	  rate	  of	  valve	  failure	   in	  elderly	  adults	   is	  due	  at	   least	   in	  part	  to	  decreased	  
activity	  in	  older	  patients.	  The	  net	  effect	  is	  that	  the	  life	  expectancy	  of	  an	  octogenarian	  
is	  shorter	  than	  the	  expected	  functional	  life	  of	  a	  bioprosthesis.	  
	  
	  
• PRE-­‐EXISTING	  CORONARY	  ARTERY	  BYPASS	  GRAFTS	  
	  
The	  morbidity	  and	  mortality	  associated	  with	  valve	  reoperation	  may	  be	  higher	  
in	   some	   patient	   populations,	   such	   as	   those	   with	   coronary	   artery	   bypass	   grafts.	  
Retrospective	  data	   indicate	   that	  operative	  mortality	   rates	   are	  high	   for	   aortic	   valve	  
replacement	   with	   pre-­‐existing	   coronary	   artery	   bypass	   grafts	   (and	   higher	   than	   for	  
combined	   aortic	   valve	   and	   bypass	   graft	   surgery)	   (70).	   In	   the	   presence	   of	   a	   patent	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internal	  mammary	  artery	   (IMA)	  graft,	   aortic	   valve	   surgery	  poses	  a	  potential	   risk	  of	  
IMA	  graft	   injury	   and	  myocardial	   infarction	   (46).	   The	   increased	   risk	   associated	  with	  
valve	   reoperation	   should	   be	   considered	   in	   choosing	   a	   valve	   for	   a	   patient	   with	  





Homograft	   aortic	   valves	   are	  most	   often	   used	   for	   treatment	   of	   endocarditis	  
because	  the	  homograft	  is	  supplied	  as	  a	  composite	  valve,	  aortic	  root,	  and	  part	  of	  the	  
anterior	  mitral	   leaflet.	   This	   additional	   tissue	  may	  be	  used	   to	   reconstruct	   the	  areas	  
adjacent	  to	  the	  valve,	  which	  can	  be	  of	  particular	  value	  if	  the	  infection	  has	  extended	  
into	  the	  annulus,	  basal	  septum,	  or	  base	  of	  the	  mitral	  valve.	  Otherwise,	  homografts	  
do	  not	  have	  any	   specific	   advantages,	   compared	   to	  other	   tissue	   valves,	   in	   terms	  of	  
durability	  or	  resistance	  to	  infection.	  
	  A	   disadvantage	   of	   homograft	   valves	   is	   that	   fibrosis	   (involving	   the	   adjacent	  
pulmonary	   artery)	   and	   calcification	   (frequently	   involving	   the	   coronary	   button	  
reattachment)	   of	   the	   composite	   root	   and	   valve	  makes	   it	  more	  difficult	   to	  perform	  
repeat	  surgical	  intervention,	  which	  often	  is	  needed	  on	  long	  term	  follow-­‐up.	  
	  
	  
• PULMONARY	  AUTOGRAFT	  (ROSS	  PROCEDURE)	  
	  
The	  Ross	  procedure	  is	  an	  alternative	  to	  valve	  replacement	  with	  a	  mechanical	  
valve	  or	  bioprosthesis.	   It	   involve	   replacing	   the	  aortic	   valve	  with	  a	  pulmonary	  valve	  
autograft	  and	  right-­‐sided	  reconstruction	  with	  an	  aortic	  or	  pulmonary	  homograft	  (71).	  
Use	   of	   the	   Ross	   procedure	   has	   been	   limited	   because	   of	   its	   technical	   complexity,	  
complications	  with	  both	  the	  aortic	  autograft	  and	  the	  pulmonic	  homograft,	  and	  the	  
availability	   of	   simpler	   and	   effective	   alternatives,	   ie,	   mechanical	   valves	   and	  
bioprostheses	  including	  stentless	  bioprosthetic	  valves.	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There	  are	  a	  number	  of	  potential	  advantages	  of	  the	  Ross	  procedure	  (71,72):	  
- Autologous	  tissue	  with	  documented	  long-­‐term	  viability	  
- Optimal	  hemodynamic	  data	  
- Regeneration	  capacity	  
- Possible	  resistance	  to	  infection	  (eg,	  0.2	  to	  0.3	  %/patient	  year	  as	  compared	  to	  
>0.4	  %/patient	  year	  for	  recipients	  of	  prosthetic	  valves).	  
- Lack	  of	  valve	  noise	  
- Freedom	  from	  anticoagulation	  due	  to	  rates	  of	  thromboembolic	  complications	  
ranging	  from	  0	  to	  up	  to	  1.2	  %	  per	  year	  
	  
Strong	   relative	   contraindications	   to	   the	   Ross	   procedure	   include	   the	   following	  
(72):	  
- Advanced	  three	  vessel	  coronary	  disease	  
- Other	  extensive	  valve	  pathology	  requiring	  replacement	  
- Severely	  depressed	  left	  ventricular	  function	  
- Multisystem	  organ	  failure	  
- Pulmonary	  valve	  pathology	  
- Marfan	  syndrome	  or	  other	  connective	  tissue	  disorders	  
- Size	  mismatch	  between	  the	  pulmonic	  and	  aortic	  annulus	  
	  
The	  Ross	  procedure	  has	  been	  used	  most	  successfully	  in	  children	  and	  adolescents,	  
but	   has	   also	   been	   performed	   in	   adults	   less	   than	   50	   years	   of	   age	  with	   single	   valve	  
pathology,	   mechanical	   or	   bioprosthetic	   valve	   failure,	   endocarditis	   limited	   to	   the	  
aortic	   root,	   and	   athletes	   or	   young	   patients	   in	   whom	   anticoagulation	   is	  
contraindicated	  and	   for	  whom	  optimal	  hemodynamics	  are	  desired	   (eg,	  a	   female	  of	  
reproductive	  age).	  	  
	  
The	  pulmonary	  autograft	  in	  the	  aortic	  position	  provides	  excellent	  hemodynamics	  
at	   rest	   and	   with	   maximum	   exercise;	   however,	   there	   may	   be	   a	   moderately	   high	  
gradient	  across	  the	  homograft	  in	  the	  pulmonary	  valve	  position	  (73).	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A	   number	   of	   studies	   have	   noted	   good	   short-­‐term	   results	   with	   the	   Ross	  
procedure.	  In	  a	  meta-­‐analysis	  of	  39	  reports	  published	  from	  2000	  to	  2008,	  the	  pooled	  
early	   mortality	   rates	   for	   consecutive	   adult	   and	   pediatric	   series,	   adult	   series	   and	  
pediatric	  series	  were	  3.0,	  3.2	  and	  4.2	  %,	  respectively	   (74).	  However	  early	  mortality	  
rates	  varied	  from	  0.3	  to	  6.8	  %	  even	  among	  these	  selected	  centers.	  
	  
Longer	  term	  results	  suggest	  a	  high	  risk	  of	  reoperation	  (75–77):	  
	  
- At	  20	  years	  after	  operation	  in	  the	  pioneering	  series	  of	  131	  patients	  (age	  11	  to	  
52),	   survival	  was	  61	  %,	   freedom	   from	  autograft	   reoperation	  was	  75	  %,	  and	  
freedom	  from	  pulmonary	  homograft	  reoperation	  was	  80	  %.	  	  
- At	   16	   years	   after	   operation	   in	   a	   series	   of	   487	   patients	   (age	   2	   days	   to	   62	  
years),	   actuarial	   survival	   was	   82	   %,	   freedom	   from	   autograft	   failure	  
(reoperation	   and	   valve-­‐related	   death)	   was	   74	   %,	   and	   freedom	   from	  
pulmonary	   allograft	   reoperation	   was	   80	   %.	   Actuarial	   freedom	   from	   valve-­‐
related	   morbidity	   (includes	   autograft	   and	   pulmonary	   allograft	   failure,	  
endocarditis,	  and	  valve-­‐related	  death)	  was	  63	  %	  at	  16	  years.	  
	  
Use	   of	   the	  Ross	   procedure	   in	   adults	   is	   controversial	   and	   the	   procedure	   is	   only	  
performed	   at	   a	   few	   experienced	   centers.	   There	   may	   be	   more	   perioperative	  
complications	   since	   the	  surgery	   is	   longer	  and	  more	  complicated	   than	  simple	  aortic	  
valve	   replacement.	   Dilation	   of	   the	   pulmonic	   autograft	   with	   autograft	   failure	   is	   a	  
significant	   late	   complication	   associated	  with	   surgical	   technique	   in	   some	   series	   but	  
not	  others.	   Since	  patients	  with	  preoperative	  aortic	   regurgitation	  and	  dilated	  aortic	  
annulus	  are	  at	  risk	  for	  future	  dilation	  and	  failure	  of	  the	  pulmonary	  autograft,	  some	  
recommend	  avoidance	  of	  the	  Ross	  procedure	  in	  such	  patients.	  On	  the	  other	  hand	  ,	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AORTIC	  VALVOTOMY	  
	  
Aortic	  valve	  replacement	  is	  the	  mainstay	  of	  treatment	  of	  symptomatic	  aortic	  
stenosis	   (AS).	   Aortic	   valve	   replacement	   offers	   substantial	   improvements	   in	  
symptoms	  and	  life	  expectancy.	  However,	  aortic	  valve	  surgery	  entails	  substantial	  risks	  
for	  some	  patients	  with	  severe	  comorbidities,	  and	  for	  some	  considered	  at	  “extreme”	  
risk,	  surgery	   is	  not	  appropriate.	   In	  others,	   technical	   limitations,	  eg,	  porcelain	  aorta,	  
may	   mean	   that	   surgery	   is	   not	   feasible.	   Percutaneous	   aortic	   valvotomy	   was	  
developed	   as	   a	   less	   invasive	   means	   to	   treat	   AS	   but	   has	   important	   limitations.	  
Subsequently	   developed	   catheter-­‐based	   techniques	   for	   aortic	   valve	   implantation	  
may	   provide	   an	   alternative	   method	   for	   treating	   AS	   in	   patients	   with	   unacceptably	  
high	  estimated	  surgical	  risks.	  
	  
Percutaneous	  aortic	  balloon	  valvotomy	   is	  a	  procedure	   in	  which	  a	  balloon	   is	  
placed	   across	   the	   stenotic	   aortic	   valve	   and	   inflated	   (78).	   The	   aim	   is	   to	   relieve	   the	  
stenosis	   by	   fracturing	   calcific	   deposits	   within	   the	   valve	   leaflets.	   Stretching	   of	   the	  
annulus	  and	  separation	  of	  the	  calcified	  commissures	  also	  may	  contribute.	  
	  
There	   are	   a	   number	   of	   important	   limitations	   to	   the	   use	   of	   percutaneous	  
valvotomy	  (78–81):	  
	  
• Despite	  a	  moderate	  reduction	  in	  the	  transvalvular	  pressure	  gradient,	  which	  is	  
often	   accompanied	   by	   an	   improvement	   in	   symptoms,	   the	   postprocedure	  
valve	  area	  rarely	  exceeds	  1.0	  cm2,	  leaving	  the	  patient	  with	  persistent	  severe	  
AS.	  
• In	   historical	   series	   (79),	   serious	   complications	   (stroke,	   aortic	   regurgitation,	  
myocardial	   infarction,	   major	   access-­‐related	   complications)	   occurred	   in	  
approximately	   10	   to	   20	  %	  of	   patients.	   In-­‐hospital	  mortality	   rates	  were	   also	  
about	   10	   to	   20	  %.	   However,	   anecdotal	   experience	   suggests	   that	  morbidity	  
and	   mortality	   in	   contemporary	   practice	   is	   better	   than	   this	   due	   to	  
improvements	  in	  balloons	  and	  technique.	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• Restenosis	   and	   clinical	   deterioration	   occur	   in	   most	   cases	   within	   6	   to	   12	  
months,	   and	   the	   long-­‐term	   outcome	   resembles	   the	   natural	   history	   of	  
untreated	   AS.	   Repeat	   balloon	   valvotomy	   can	   be	   performed,	   but	   most	  
patients	  fail	  within	  six	  months.	  
	  
Given	   the	   limitations	  observed	  with	  aortic	  valvotomy,	   the	  2006	  ACC/AHA	  valve	  
disease	   guidelines	   (with	   2008	   update)	   concluded	   that	   balloon	   valvotomy	   is	   not	  a	  
substitute	   for	  valve	   replacement	   in	  adults,	  although	  selected	  young	  adults	  without	  
valve	   calcification	   may	   represent	   an	   exception	   (table	   6)	   (13).	   In	   addition,	   balloon	  
valvotomy	  is	  frequently	  used	  in	  children	  with	  valvular	  AS.	  
	  
Table	  6.	  2008	  ACC/AHA	  guideline	  summary:	  Balloon	  aortic	  valvotomy	  (BAV)	  for	  aortic	  
stenosis	  (AS)	  in	  adolescents	  and	  young	  adults	  
	  
BAV	  is	  indicated	  in	  the	  following	  settings	  is	  this	  population:	  
•	  With	   symptoms	   of	   angina,	   syncope,	   or	   dyspnea	   on	   exertion	   and	   catheterization	  
peak	  left	  ventricular	  (LV)-­‐to-­‐peak	  aortic	  gradient	  greater	  than	  or	  equal	  to	  50	  mmHg*	  
in	  the	  absence	  of	  a	  heavily	  calcified	  valve.	  
•	  For	  asymptomatic	  individuals	  with	  catheterization	  peak	  LV-­‐to-­‐peak	  aortic	  gradient	  
>60	  mmHg.	  
•	  For	  asymptomatic	  individuals	  with	  ST	  or	  T	  wave	  changes	  over	  the	  left	  precordium	  
on	  the	  electrocardiogram	  (ECG)	  at	  rest	  or	  with	  exercise	  and	  a	  peak	  LV-­‐to-­‐peak	  aortic	  
gradient	  >50	  mmHg*.	  
BAV	  is	  reasonable	  in	  the	  following	  settings	  in	  this	  population:	  
•	   Asymptomatic	   individuals	   who	   want	   to	   play	   competitive	   sports	   or	   become	  
pregnant	  who	  have	  a	  catheterization	  peak	  LV-­‐to-­‐peak	  aortic	  gradient	  >50	  mmHg*.	  
•	  BAV	  is	  probably	  recommended	  over	  valve	  surgery	  if	  BAV	  is	  possible.	  Such	  patients	  
should	  be	  referred	  to	  a	  center	  with	  expertise	  with	  BAV.	  
BAV	  should	  NOT	  be	  performed	  in	  the	  following	  setting	  in	  this	  population:	  
•	   Asymptomatic	   individuals	   who,	   have	   a	   catheterization	   peak	   LV-­‐to-­‐peak	   aortic	  
gradient	  <40	  mmHg	  without	  symptoms	  or	  ECG	  changes.	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Although	  the	  evidence	  is	  not	  well	  established,	  the	  guidelines	  noted	  two	  specific	  
settings	  in	  adults	  in	  which	  balloon	  valvotomy	  might	  be	  reasonable	  :	  
	  
• As	  a	  bridge	  to	  surgery	  in	  hemodynamically	  unstable	  patients	  who	  are	  at	  high	  
risk	   for	   aortic	   valve	   replacement.	  However,	  mortality	   remains	  high	   in	   these	  
patients	  after	  valvotomy	  (82).	  	  
• Use	   for	  palliation	   in	  patients	  with	  serious	  comorbid	  conditions	   that	  prevent	  
performance	  of	  aortic	  valve	  replacement.	  
	  
In	   addition,	   there	   are	   two	  other	   settings	   in	  which	  balloon	   valvotomy	  has	   been	  
considered:	  
	  
• As	  a	  bridge	  to	  delivery	  in	  symptomatic	  pregnant	  women.	  Although	  there	  are	  
case	   reports	   suggesting	   success,	   balloon	   valvotomy	   can	   induce	   aortic	  
regurgitation	   even	   in	   experienced	   hands,	   the	   postdilation	   bicuspid	   aortic	  
valve	   remains	   susceptible	   to	   infective	   endocarditis	   irrespective	   of	   its	  
functional	   state,	   the	   ascending	   aorta	   still	   harbors	   an	   abnormal	  media,	   and	  
recurrent	  stenosis	  is	  common	  within	  6	  to	  12	  months.	  	  
• In	   patients	  who	   require	   urgent	   noncardiac	   surgery.	  However,	   the	  ACC/AHA	  
guidelines	  and	  others	  have	  concluded	  that	  most	  asymptomatic	  patients	  with	  
severe	  AS	  can	  undergo	  urgent	  noncardiac	  surgery	  at	  relatively	   low	  risk	  with	  
careful	   intraoperative	  and	  postoperative	  management,	   including	  monitoring	  
of	  anesthesia	  and	  careful	  attention	  to	   fluid	  balance.	  Balloon	  valvotomy	  was	  
not	   recommended;	   aortic	   valve	   replacement	   should	   be	   considered	   if	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TRANSCATHETER	  AORTIC	  VALVE	  IMPLANTATION	  (TAVI)	  
	  
Transcatheter	   aortic	   valve	   implantation	   has	   been	   developed	   for	   the	  
treatment	  of	  patients	  with	  severe	  symptomatic	  AS	  who	  have	  an	  unacceptably	  high	  
estimated	   surgical	   risk,	   or	   in	  whom	   TAVI	   is	   preferred	   due	   to	   technical	   issues	  with	  
surgery,	   eg,	   a	   porcelain	   aorta	   or	   prior	   significant	   mediastinal	   radiation,	   prior	  
pericardiectomy	   with	   dense	   adhesions	   or	   prior	   sternal	   infection	   with	   complex	  
reconstruction,	  or	  a	  patent	   left	   internal	  mammary	  graft	   lying	  beneath	   the	  sternum	  
(as	   identified	  by	  computed	  tomography	  angiography).	  Thus,	  accurate	  estimation	  of	  
the	   risk	   of	   surgical	   aortic	   valve	   replacement	   performed	   by	   an	   experienced	  
cardiothoracic	   surgeon	   and	   multidisciplinary	   valve	   team	   is	   vital	   to	   appropriate	  
evaluation	   of	   potential	   candidates	   for	   this	   emerging	   experimental	   procedure.	   Risk	  
calculators	   are	   available	   to	   estimate	   the	   risk	   of	   valvular	   surgery.	   However,	   risk	  
estimates	   are	   subject	   to	   inaccuracies	   (eg,	   the	   logistic	   EuroSCORE	   appears	   to	  
overestimate	   mortality	   risk	   in	   patients	   undergoing	   high-­‐risk	   aortic	   valve	  
replacement)	   and	   the	  models	   do	   not	   account	   for	   some	   clinical	   characteristics	   (eg,	  
porcelain	   aorta,	   systemic	   pulmonary	   hypertension,	   or	   RV	   dysfunction)	   that	   may	  
impact	  surgical	  mortality	  (see	  further	  in	  the	  present	  section).	  In	  patients	  undergoing	  
aortic	  valve	  replacement,	  the	  Society	  of	  Thoracic	  Surgeons	  (STS)	  model	  may	  provide	  
more	  accurate	  risk	  stratification	  than	  the	  logistic	  EuroSCORE).	  Of	  note,	  these	  scoring	  
systems	  are	  only	  applicable	  to	  patients	  undergoing	  surgery	  and	  are	  not	  validated	  nor	  
considered	  accurate	  in	  a	  TAVI	  eligible	  cohort	  of	  patients.	  However,	  no	  other	  scoring	  
systems	  are	  currently	  available	  although	  they	  are	  being	  developed.	  
	  
	  
• DEVICE	  DESCRIPTION	  
	  
At	   the	   present	   time,	   the	  most	   data	   available	   for	   TAVR	   are	   based	   upon	   2	   specific	  
devices—the	   Sapien	   valve	   (Edwards	   Life	   Sciences,	   Inc.,	   Irvine,	   CA,	   USA)	   and	   the	  
CoreValve	  (Medtronic,	  Inc.,	  Minneapolis,	  MN,	  USA)	  (Figure	  6).	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The	  first	  device	  is	  composed	  of	  a	  trileaflet	  bovine	  pericardial	  valve	  mounted	  
with	   a	   tubular	   slotted	   balloon-­‐expandable	   stent	   composed	   of	   a	   cobalt	   chromium	  
alloy.	  The	  Sapien	  valve	   is	  available	   in	  23-­‐mm	  and	  26-­‐mm	  sizes	   in	  the	  United	  States	  
and	  23-­‐mm,	  26-­‐mm,	  and	  29-­‐mm	  sizes	  in	  Europe.	  The	  initial	  devices	  required	  a	  22-­‐	  or	  
24-­‐French	   sheath	   for	   delivery	   of	   the	   prosthesis.	   Recent	   iterations	   (NovaFlex)	   have	  
decreased	   this	   to	   18-­‐French.	   The	   first	   and	   second	   generations	   of	   this	   device	   have	  
been	   tested	   in	   randomized	   controlled	   trials	   for	   both	   transfemoral	   and	   transapical	  
implantation.	  
	  
The	   second	   device	   (CoreValve)	   is	   comprised	   of	   3	   porcine	   pericardial	   tissue	  
leaflets	  mounted	  in	  a	  self-­‐	  expanding	  nitinol	  frame.	  It	  is	  available	  in	  3	  sizes—26	  mm,	  
29	  mm,	  and	  31	  mm.	  This	  valve	  has	  also	  continued	  to	  evolve,	  with	  the	  initial	  devices	  
being	  25-­‐French,	  but	  now	  18-­‐French	  delivery	  sheaths	  are	  used.	  This	  valve	  has	  only	  
been	  used	  by	  a	  retrograde	  approach—either	  via	  transfemoral,	  subclavian,	  or	  direct	  
aortic	  access.	  
	  
Specific	  anatomic	  issues	  must	  be	  considered	  in	  device	  design.	  These	  include	  
the	  rigid	  structure	  of	  the	  pattern	  of	  valvular	  calcification	  and	  aortic	  annulus,	  and	  the	  
need	   for	   as	   full	   apposition	   as	   possible	   to	   the	   annulus	   in	   an	   attempt	   to	   minimize	  
periprosthetic	   leak	   which,	   given	   sometimes	   eccentric,	   bulky	   calcification,	   may	   be	  
difficult.	   The	   close	   proximity	   to	   the	   coronary	   ostia,	   the	   width	   and	   height	   of	   the	  
sinuses,	   the	  membranous	  ventricular	   septum	  with	   the	  His	  bundle	  and	   the	  anterior	  
leaflet	  of	  the	  mitral	  valve	  are	  also	  important	  anatomical	  considerations.	  In	  addition,	  
the	  size	  and	  degree	  of	  severity	  of	  peripheral	  arterial	  disease	  are	  all	  factors	  that	  could	  
limit	  catheter	  size.	  Other	  issues	  include	  avoidance	  of	  central	  prosthetic	   leak,	   leaflet	  
durability,	   hemodynamic	   performance,	   ability	   to	   treat	   both	   tricuspid	   and	   bicuspid	  
valve	   anatomy,	   surfaces	   designed	   to	   minimize	   thrombogenicity,	   and	   the	   need	   to	  
optimally	  position	  the	  devices	  and	  retrieve	  and	  reposi-­‐	  tion	  when	  necessary	  (83).	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Figure	  6.	  Sapien	  (left)	  and	  CoreValve	  (right)	  valves	  
	  
Source:	  Edwards	  Lifesciences.	  Medtronic,	  Inc.	  
	  
Fundamental	   issues	   for	   all	   current	   and	   future	   devices	   are	   hemodynamic	  
results,	   valve	   durability,	   and	   residual	   or	   new	   aortic	   regurgitation	   (AR).	   The	   initial	  
hemodynamic	   performance	   of	   TAVI	   valves	   must	   be	   similar	   or	   superior	   to	   that	  
obtained	   with	   surgical	   AVR.	   This	   is	   crucial	   because	   high	   residual	   transprosthetic	  
gradients	   result	   in	   less	   symptomatic	   improvement	   and	   poorer	   regression	   of	   left	  
ventricular	  mass	   [95].	   These	   transprosthetic	   gradients	   are	   a	   function	   of	   prosthetic	  
size	  as	  well	   as	   the	   specific	   type	  of	  prosthesis	   and	   can	   result	   in	  patient–	  prosthesis	  
mismatch.	  Typical	  immediate	  postprocedural	  gradients	  after	  surgical	  AVR	  range	  from	  
8	  mm	  Hg	  to	  12	  mm	  Hg,	  whereas	  the	  AV	  area	  or	  effective	  orifice	  area	  (EOA)	  ranges	  
from	  1.4	  to	  1.9	  cm2.	  	  
	  
There	  are	  only	  limited	  clinical	  data	  on	  the	  durability	  of	  TAVR	  valves—up	  to	  2	  
years—in	  the	  PARTNER	  trial	  and	  up	  to	  5	  years	  in	  other	  registry	  experiences	  (84–86).	  
Although	   the	   absolute	  number	  of	   patients	   is	   small,	   there	  have	  been	  no	   reports	   of	  
structural	   valve	   deterioration.	   The	   fundamental	   clinical	   need	   for	   durability	   may	  
depend	   in	  part	  on	   the	   specific	   patient	  population.	   In	   the	  PARTNER	   trial,	   the	  mean	  
age	  at	  implant	  was	  83	  years,	  and	  serious	  comorbidities	  were	  frequent.	  In	  this	  setting,	  
the	   need	   for	   durability	   of	   20	   years	   is	   less	   important	   than	   if	   the	   patient	   selection	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criteria	  are	  broadened	  to	  include	  patients	  in	  their	  early	  to	  mid	  60s	  who	  have	  isolated	  
AS	  without	   comorbid	   conditions.	   In	   this	   latter	   group,	   the	   TAVI	   valve	  must	   have	   at	  
least	  equivalent	  clinical	  durability	  to	  currently	  available	  surgically	  implanted	  valves.	  
	  
	  
• DELIVERY	  TECHNIQUES	  
	  
Two	  major	   catheter-­‐based	   techniques	   for	   replacing	   the	   aortic	   valve	   have	   been	  
investigated:	   retrograde	   percutaneous	   implantation	   and	   direct	   apical	   puncture.	   In	  
addition,	   there	   is	   rapidly	   growing	   use	   of	   direct	   aortic	   access	   via	   either	  
ministernotomy	  or	  right	  anterior	  thoracotomy	  
	  
a) Retrograde	  transfemoral	  approach	  	  	  
	  
A	   retrograde	   femoral	   arterial	   approach	   (transfemoral	   or	   TF)	   via	   the	  aortic	   arch	  
and	   through	   the	   stenotic	   valve	   is	   an	   alternative	   to	   the	   antegrade	   approach,	   and	  
devices	   were	   designed	   to	   overcome	   some	   of	   the	   limitations	   seen	   with	   the	   initial	  
transseptal	   antegrade	   delivery.	   Two	   stent-­‐valve	   devices	   with	   slightly	   different	  
designs	   have	  been	   successfully	   implanted	   in	   humans	  using	   the	   retrograde	   femoral	  
approach:	   a	   balloon-­‐expandable	   valve	   (Edwards	   SAPIEN,	   which	   has	   replaced	   the	  
Cribier-­‐Edwards	   valve)	   and	   a	   self-­‐expanding	   valve	   (Medtronic	   CoreValve)	   (87).	   The	  
Medtronic	   CoreValve	   had	   also	   been	   delivered	   in	   a	   retrograde	   fashion	   from	   the	  
subclavian/axillary	  artery	  (88)	  and	  via	  direct	  aortic	  access	  via	  either	  ministernotomy	  
or	  right	  anterior	  thoracotomy.	  
	  
b) Transapical	  approach	  
	  
An	   alternate	   catheter-­‐based	   approach	   consists	   of	   direct	   left	   ventricular	   apical	  
puncture	   and	   antegrade	   aortic	   valve	   implantation	   via	   a	   small	   anterolateral	  
thoracotomy	  without	  cardiopulmonary	  bypass	  or	  sternotomy	  (transapical	  approach	  
or	  TA).	  This	  approach	  is	  particularly	  suited	  to	  patients	  with	  severe	  peripheral	  artery	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disease	  and	  heavily	  calcified	  ascending	  aorta	  and	  arch	  (porcelain	  aorta)	  who	  have	  an	  
increased	  risk	  of	  stroke	  and	  other	  embolic	  events	  using	  other	  approaches.	  
	  
	  
• OUTCOMES	  OVERVIEW	  
	  
- Comparison	  to	  medical	  therapy	  
	  
Evidence	  of	  a	  benefit	  of	  TAVI	  compared	  to	  standard	  medical	  care	  was	  provided	  
by	  the	  PARTNER	  multicenter	  trial	  (cohort	  B)	  (7).	  The	  investigators	  randomly	  assigned	  
358	   patients	   with	   aortic	   stenosis	   who	  were	   not	   considered	   surgical	   candidates	   to	  
either	   standard	   therapy	   (including	   balloon	   aortic	   valvotomy)	   or	   TAVI	   with	   an	  
Edwards	   SAPIEN	  valve	   via	   transfemoral	   approach.	   The	   two	   treatment	   groups	  were	  
similar	  although	  the	  logistic	  EuroSCORE	  was	  slightly	   lower	   in	  the	  TAVI	  group	  (mean	  
26.4	  versus	  30.4).	  The	  following	  findings	  were	  noted:	  
	  
• At	  one	  year,	  the	  rate	  of	  death	  was	  reduced	  with	  TAVI	  compared	  to	  standard	  
therapy	  (HR	  0.44,	  95%	  CI	  0.40	  to	  0.74).	  The	  rate	  of	  the	  composite	  end	  point	  
of	   death	   or	   repeat	   hospitalization	  was	   also	   reduced	  with	   TAVI	   (42.5	   versus	  
72.6	  %).	  	  
• Among	  survivors	  at	  one	  year,	  75	  %	  who	  had	  undergone	  TAVI	  as	  compared	  to	  
42	  %	  who	  had	   received	   standard	   therapy	  had	  no	  or	  mild	   symptoms	   (NYHA	  
functional	  class	  I	  or	  II).	  	  
• At	  30	  days,	  the	  TAVI	  group	  had	  more	  major	  vascular	  complications	  (16	  versus	  
1	  %)	  and	  more	  major	  strokes	  (5	  versus	  1	  %,	  p	  =	  0.06).	  	  
• Among	  patients	  who	  underwent	  TAVI,	  at	  30	  days	  the	  mean	  aortic	  valve	  area	  
increased	   from	   0.6±0.2	   cm2	  to	   1.5±0.5	   cm2,	   and	   the	   mean	   aortic	   valve	  
gradient	  decreased	  from	  44.5±15.7	  to	  11.1±6.9	  mm	  Hg.	  These	  improvements	  
were	  maintained	  at	  one	  year.	  	  
• In	  the	  TAVI	  group,	  moderate	  or	  severe	  paravalvular	  aortic	  regurgitation	  was	  
identified	  in	  11.8	  %	  at	  30	  days	  and	  in	  10.5	  %	  at	  one	  year.	  Moderate	  or	  severe	  
transvalvular	  aortic	  regurgitation	  was	  observed	  in	  1.3	  %	  at	  30	  days	  and	  4.2	  %	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at	  one	  year.	  In	  the	  standard	  therapy	  group,	  moderate	  or	  severe	  transvalvular	  




- Comparison	  to	  surgical	  therapy	  	  
	  
	  	   The	  699	  patients	  in	  cohort	  A	  of	  the	  PARTNER	  trial	  were	  randomly	  assigned	  to	  
undergo	   either	   TAVI	   (by	   transfemoral	   or	   transapical	   approach)	   or	   surgical	   aortic	  
valve	  replacement	  (89).	  The	  following	  findings	  were	  noted:	  
	  
• Mortality	  rates	  in	  the	  TAVI	  and	  surgical	  group	  were	  similar	  at	  30	  days	  (3.4	  and	  
6.5	  %,	  p	  =	  0.07)	  and	  at	  one	  year	  (24.2	  and	  26.8	  %).	  	  
• Strokes	  and	   transient	   ischemic	  attacks	  were	  more	   frequent	  after	   TAVI	   than	  
after	   surgical	   AVR	   at	   both	   30	   days	   (5.5	   versus	   2.4	  %)	   and	   at	   one	   year	   (8.3	  
versus	   4.3	   %).	   Rates	   of	   major	   stroke	   in	   the	   TAVI	   and	   surgical	   group	   were	  
similar	  at	  30	  days	  (3.8	  and	  2.1	  %)	  but	  continued	  to	  trend	  higher	  for	  TAVI	  at	  
one	  year	  (5.1	  and	  2.4	  %,	  p	  =	  0.07).	  	  
• More	  patients	  undergoing	  TAVI	  reported	  symptom	  improvement	  at	  30	  days,	  
but	  at	  one	  year	  symptom	  improvement	  was	  similar	  in	  the	  two	  groups.	  	  
• Differences	  in	  certain	  30-­‐day	  adverse	  event	  rates	  were	  observed:	  
• TAVI	  was	  associated	  with	  more	  frequent	  major	  vascular	  complications	  (11.0	  
versus	  3.2	  %).	  
• Surgical	  aortic	  valve	   replacement	  was	  associated	  with	  more	   frequent	  major	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Early	  outcomes	  were	  reported	  following	  retrograde	  implantation	  of	  the	  Edwards	  
SAPIEN	  valve	  between	  November	  2007	  and	  January	  2009	  in	  463	  patients	  (mean	  age	  
82	  years)	  with	  high	  estimated	  surgical	  risk	  (mean	  logistic	  EuroSCORE	  26)	  (90).	  	  
	  
The	  following	  findings	  were	  noted:	  
• Procedural	  success	  was	  95	  %.	  	  
• Procedural	  outcomes	   included	  conversion	   to	  open	  aortic	  valve	   replacement	  
surgery	  in	  1.7	  %,	  valve-­‐in-­‐valve	  implantation	  (a	  SAPIEN	  valve	  placed	  within	  a	  
SAPIEN	   valve)	   due	   to	   malposition	   or	   moderate/severe	   aortic	   regurgitation	  
after	  placement	  of	  the	  first	  SAPIEN	  valve	  in	  0.6	  %,	  greater	  than	  moderate	  (2+)	  
aortic	  regurgitation	   in	  1.6	  %,	  coronary	  obstruction	   in	  0.7	  %,	  and	  transfusion	  
was	  required	  in	  9.9	  %.	  	  
	  
Major	   complications	   at	   30	   days	   included	   death	   (6.3	   %),	   stroke	   (2.4	   %),	   renal	  
failure	  requiring	  dialysis	  (1.3	  %),	  and	  heart	  block	  resulting	  in	  permanent	  pacemaker	  
implantation	   (6.7	  %).	   Vascular	   complications	   included	   access-­‐related	   complications	  
(17.9	  %),	  aortic	  dissection	  (1.9	  %),	  and	  non-­‐access-­‐related	  complications	  (1.1	  %).	  
In	  an	  echocardiographic	  study	  of	  88	  patients	  undergoing	  retrograde	  Cribier-­‐Edwards	  
or	  Edwards	  SAPIEN	  valve	  implantation,	  the	  mean	  transaortic	  valve	  gradient	  fell	  from	  
a	  preprocedure	  baseline	  of	  39±14	  mmHg	  to	  9±3	  mmHg	  one	  day	  after	  the	  procedure	  
and	  was	  11±4	  two	  years	  later	  (91).	  
	  
Similar	  results	  were	  found	  in	  a	  multicenter	  study	  of	  retrograde	  implantation	  of	  a	  
self-­‐expanding	   stent	   valve	   (CoreValve)	   in	  646	  patients	   (mean	  age	  81)	  with	  a	  mean	  
logistic	  EuroSCORE	  of	  23	  (92):	  
• Procedure	   success	   was	   97	   %	   and	   the	   mean	   transaortic	   valve	   gradient	  
decreased	  from	  49	  to	  3	  mmHg.	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• Procedural	   outcomes	   included	   death	   in	   1.5	   %,	   conversion	   to	   open	   aortic	  
valve	   replacement	   surgery	   in	   0.5	   %,	   and	   implantation	   of	   a	   second	   valve	  
(including	   valve-­‐in-­‐valve)	   in	   2.6	   %.	   Paravalvular	   regurgitation	   was	   common	  
but	  usually	  mild	  and	  not	  more	  than	  moderate.	  	  
	  
At	   30	   days,	   mortality	   was	   8	   %,	   heart	   block	   was	   treated	   with	   permanent	  
pacemaker	  implantation	  in	  9.3	  %,	  myocardial	  infarction	  occurred	  in	  0.6	  %	  and	  stroke	  





The	   following	  early	  outcomes	  were	   reported	   following	   transapical	   implantation	  
of	   the	   Edwards	   SAPIEN	   valve	   in	   575	   patients	   (mean	   age	   81	   years)	   with	   logistic	  
EuroSCORE	  of	  29%	  (90,93–95).	  	  
• The	  valve	  prosthesis	  was	  implanted	  successfully	  in	  93	  %	  with	  a	  3.5	  %	  rate	  of	  
conversion	   to	   open	   surgery.	   The	   early	   incidence	   of	   greater	   than	  moderate	  
(2+)	  aortic	  regurgitation	  was	  2.3	  %.	  	  
• At	   30	   days,	   major	   complications	   included	   death	   (10.3	   %),	   stroke	   (2.6	   %),	  
major	  vascular	  complication	   (2.4	  %),	  myocardial	   infarction	   (0.7	  %),	  need	   for	  
dialysis	   (7.1	   %),	   pacemaker	   implantation	   (7.3	   %),	   and	   bleeding	   requiring	  
reoperation	  (2.1	  %).	  	  
	  
Outcomes	   for	   100	   patients	   undergoing	   transapical	   aortic	   valve	   implantation	  
(mean	   age	   83,	   mean	   logistic	   EuroSCORE	   29%	   were	   comparable	   to	   those	   for	   100	  
propensity-­‐matched	   controls	   undergoing	   conventional	   aortic	   valve	   replacement	  
(mean	  age	  82,	  mean	  EuroSCORE	  30)	  (96).	  Transapical	  aortic	  valve	  implantation	  was	  
successful	   in	   97	   patients,	   and	   three	  patients	   required	   conversion	   to	   open	   surgery.	  
There	  were	  no	  strokes	  in	  the	  transapical	  group	  and	  two	  strokes	  in	  the	  conventional	  
group.	  The	  mortality	  rates	  for	  the	  transapical	  and	  conventional	  surgery	  groups	  were	  
similar:	  10	  and	  15	  %	  at	  30	  days	  and	  27	  and	  31	  %	  at	  one	  year.	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• ONE	  AND	  TWO	  YEAR	  OUTCOMES	  
	  
One	   year	   outcomes	   were	   reported	   for	   1038	   patients	   from	   32	   centers	   in	   the	  
European	   Edwards	   SAPIEN	   registry	   (95).	   Patients	   treated	   with	   the	   transapical	  
approach	   (n	   =	   575)	   have	   greater	   frequency	   of	   comorbidities	   and	   higher	   logistic	  
EuroSCORE	   (29	   versus	   25.8	   %)	   compared	   to	   those	   treated	   with	   the	   transfemoral	  
approach.	  
• One	   year	   mortality	   rates	   were	   27.9	   and	   18.9	   %	   for	   transapical	   and	  
transfemoral	  patients,	  respectively.	  
• Multivariable	   analysis	   identified	   logistic	   EuroSCORE,	   renal	   disease,	   liver	  
disease,	  and	  smoking	  as	  the	  variables	  with	  the	  highest	  hazard	  ratios	  for	  one	  
year	  mortality.	  
	  
Early	   and	   two-­‐year	   outcomes	   were	   reported	   for	   a	   multicenter	   cohort	   of	   126	  
patients	   with	   symptomatic	   severe	   aortic	   stenosis	   who	   received	   the	   CoreValve	  
between	   2006	   and	   2008	   (97).	   The	   mean	   EuroSCORE	   was	   23	   %.	   The	   cohort	   was	  
retrospectively	  classified	  into	  moderate	  surgical	  risk	  (54	  patients),	  high-­‐risk	  operable	  
(51	  patients),	  and	  high-­‐risk	  inoperable	  (21	  patients)	  groups.	  
• The	   technical	   success	   rate	   was	   83.1	   %.	   Thirty-­‐day	   mortality	   was	   15.2	   %	  
without	   significant	  differences	   in	   the	   subgroups.	  Of	  note,	   this	   study	   started	  
enrollment	   before	   other	   studies	   (90,92)	  and	   the	   lower	   observed	   technical	  
success	   rate	   as	  well	   as	   higher	   early	  mortality	   rate	   are	   likely	   largely	   due	   to	  
learning	  curve	  issues.	  
• At	  two	  years,	  mortality	  was	  38.1	  %	  with	  a	  significantly	  higher	  mortality	  in	  the	  
combined	   high-­‐risk	   groups	   as	   compared	   to	   the	   moderate-­‐risk	   group	   (45.8	  
versus	  27.8	  %).	  
• Functional	   class	   improved	   in	   80	  %	  of	   patients	   and	   remained	   stable	   at	   two-­‐
year	   follow-­‐up.	  The	  mean	  aortic	   valve	  gradient	  was	  unchanged	  at	   two-­‐year	  
follow-­‐up	  (8.5	  at	  30	  days	  and	  9.0	  at	  2	  years).	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Recent	   findings	   from	  2-­‐year	   analysis	   of	   the	   randomized	  PARTNER	   trial	  were	   as	  
follows:	   mortality	   after	   TAVI	   remained	   similar	   to	   that	   after	   surgical	   replacement,	  
stroke	   frequency	   was	   similar	   in	   the	   surgery	   and	   TAVI	   groups	   after	   30	   days,	  
periprocedural	   complications	   (strokes,	  major	   bleeding,	   and	  major	   vascular	   events)	  
affected	   mortality	   after	   TAVR	   or	   surgical	   replacement;	   aortic	   regurgitation	   (even	  
mild)	   after	   TAVI	   was	   associated	   with	   increased	   long-­‐term	   mortality,	   and	   valve	  
performance	  in	  the	  TAVI	  group	  was	  main-­‐	  tained	  during	  follow-­‐up	  and	  was	  similar	  to	  
that	  in	  the	  surgery	  group	  (85).	  
	  
	  
Early	  (30-­‐day)	  mortality	  after	  TAVI	  has	  decreased	  to	  approximately	  5%	  in	  several	  
recent	   studies,	   probably	   because	   of	   a	   combination	   of	   improvements	   in	   patient	  
selection,	  procedural	  tech-­‐	  niques,	  and	  device	  technologies.	  However,	  1	  and	  2-­‐year	  
mortality	  rates	  have	  remained	  above	  20%	  and	  30%,	  respectively,	  rais-­‐	  ing	  a	  concern	  
that	  TAVI	  may	  be	  associated	  with	  important	  late	  complications.	  The	  results	  from	  the	  
PARTNER	  trial	   reveal	  similarly	  high	  mortality	  at	  2	  years	  with	  TAVI	  and	  with	  surgical	  
replacement,	   indicating	   that	  coexisting	  conditions	  play	  a	   role	   in	   late	  mortality.	  The	  
multivariable	   analysis	   from	   the	   combined	   TAVI	   and	   surgery	   groups	   affirms	   the	  
importance	   of	   coexisting	   conditions,	   because	   the	   STS	   risk	   score	   was	   a	   significant	  





A	  valve-­‐in-­‐valve	  procedure	   involves	  catheter-­‐based	  valve	   implantation	  inside	  an	  
already	  implanted	  bioprosthetic	  valve.	  This	  approach	  may	  provide	  an	  alternative	  to	  
replacement	   of	   a	   degenerated	   surgically-­‐implanted	   valve,	   or	   a	  means	   of	   salvaging	  
suboptimal	   implantation	   of	   a	   catheter-­‐based	   valve	   during	   the	   initial	   implantation	  
procedure.	  
	  
Preliminary	   reports	   have	   demonstrated	   the	   feasibility	   of	   transcatheter	  
placement	   of	   a	   prosthetic	   valve	   within	   a	   degenerated	   bioprosthetic	   valve.	   As	   an	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example,	   valve-­‐in-­‐valve	   implantation	  was	   performed	   on	   24	   high-­‐risk	   patients	   with	  
aortic	  (n	  =	  10),	  mitral	  (n	  =	  7),	  pulmonary	  (n	  =	  6),	  or	  tricuspid	  (n	  =	  1)	  failed	  (stenotic	  
and/or	   regurgitant)	   bioprostheses	   (98).	   Implantation	   was	   unsuccessful	   for	   one	  
(mitral)	  case.	  There	  were	  no	  deaths	  during	  the	  procedure.	  There	  was	  one	  stroke	  and	  
one	   death	   in	   30	   days;	   the	   death	   was	   related	   to	   attempted	   transseptal	   mitral	  
positioning.	   The	   NYHA	   functional	   class	   improved	   from	   88	   %	   in	   class	   III	   or	   IV	   	   at	  
baseline	  to	  88	  %	  in	  class	  I	  or	  II	  at	  last	  follow-­‐up.	  
	  
Valve-­‐in-­‐valve	   implantation	   has	   been	   used	   to	   salvage	   suboptimal	   initial	  
transcatheter	   aortic	   valve	   implantation	   and	   significant	   paravalvular	   aortic	  
regurgitation.	   In	   a	   series	   using	   Edwards	   SAPIEN	   valves,	   valve-­‐in-­‐valve	   implantation	  
was	  performed	  in	  0.6	  %	  of	  463	  retrograde	  procedures	  and	  3.3	  %	  of	  575	  transapical	  
antegrade	   procedures.	   In	   a	   series	   of	   646	   retrograde	   CoreValve	   procedures,	  
moderate	   to	   severe	   aortic	   regurgitation	   during	   the	   implantation	   procedure	   was	  
treated	   with	   balloon	   re-­‐dilatation	   (in	   21.2	   %	   of	   procedures)	   and/or	   valve-­‐in-­‐valve	  
placement	   (in	   2.6	   %)	   (92).	   None	   of	   the	   628	   patients	   with	   successful	   CoreValve	  
implantation	  had	  greater	  than	  moderate	  aortic	  regurgitation.	  
	  
	  
• TECHNOLOGY	  EVOLUTION	  
	  
Next-­‐generation	   devices	   promise	   the	   potential	   for	   im-­‐	   provements,	   offering	  
expanded	   clinical	   utility	   with	   ad-­‐	   vances	   that	   include:	   lower	   profile	   delivery	  
catheters, more	  accurate	  positioning,	  reduced	  paravalvular	  leak,	  and	  ability	  to	  either	  
reposition	   or	   even	   retrieve	   	   (Figure	   7)	   (99).	  Many	   of	   the	   new	   device	   technologies	  
utilize	  a	  self-­‐expandable,	  high	  radial	  strength	  repositionable	  prosthesis	  consisting	  of	  
pericardial	   tissue	   on	   a	   nitinol	   frame.	   Two	   additional	   valves	   have	   recently	   received	  
approval	   for	   commercial	   sale	   in	   Europe.	   The	   JenaValve	   (JenaValve	   Technology,	  
Munich,	  Germany)	  and	  Acurate	  Valve	  (Symetis,	  Inc.,	  Lausanne,	  Switzerland)	  are	  both	  
delivered	  currently	  via	  a	  transapical	  approach.	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   Other	  valve	  designs	  currently	  in	  early	  clinical	  studies	  include	  Portico	  Valve	  (St.	  
Jude	  Medical,	   St.	   Paul,	  MN,	  USA),	  Direct	   Flow	  Medical	   (Direct	   Flow	  Medical,	   Santa	  
Rosa,	   CA,	  USA),	   and	   Sadra	   Lotus	  Valve	   (Sadra	  Medical,	   Los	  Gatos,	   CA,	  USA).	  Other	  
new	   designs	   include	   flexible	   sealing	   membranes	   aimed	   at	   more	   optimal	  
conformation	  to	  the	  calcified	  native	  annulus	  to	  reduce	  paravalvular	  leaks.	  New	  valve	  
designs	  and	  materials	  can	  also	  pro-­‐	  vide	  the	  possibility	  of	  new	  prosthesis	  technology.	  
The	  Lutter	  valve	  was	  created	  in	  an	  effort	  to	  create	  a	  more	  physiological	  heart	  valve	  
by	   utilizing	   tissue	   engineering	   (100).	   The	   PercValve	   (Advanced	   Bioprosthetic	  
Surfaces,	  San	  Antonio,	  TX,	  USA)	  uses	  nanotechnology	  in	  its	  elastic	  nitinol	  frame	  and	  
leaflets.	   These	   leaflets	   are	   designed	   to	   allow	   for	   the	   growth	   of	   endothelial	   cells,	  
essentially	  converting	  it	  to	  a	  tissue	  valve.	  Initial	  animal	  studies	  have	  shown	  complete	  
endothelialization	  of	  the	  e-­‐nitinol	  leaflets	  within	  10	  days	  and	  may	  eliminate	  the	  need	  
for	  anticoagulation	   (101).	  A	   final	  novel	  approach	   involves	  anchoring	   the	  prosthesis	  
by	   using	   an	   injectable	   polymer	   that	   cures	   in	   position	   to	   maintain	   the	   implant	  
permanently	  in	  place.	  The	  outcome	  with	  these	  new	  technologies	  will	  be	  the	  focus	  of	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Figure	  7.	  New	  transcatheter	  valve	  designs	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5.	  Estimation	  of	  operative	  risk	  in	  aortic	  valve	  surgery	  
	  
REGISTRIES	  AND	  RISK	  SCORES	  
	  
Current	  data	  from	  The	  Society	  of	  Thoracic	  Surgeons	  (STS)	  registry	  documents	  
a	  mortality	  that	  is	  under	  3%	  for	  all	  patients	  undergoing	  AVR.	  As	  with	  any	  procedure,	  
operative	   mortality	   is	   strongly	   correlated	   with	   the	   severity	   of	   the	   disease	   and	  
comorbidity	   of	   patients.	   The	   operative	   risks	   can	   be	   estimated	   with	   online	   risk	  
calculators	   from	   the	   STS	   and	   the	   European	   System	   for	   Cardiac	   Operative	   Risk	  
Evaluation	  (EuroSCORE).	  	  
	  
In	  selected	  patients	  with	  minimal	  comorbidity,	  mortality	  and	  major	  morbidity	  
are	  under	  1%	  each	  in	  many	  centers.	  In	  general,	  perioperative	  stroke	  rates	  are	  1.5%	  
and	  other	  major	   complications	  are	   relatively	   rare.	  Renal	   failure,	  pulmonary	   failure,	  
and	   gastrointestinal	   complications	   are	   not	   common.	   As	   older,	   more	   frail	   patients	  
with	  extensive	  comorbidities	  undergo	  AVR,	  the	  risk	  of	  death	  and	  morbid-­‐	  ity	  as	  well	  
as	   length	   of	   hospitalization	   increases	   significantly.	   In	   addition	   to	   comorbidity,	  
preoperative	   functional	   performance	   is	   also	   a	   maker	   of	   postoperative	  
morbidity/mortality	  (58).	  
	  
Patient	   selection	   for	   AVR	   for	   AS	   is	   well	   outlined	   by	   ACC/AHA	   and	   ESC	  
guidelines	   as	   previously	   described	   (13,14).	   Problems	   arise	  when	   the	   clinicians	   and	  
patients	   note	   significant	   symptoms	   and	   significant	   structural	   disease	   that	   are	  
complicated	  by	  the	  presence	  of	  significant	  comorbidity.	  While	  current	  STS	  risk	  score	  
and	  EuroSCORE	  give	  information	  concerning	  short-­‐term	  operative	  risks	  and	  benefits,	  
they	   are	   not	   able	   to	   predict	   symptom	   resolution,	   quality-­‐of-­‐life	   improvement,	   or	  
return	  to	  independent	  living.	  
	  
Although	   a	   number	   of	   risk	   algorithms	   for	   cardiac	   surgery	   have	   been	  
developed,	  the	  STS	  and	  logistic	  EuroSCORE	  are	  the	  most	  commonly	  used.	  While	  both	  
are	   accurate	   in	   low-­‐risk	   patients,	   accuracy	   is	   less	   in	   higher	   risk	   subsets.	   These	   2	  
scores	  include	  different	  covariates.	  The	  logistic	  EuroSCORE	  is	  based	  on	  12	  covariates	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derived	   from	   14,799	   patients	   undergoing	   all	   types	   of	   cardiac	   operations	   (mostly	  
coronary	  bypass)	   in	  8	  European	  countries	   in	  1995.	  On	  the	  other	  hand,	   the	  STS	  risk	  
predictor	  is	  based	  on	  24	  covariates	  derived	  from	  67,292	  patients	  undergoing	  isolated	  
AVR	  only	  in	  the	  United	  States	  over	  a	  relatively	  more	  contemporary	  period	  between	  
2002	  and	  2006.	  	  
	  
The	  present	  models	  do	  not	  include	  some	  risk	  factors	  that	  may	  be	  particularly	  
important	   in	   the	   prediction	   of	   outcomes	   for	   very	   high-­‐risk	   populations	   including	  
frailty,	  porcelain	  aorta,	   and	   the	  presence	  of	  hepatic	  dysfunction,	   although	  all	   have	  
been	   added	   to	   a	   recent	   upgraded	   EuroSCORE	   version	   (EuroSCORE	   2)	   which	   is	  
currently	  under	  development	  (102,103).	  
	  
The	   prognostic	   value	   of	   the	   risk	   models	   depends	   upon	   the	   population	   to	  
which	   the	   models	   are	   applied.	   Several	   studies	   have	   found	   that	   the	   EuroSCORE	  
overestimates	  mortality	  for	  various	  cardiac	  surgery	  populations	  (104–106),	  including	  
patients	   undergoing	  mitral	   valve	   surgery,	   and	   patients	   undergoing	   high-­‐risk	   aortic	  
valve	  replacement	  (107–109).	  
	  
In	  patients	  undergoing	  aortic	  valve	  replacement,	  the	  STS	  model	  may	  provide	  
more	   accurate	   perioperative	   risk	   estimation	   than	   the	   EuroSCORE	   (109).	   In	   various	  
studies,	  the	  EuroSCORE	  often	  overestimated	  perioperative	  risk,	  while	  the	  STS	  model	  
has	  been	  observed	  to	  under	  or	  overestimate	  early	  postoperative	  mortality	  (12,110).	  
The	  EuroSCORE	  and	  STS	  score	  also	  correlate	  with	  long-­‐term	  postoperative	  mortality	  
risk,	   though	   the	   relative	   strengths	   of	   these	   associations	   varies	   among	   series,	   and	  
other	  clinical	  factors	  (such	  as	  presence	  of	  renal	  failure)	  may	  have	  greater	  predictive	  
value	  in	  some	  groups.	  
	  
	  
SPECIFIC	  SURGICAL	  RISKS:	  STROKE	  
	  
	  Although	   ischemic	   stroke	   can	   result	   from	  many	   causes	   after	   AVR,	   a	  major	  
concern	  is	  the	  role	  of	  thromboembolism.	  The	  risks	  of	  thromboembolism	  are	  usually	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greater	  in	  the	  first	  few	  days	  and	  months	  after	  bioprosthetic	  AVR	  implantation	  before	  
the	   sewing	   ring	   of	   the	   prosthesis	   is	   endothelialized;	   risks	   after	   mechan-­‐	   ical	   AVR	  
continue.	   The	   risk	  of	   stroke	  within	  30	  days	  among	  67,292	   cases	  of	  AVR	   in	   the	  STS	  
Registry	  was	  1.5%;	  this	  data	  set	  was	  used	  to	  develop	  a	  model	  for	  predicting	  30-­‐day	  
stroke	   risk	   (58).	   Overall,	   embolic	   stroke	   risks	   are	   greater	   with	   mechanical	   valves,	  
which	  require	  long-­‐term	  oral	  anticoagulation,	  than	  with	  bioprosthetic	  valves,	  which	  
have	  a	  0.7%	  per	  year	  risk	  of	  thromboembolism	  in	  patients	  with	  normal	  sinus	  rhythm	  





	  Aside	   from	  other	  surgical	  complications	  of	   renal,	  hepatic,	  neurological,	  and	  
pulmonary	  disease	  compromise,	  a	  major	  risk	  of	  conventional	  AVR	   is	  sternal	  wound	  
infection.	  In	  most	  centers,	  this	  risk	  is	  under	  1%	  for	  deep	  infection,	  but	  the	  risk	  of	  any	  
type	  of	  infection	  is	  still	  present	  and	  particularly	  increased	  in	  patients	  with	  diabetes,	  
obesity,	  smoking,	  immunosuppressive	  therapy,	  and	  prior	  radiation	  therapy.	  With	  the	  
advent	   of	   negative	   pressure	   wound	   therapy	   and	   continued	   advances	   in	   surgical	  
technique,	  these	  risks	  are	  now	  rarely	  fatal,	  but	  remain	  morbid.	  	  
	  
	  
INOPERABILITY	  OR	  PROHIBITIVE	  RISK	  
	  
Despite	  substantial	   contemporary	  experience	  with	  successful	  AVR	   in	  elderly	  
patients,	  multiple	  series	  have	  documented	  that	  30%	  to	  40%	  of	  patients	  with	  severe	  
AS	   do	   not	   undergo	   surgery	   owing	   to	   advanced	   age,	   LV	   dysfunction,	   multiple	  
coexisting	   conditions,	   and	   patient	   preference	   or	   physician	   recommendation	   (111–
113).	  
	  
The	   definitions	   used	   to	   describe	   patient	   populations	   considered	   for	   TAVI	  
vary;	  for	  example,	  prohibitive	  risk	  would	  describe	  a	  patient	  in	  whom	  the	  procedure	  
could	   be	   performed	   from	   a	   technical	   standpoint	   but	   would	   be	   associated	   with	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prohibitively	   high	   morbidity	   and	   mortality.	   Inoperability	   might	   identify	   a	   patient	  
group	   in	  whom	   technical	   success	  would	   not	   be	   possible;	   for	   example,	   no	   vascular	  
access.	  Different	   trials	  have	  used	   these	   terms	   for	  patient	  enrollment;	   for	  example,	  
the	   CoreValve	   Trial	   identifies	   extreme	   risk,	   whereas	   the	   PARTNER	   (Placement	   of	  
AoRtic	  TraNscathetER	  Valve)	  Trial	  used	  the	  term	  inoperable	  (7).	  	  
	  
Assessment	   of	   inoperability	   is	   also	   driven	   by	   surgeon	   and	   institutional	  
experience	   and	   thus	   varies.	  Whereas	   practice	   guidelines	   have	   been	   developed	   to	  
assist	  physicians	  and	  surgeons	  in	  determining	  appropriate	  use	  of	  treatment	  options,	  
there	   are,	   however,	   no	   specific	   recom-­‐	   mendations	   for	   defining	   inoperability.	  
Current	  ACCF/	  AHA	  guidelines	  acknowledge	  that	  special	  considerations	  are	  required	  
for	   the	   management	   of	   advanced	   elderly	   patients	   with	   AS,	   since	   age-­‐related	   and	  
comorbid	   conditions	   commonly	   exist	   in	   patients	   in	   their	   80s	   and	   90s	   even	   though	  
AVR	  is	  technically	  feasible	  even	  in	  this	  group	  (13,14).	  
	  
In	   the	  absence	  of	   literature	  evidence	  and	  guidelines	   recommendations,	   the	  
determination	  of	  inoperability	  in	  any	  given	  patient	  depends	  on	  the	  judgment	  of	  the	  
medical	  team.	  It	  is	  generally	  agreed	  that	  patients	  with	  limited	  life	  expectancy	  due	  to	  
concurrent	  conditions	  such	  as	  malignancy,	  dementia,	  primary	   liver	  disease,	  chronic	  
obstructive	  pulmonary	  disease	  (COPD),	  among	  others,	  are	  not	  appropriate	  for	  AVR.	  
Frailty	  and	  related	  conditions	  of	  debility	  and	  deconditioning	  are	  known	  to	  result	   in	  
inability	  to	  recover	  from	  major	  heart	  surgery	  such	  as	  AVR,	  despite	  operative	  survival	  
and	   hospital	   discharge.	   These	   conditions	   can	   potentially	   con-­‐	   tribute	   to	   increased	  
surgical	  mortality	  and	  morbidity	  in	  the	  elderly	  (114).	  
	  
Inoperability	   from	   the	   surgeon’s	   judgment	   may	   result	   from	   technical	  
considerations	   that	   preclude	   safe	   performance	   of	   AVR,	   such	   as	   prior	   mediastinal	  
irradiation,	   porcelain	   aorta	   or	   severe	   periannular	   calcification,	   severe	   aortic	  
atheromatous	  disease,	  prior	  cardiac	  operations,	  among	  others	  including	  the	  internal	  
mammary	  artery	  crossing	  the	  midline.	  Although	  infrequent,	  aortic	  valve	  bypass	  with	  
a	  LV	  apex-­‐to-­‐descending	  aortic	  conduit	  has	  been	  used	  in	  some	  patients	  with	  severe	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   80	  








	   	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  











II.	  METHODS	  	   	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   82	  
	   	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   83	  
1.	  Work	  hypothesis	  
	  
	  




• Preoperative	   risk	   factors	   or	   comorbidities	   play	   a	   different	   role	   on	  
perioperative	   mortality	   in	   high-­‐risk	   aortic	   valve	   replacement	   surgery	  




This	  work	  seeks	  to	   identify	  these	  factors	  and	  quantify	  their	  potential	   impact	  on	  
mortality	   in	   order	   to	   evaluate	   and	   discriminate	   future	   patients	   towards	   the	  most	  
appropriate	  surgical	  technique.	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This	  retrospective	  study	  presents	  de	  data	  of	  a	  consecutive	  series	  of	  patients	  
who	   underwent	   aortic	   valve	   replacement	   surgery	   (+/-­‐coronary	   artery	  
revascularization)	   in	   a	   single	   institution	   (Consorcio	   Hospital	   General	   Universitario,	  




1. To	   design	   a	   statistical	   model	   for	   preoperative	   scoring	   and	   patient	  
discrimination	  towards	  transcatheter	  or	  conventional	  aortic	  valve	  surgery	   in	  
high-­‐risk	  patients,	  based	  in	  the	  observed	  mortality	  between	  both	  groups	  and	  
the	   variables	   identified	   as	   independent	   predictors	   for	   that	   mortality	   after	  
statistical	  analysis)	  
	  
2. To	   assess	   a	   comparative	   study	   of	   operative	   outcomes	   (perioperative	  
mortality	  and	  major	  morbidity)	  between	   the	  novel	  TAVI	   technique	  versus	  a	  
statistically	   matched	   control	   group	   formed	   among	   patients	   who	   received	  
conventional	  aortic	  valve	  surgery	  during	  the	  same	  period.	  	  
	  
3. To	   assess	   a	   comparative	   study	   of	   operative	   outcomes	   with	   the	   composite	  
endpoint	   of	   perioperative	   mortality,	   major	   cardiovascular	   or	   neurologic	  
events	   (MACCE)	   between	   the	   novel	   TAVI	   technique	   versus	   a	   statistically	  
matched	   control	   group	   formed	   among	   patients	   who	   received	   conventional	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SECONDARY	  ENDPOINTS	  
	  
1. To	  describe	  the	  observed	  intensive	  care	  and	  hospital	  length	  of	  stay	  between	  
the	  TAVI	  and	  the	  matched	  AVR	  control	  groups.	  
	  
2. To	   describe	   and	   compare	   postoperative	   pacemaker	   rhythm	   rates	   between	  
the	  TAVI	  and	  the	  matched	  AVR	  control	  groups.	  	  
	  
3. To	   describe	   and	   compare	   long	   term	   survival	   between	   the	   TAVI	   and	   the	  
matched	  AVR	   control	   groups,	   and	   assess	   the	   possibility	   of	   time	   or	   learning	  
curve	  effect	  in	  the	  techniques.	  	  
	  
4. To	   describe	   postoperative	   outcomes	   of	   TAVI	   subgroups:	   transfemoral	   (TF)	  
and	  transapical	  (TA)	  approaches.	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3.	  Patient	  selection	  
	  




Selection	   of	   candidates	   for	   TAVI,	   especially	   risk	   assessment,	   involved	   a	   multi-­‐
disciplinary	   consultation	  between	  one	  cardiologist,	   and	   two	  cardiac	   surgeons,	  with	  
the	   additional	   collaboration	   of	   imaging	   specialists	   and	   anesthesiologists	   whenever	  
was	  necessary.	  
	  
Patient	   selection	  criteria	   for	  TAVI	  was	  based	  on	   four	  steps:	  a)	   confirmation	   the	  
severity	   of	   AS;	   b)	   evaluation	   of	   symptoms;	   c)	   analysis	   of	   the	   risk	   of	   surgery	   and	  
evaluation	  of	  life	  expectancy	  and	  quality	  of	  life;	  d)	  assessment	  of	  the	  feasibility	  and	  
exclusion	  of	  contraindications	  for	  TAVI.	  
	  
a) Confirmation	  of	  the	  severity	  of	  aortic	  stenosis	  
	  
TAVI	  was	   performed	   only	   in	   severe	   aortic	   stenosis	   (AS).	   Echocardiography	  was	  
the	   preferred	   tool	   to	   assess	   the	   severity	   of	   AS	   according	   to	   a	   combination	   of	  
measurements	   of	   valve	   area	   and	   flow-­‐dependent	   indices.	   Low-­‐dose	   dobutamine	  
echocardiography	  was	   useful	   to	   differentiate	   between	   severe	   and	   ‘pseudo	   severe’	  
AS	  in	  patients	  with	  low	  LV	  ejection	  fraction	  and	  low	  gradient.	  
	  
b) Evaluation	  of	  symptoms	  
	  
TAVI	  was	  only	  proposed	  in	  patients	  with	  severe	  symptoms	  that	  can	  definitely	  be	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c) Analysis	  of	  the	  risks	  of	  surgery,	  and	  evaluation	  of	  life	  expectancy	  and	  quality	  
of	  life	  
	  
TAVI	   was	   restricted	   to	   patients	   at	   high-­‐risk	   (predicted	   logistic	   EuroSCORE	  
mortality	   over	   15%)	   or	   with	   contraindications	   for	   conventional	   surgery.	   The	   team	  
took	   into	   account	   risk	   factors	   that	   are	   not	   covered	   in	   scores	   but	   often	   seen	   in	  
practice	  such	  as	  chest	  radiation,	  previous	  aorto-­‐coronary	  bypass	  with	  patent	  grafts,	  
porcelain	  aorta,	  liver	  cirrhosis,	  etc.	  	  
At	   this	   stage,	   TAVI	   was	   not	   recommended	   for	   patients	   who	   simply	   refused	  
surgery	  on	  the	  basis	  of	  personal	  preference.	  
Life	   expectancy	   was	   considered	   to	   be	   most	   significantly	   influenced	   by	  
comorbidities	  (which	  were	  carefully	  looked	  for),	  rather	  than	  age	  alone.	  TAVI	  was	  not	  
performed	  in	  patients	  whose	  life	  expectancy	  was	  considered	  to	  be	  below	  1	  year.	  
	  
	  
d) Assessment	  of	   feasibility	  and	  exclusion	  of	   contraindications	  of	   transcatheter	  
aortic	  valve	  implantation	  
	  
The	  following	  steps	  were	  taken	  to	  assess	  the	  feasibility	  of	  TAVI:	  
	  
-­‐ Assessment	  of	  the	  coronary	  anatomy	  
	  
Coronary	   angiography	   was	   systematically	   performed.	   If	   associated	   coronary	  
artery	   disease	   requiring	   percutaneous	   revascularization	   was	   found,	   whether	   to	  
proceed	  previously	  to	  the	  valve	   implant	  or	   in	  a	  hybrid	  manner	  (concomitant	  to	  the	  
TAVI	   procedure)	   ,	   was	   subject	   of	   individualized	   discussion	   based	   on	   the	   patient’s	  
clinical	   condition	   and	   anatomy.	   TAVI	   was	   recommended	   in	   patients	   with	   severe	  
proximal	  coronary	  stenoses	  not	  amenable	  to	  percutaneous	  coronary	  interventions.	  
On	   the	   other	   hand,	   the	   position	   of	   the	   coronary	   arteries	   relative	   to	   the	   aortic	  
cusps	   was	   assessed	   using	   aortography	   and	   multislice	   computed	   vascular	  
tomography.	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-­‐ Measurement	  of	  the	  aortic	  annulus	  
	  
Correct	  sizing	  of	  the	  valve	  was	  critical	  to	  minimize	  the	  potential	  for	  paravalvular	  
leakage	  and	  to	  avoid	  prosthesis	  migration	  after	  placement;	  however,	  a	  gold	  standard	  
method	  of	  measurement	  was	  not	  established.	  TEE	  was	  found	  to	  show	  larger	  values	  
than	   transthoracic	   echocardiography,	   thus,	   it	   was	   performed	   if	   borderline	   values	  
lead	  to	  doubt	  the	  feasibility	  of	  the	  procedure.	  (Fig.1)	  
Multislice	  computed	  tomography	  or	  magnetic	  resonance	  imaging	  were	  used	  
for	   this	   purpose.	   Finally,	   aortography	   measurements	   performed	   during	  
balloon	  valvuloplasty	  were	  also	  useful.	  	  
Echocardiography	  was	   the	  preferred	   tool	   for	   the	  assessment	  of	   the	  morphology	  of	  
the	  LV	  outflow	  tract	  and,	  before	  implanting	  self-­‐expandable	  devices,	  the	  dimensions	  
of	  the	  aortic	  root.	  
	  
-­‐ Evaluation	  of	  size,	  tortuosity,	  and	  calcification	  of	  peripheral	  arteries	  
	  
Vascular	   angiography	   was	   the	   reference;	   however,	   multislice	   computed	  
tomography	  was	   also	   used	   (or	  magnetic	   resonance	   imaging	   in	   patients	  with	   renal	  
insufficiency).	  
	  
Fig.	  1.	  Measurement	  of	  the	  aortic	  annulus	  by	  ultrasound	  imaging.	  
	  
	  
Source:	  Edwards	  Lifesciences	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INCLUSION CRITERIA FOR TAVI PROCEDURE (116) 
1. Patients must have co-morbidities such that the surgeon and cardiologist 
concur that the predicted risk of operative mortality is ≥15% as measured by 
logistic EuroSCORE scale. 
2. Patient has senile degenerative aortic valve stenosis with 
echocardiographically derived criteria: mean gradient >40 mmHg or jet 
velocity greater than 4.0 m/s or an initial aortic valve area of < 0.8 cm2	  
3. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated 
by NYHA Functional Class II or greater	  
4. The subject or the subject's legal representative has been informed of the 
nature of the study, agrees to its provisions and has provided written informed 
consent.	  
5. The subject, after formal consults by a cardiologist and two cardiovascular 
surgeons agree that medical factors and co-morbidities preclude conventional 
operation, based on a conclusion that the probability of death or serious, 





Contraindications	  for	  TAVI	  were	  considered	  as	  general,	  approach-­‐	  or	  device-­‐specific.	  
	  
-­‐ General	  contraindications	  for	  TAVI:	  
o Aortic	  annulus	  <18	  or	  >25	  mm	  for	  balloon-­‐expandable	  and	  <20	  or	  >27	  
for	  self-­‐expandable	  devices	  
o Bicuspid	  valves	  (because	  of	  the	  risk	  of	  incomplete	  deployment	  of	  the	  
prosthesis)	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o Presence	   of	   asymmetric	   heavy	   valvular	   calcification,	   which	   may	  
compress	  the	  coronary	  arteries	  during	  TAVI	  (Fig	  2.)	  
o Aortic	  root	  dimension	  >45	  mm	  at	  the	  aorto-­‐tubular	   junction	  for	  self-­‐
expandable	  prostheses.	  
o Presence	  of	  apical	  LV	  thrombus.	  







Source:	  Edwards	  Lifesciences	  
	  
	  
The	  complete	  list	  for	  exclusion	  criteria	  are	  presented	  on	  Table	  2.	  	  
	  
Table	  2.	  
EXCLUSION CRITERIA FOR TAVI PROCEDURE (116)	  
1. Evidence of an acute myocardial infarction ≤ 1month before the intended 
treatment	  
2. Aortic valve is a congenital unicuspid or bicuspid valve; or is non-calcified	  
3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with 
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   92	  
predominant aortic regurgitation >3+)	  
4. Any therapeutic invasive cardiac procedure performed within 30 days of the 
index procedure.	  
5. Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe 
(greater than 3+) mitral insufficiency	  
6. Blood dyscrasias as defined: Leukopenia, acute anemia, 
thrombocytopenia, history of bleeding diathesis or coagulopathy	  
7. Hemodynamic instability requiring inotropic support or mechanical heart 
assistance.	  
8. Need for emergency surgery for any reason	  
9. Hypertrophic cardiomyopathy with or without obstruction	  
10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation	  
11. Active peptic ulcer or upper GI bleeding within the prior 3 months	  
12. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, 
or clopidogrel, or sensitivity to contrast media, which cannot be adequately 
pre-medicated	  
13. Native aortic annulus size < 16mm or > 27mm per the baseline echo as 
estimated by the LVOT	  
14. Patient has been offered surgery but has refused surgery.	  
15. Recent (within 6 months) CVA or a TIA	  
16. Life expectancy < 12 months due to non-cardiac co-morbid conditions.	  
17. Significant aortic disease, including abdominal aortic or thoracic aneurysm 
defined as maximal luminal diameter 5cm or greater; marked tortuosity 
(hyperacute bend), aortic arch atheroma or narrowing (especially with 
calcification and surface irregularities) of the abdominal or thoracic aorta, 
severe "unfolding" and tortuosity of the thoracic aorta (applicable for 
transfemoral patients only).	  
18. Iliofemoral vessel characteristics that would preclude safe placement of at 
least an 18F introducer sheath such as severe obstructive calcification, 
severe tortuosity or vessels size less than 6 mm in diameter (applicable for 
transfemoral patients only).	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• TRANSFEMORAL	  OR	  TRANSAPICAL	  INDICATIONS	  
	  
The	  specific	  indications	  for	  transfemoral	  and	  transapical	  approaches	  were	  discussed	  
according	  to	  patient	  condition	  and	  local	  expertise	  of	  the	  Heart	  Team.	  
	  
Fig.	  3.	  Transfemoral	  and	  transapical	  approaches	  
Source:	  Edwards	  Lifesciences	  
	  
-­‐ Contraindications	  of	  the	  transfemoral	  approach:	  
o Iliac	   arteries:	   severe	   calcification,	   tortuosity,	   small	   diameter	   (<6mm	  
for	  CoreValve	  devices,	   <7mm	   for	  Edwards	  SAPIEN	  devices),	  previous	  
aorto-­‐femoral	  bypass	  (Fig	  4,	  5,6).	  
o Aorta:	   severe	   angulation,	   severe	   atheroma	   of	   the	   arch,	   coarctation,	  
aneurysm	  of	  the	  abdominal	  aorta	  with	  protruding	  mural	  thrombus.	  
o Presence	   of	   bulky	   atherosclerosis	   of	   the	   ascending	   aorta	   and	   arch	  
detected	  by	  TEE	  or	  CT	  (Fig	  7.)	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Source:	  Edwards	  Lifesciences	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Fig.	  6.	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Source:	  Edwards	  Lifesciences	  
	  
-­‐ Contraindications	  for	  the	  transapical	  approach	  (Fig	  9,10):	  
o previous	  surgery	  of	  the	  LV	  using	  a	  patch,	  such	  as	  the	  Dor	  procedure;	  
o calcified	  pericardium;	  
o severe	  respiratory	  insufficiency;	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Fig.	  9.	  Preferences	  for	  transapical	  or	  transfemoral	  approaches	  I	  	  
	  
Source:	  Edwards	  Lifesciences	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Fig.10.	  Preferences	  for	  transapical	  or	  transfemoral	  approaches	  II.	  
	  
Source:	  Edwards	  Lifesciences	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CONTROL	  (AVR)	  GROUP	  
	  
Control	  group	  was	  formed	  in	  a	  retrospective	  review	  of	  the	  Consorcio	  Hospital	  
General	   Universitario	   database	   of	   patients	  who	   received	   conventional	   aortic	   valve	  
replacement	  (AVR)	  surgery	  (isolated	  AVR	  or	  combined	  with	  coronary	  artery	  bypass)	  
between	   2007	   and	   2011.	   Only	   patients	   with	   degenerative	   calcific	   aortic	   stenosis	  
(either	   pure	   aortic	   stenosis	   or	   associated	   with	   significant	   regurgitation)	   were	  
included.	   Selection	   criteria	   excluded	   different	   ethiologies	   rather	   than	   calcific	   AS	  
(rheumatic,	   endocarditis,	   etc),	   emergent	   status,	   pure	   aortic	   regurgitation	   and	  
combined	  surgery	  of	  the	  aortic	  root.	  
	  
Statistically	  selected	  controls	  inside	  this	  group	  were	  identified	  by	  propensity	  
core	   matching	   and	   logistic	   regression	   criteria	   to	   match	   cases	   in	   the	   experimental	  
group.	  (will	  be	  described	  forward	  in	  the	  present	  section)	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4.	  Procedures	  
	  
ANESTHETIC	  CONSIDERATIONS	  	  
In	   patients	  with	   aortic	   stenosis	   attempts	   should	   be	  made	   to	   avoid	   tachycardia	  
with	  the	  choice	  of	  premedication	  and	  induction	  of	  anesthesia.	  Preload	  and	  afterload	  
are	   closely	  monitored	  and	  maintained	   in	   the	  early	   stages	  of	   the	  operation.	  During	  
induction	   and	   maintenance	   of	   anesthesia,	   an	   alpha-­‐adrenergic	   agent,	   such	   as	  
phenylephrine	  may	  be	  necessary	  to	  sustain	  adequate	  systemic	  pressures.	  A	  narcotic-­‐
based	  anesthetic	  agent	  avoids	  myocardial	  depression,	  hypotension	  and	  arrhythmias.	  
Atrial	   flutter	   or	   fibrillation	   is	   treated	   with	   synchronized	   cardioversion	   to	   avoid	  
reduction	  in	  cardiac	  output.	  If	  the	  patient’s	  cardiac	  status	  deteriorates	  on	  induction,	  
emergency	  institution	  of	  cardiopulmonary	  bypass	  may	  be	  required.	  	  
	  
-­‐ Monitoring:	   ECG,	   1	   invasive	   arterial	   pressure	   line,	   O2	   saturation,	  
capnography,	   anesthetic	   gases	   concentration	   and	   temperature.	  Mechanical	  
ventilation	  monitoring	  and	  neuromoritoring	  (BIS®	  and	  INVOS®)	  
-­‐ Central	   venous	   access:	   Preferably	   right	   internal	   jugular	   vein.	   Trilumen	  
catheter	  with	  venous	  pressure	  monitoring	  and	  Swan-­‐Ganz®	  catheter	  access.	  	  
-­‐ Fluid	  output:	  standard	  Foley®	  urinary	  catheter	  
-­‐ Temperature	  monitoring:	  nasopharyngeal	  and/or	  tympanic	  probes	  
-­‐ External	  pacemaker:	  St.	  Jude	  Medical®	  8083	  external	  pulse	  generator	  
-­‐ Anticoagulation:	  Activated	  clotting	   times	  >250	   seconds	   for	  TAVI	  procedures	  
and	  >300	  for	  conventional	  AVR.	  
	  
	  
TRANSESOPHAGEAL	  ULTRASOUND	  MONITORING.	  	  
	  
For	  the	  presurgical	  evaluation,	  the	  standard	  views	  according	  to	  the	  guidelines	  
of	   the	   American	   Society	   of	   Echocardiography	   and	   the	   Society	   of	   Cardiovascular	  
Anesthesiologists	  are	  used.	  (Shanewise	  JS,	  Anesth	  Analg	  1999)	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The	   transgastric	   short-­‐axis	   view	   (TG	  mid-­‐SAX)	   is	   chosen	   initially	   to	  estimate	  
the	  left	  ventricular	  function	  and	  screen	  for	  regional	  wall	  motion	  abnormalities	  in	  the	  
left	   ventricle.	   Reliable	   and	   valid	   assessments	   of	   the	   degree	   of	   aortic	   stenosis	   are	  
made	  by	  using	  Doppler	  measurements	  in	  the	  transgastric	  longaxis	  view	  (TG	  LAX)	  or	  
in	  the	  deep	  transgastric	  long-­‐axis	  view	  (deep	  TG	  LAX).	  
	  
Pressure	  gradients	  should	  be	  measured	  under	  constant	  and	  optimal	   loading	  
conditions.	   In	   addition,	   left	   ventricular	   outflow	   tract	   blood	   flow	   profiles	   are	  
registered	  using	  pulsed-­‐wave	  Doppler	   in	  order	   to	  exclude	  any	  subvalvular	  stenosis.	  
The	   evaluation	   is	   completed	   by	   the	  measurement	   of	   left	   ventricular	   outflow	   tract	  
and	  aortic	  root	  diameters.	  	  
	  
For	   further	  evaluation	  of	   the	  aortic	   valve,	   the	  midesophageal	   long-­‐axis	   (ME	  
AV	  LAX)	  and	  midesophageal	  short-­‐axis	  (ME	  AV	  SAX)	  views	  are	  used.	  The	  ME	  AV	  SAX	  
allows	   the	   leaflets	   to	   be	   examined	   for	   morphology.	   The	   annulus	   of	   the	   diseased	  
valve	  also	  should	  be	  inspected	  for	  the	  presence	  of	  calcification.	  
	  
ME	  AV	  LAX	  is	  used	  for	  the	  standard	  measurement	  of	  aortic	  root	  diameter	  as	  
well	   as	   the	   diameters	   of	   the	   sinus	   of	   Valsalva,	   the	   sinotubular	   junction,	   and	   the	  
ascending	  aorta.	  	  
	  
The	   postsurgical	   evaluation	   focuses	   on	   valve	   position,	   valve	   function	  
(regurgitation	   and	   stenosis),	   presence	   of	   new	   regional	   wall	   motion	   abnormalities	  
(clue	   to	   coronary	   ostial	   obstruction),	   and	   the	   assessment	   of	   the	   biventricular	  
function.	  The	  sutureless	  implantation	  technique	  of	  stent-­‐fixed	  aortic	  valve	  prosthesis	  
means	   that	   the	   risk	   of	   paravalvular	   aortic	   regurgitation	   is	   significantly	   higher	   than	  
conventional	   AVR.	   The	   detection,	   localization,	   and	   quantification	   of	   aortic	  
regurgitation	   are	   crucial	   to	   guide	   intraoperative	   decision	  making.	   Paravalvular	   and	  
intravalvular	   regurgitation	   should	   be	   evaluated	   in	  multiple	   views	   including	   the	  ME	  
AV	  LAX,	  the	  ME	  AV	  SAX,	  deep	  TG	  LAX,	  and	  the	  TG	  LAX	  views.	  The	  severity	  of	  aortic	  
regurgitation	  can	  be	  quantified	  by	  the	  pressure	  half-­‐time	  method	  and	  regurgitation	  
jet	  width	  in	  relation	  to	  the	  left	  ventricular	  outflow	  tract.	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The	  echocardiographer	  and	   the	  anesthesiologist	  must	  be	  aware	  of	  multiple	  
rare	  cardiac	  complications	  throughout	  the	  procedure	  such	  as	  coronary	  obstruction,	  
mitral	   valve	   injury,	   annular	   and	   root	   rupture,	   aorto-­‐atrial	   shunt,	   and	   cardiac	  
perforation	   with	   the	   development	   of	   sudden	   cardiac	   tamponade.	   Thus,	  
perioperative	   TEE	   is	   a	   baseline,	   essential	   assessment	   for	   instantaneous	   valve	  




TRANSCATHETER	  AORTIC	  VALVE	  IMPLANT	  
	  
• GENERAL	  OVERVIEW	  
	  
TAVI	   is	   currently	   carried	   out	   using	   two	   different	   approaches	   (retrograde	  
transfemoral	  and	  anterograde	  transapical),	  which	  share	  the	  same	  main	  principles.	  All	  
procedures	  are	   carried	  out	  under	  general	   anesthesia,	   although	   regional	  anesthesia	  
may	  suffice	  for	  transfemoral	  patients.	  
	  
Peri-­‐procedural	   transoesophageal	   echocardiography	   (TEE)	   monitoring	   is	  
mandatory	  to	  correctly	  position	  the	  valve	  as	  well	  as	  to	  detect	  complications.	  
	  
After	   crossing	   the	   aortic	   valve,	   BAV	   is	   performed	   to	   pre-­‐dilate	   the	   native	  
valve	  and	  serve	  as	  a	  rehearsal	  for	  TAVI.	  Simultaneous	  rapid	  pacing	  decreases	  cardiac	  
output,	   stabilizing	   the	   balloon	   during	   inflation.	   Normal	   blood	   pressure	   must	   be	  
completely	  recovered	  between	  sequences	  of	  rapid	  pacing.	  
	  
The	  following	  imaging	  methods	  can	  be	  used	  to	  position	  the	  prosthesis	  at	  the	  
aortic	  valve:	  
	  
-­‐ Fluoroscopy	  to	  assess	  the	  level	  of	  valve	  calcification.	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-­‐ Aortography,	   using	   different	   views,	   performed	   at	   the	   beginning	   of	   the	  
procedure	  and	  eventually	  repeated	  with	  the	  undeployed	  prosthesis	  in	  place,	  
to	   determine	   the	   position	   of	   the	   valve	   and	   the	   plane	   of	   alignment	   of	   the	  
aortic	  cusps.	  
-­‐ Echocardiography:	   TEE	   is	   helpful,	   in	   particular,	   in	   cases	   with	   moderate	  
calcification.	  Three	  dimensional	  real-­‐time	  TEE	  provides	  an	  additional	  value.	  
	  
When	  positioning	  is	  considered	  correct,	  the	  prosthesis	   is	  released.	  Rapid	  pacing	  
is	  used	  at	  this	  stage	  in	  balloon	  expandable	  but	  not	  in	  self-­‐expanding	  devices.	  
	  
Immediately	   after	   TAVI,	   aortography	   and,	   whenever	   available,	   TEE	   or,	   in	   the	  
absence	   of	   TEE,	   eventually	   Transthoracic	   echocardiogram	   (TTE)	   are	   performed	   to	  
assess	   the	   location	   and	   degree	   of	   aortic	   regurgitation	   and	   the	   patency	   of	   the	  
coronary	   arteries	   and	   to	   rule	   out	   complications	   such	   as	   haemopericardium,	   and	  
aortic	  dissection.	  The	  haemodynamic	  results	  are	  assessed	  using	  pressure	  recordings	  
and/or	  echocardiography.	  
	  
After	  the	  procedure,	   the	  patients	  should	  stay	   in	   intensive	  care	  for	  at	   least	  24	  h	  
and	   be	   closely	   monitored	   for	   several	   days	   especially	   as	   regards	   haemodynamics,	  
vascular	   access,	   rhythm	   disturbances	   (especially	   late	   atrioventricular	   block),	   and	  
renal	  function.	  
	  
The	  following	  are	  the	  specific	  issues	  related	  to	  the	  different	  approaches.	  
	  
-­‐ In	  the	  transfemoral	  approach,	  close	  attention	  should	  be	  paid	  to	  the	  vascular	  
access.	  
-­‐ The	  common	  femoral	  artery	  can	  be	  either	  prepared	  surgically	  or	  approached	  
percutaneously.	  Echo-­‐guided	  femoral	  access	  could	  be	  useful.	  Manipulation	  of	  
the	   introductory	   sheaths	   should	   be	   careful	   and	   fluoroscopically	   guided.	  
Depending	   on	   the	   size	   of	   the	   device,	   closure	   of	   the	   vascular	   access	   can	   be	  
effected	  surgically	  or	  using	  a	  percutaneous	  closure	  device.	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-­‐ For	   the	   transapical	   approach,	   femoral	   access	   and	   cardiopulmonary	   bypass	  
should	  be	  on	  standby	  in	  patients	  in	  whom	  surgical	  conversion	  is	  an	  option	  in	  
case	   of	   complications.	   The	   technique	   requires	   an	   antero-­‐lateral	   mini-­‐
thoracotomy,	  pericardiotomy,	   identification	  of	   the	  apex,	  and	   then	  puncture	  
of	   the	   left	   ventricle	   using	   a	   needle	   through	   purse-­‐string	   sutures.	  
Subsequently,	   an	   introductory	   sheath	   is	   positioned	   in	   the	   LV,	   and	   the	  
prosthesis	  is	  implanted	  using	  the	  anterograde	  route.	  
	  
Administer	   a	   bolus	   of	   heparin	   at	   the	   start	   of	   the	   procedure.	   During	   the	  




• TRANSAPICAL	  APPROACH	  
	  
a) Baseline	  parameters	  
	  
1. Place	  radial	  arterial	  line	  for	  continuous	  arterial	  blood	  pressure	  monitoring.	  
2. Place	   an	   internal	   jugular	   vein	   line	   for	  monitoring	   central	   venous	   pressures	  
and	  volumes	  via	  standard	  techniques.	  
3. Prepare	  and	  place	  a	  6F	  (2.0	  mm)	  sheath	  into	  a	  femoral	  artery,	  per	  standard	  
techniques.	  Through	  the	  femoral	  artery	  sheath,	  advance	  a	  5F	  (1.67	  mm)	  or	  6F	  
(2.0	   mm)	   pigtail	   catheter	   into	   the	   descending	   aorta	   and	   perform	   a	   supra-­‐
aortic	  angiogram	  with	  the	  projection	  of	  the	  native	  aortic	  valve	  perpendicular	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Fig.	  11.	  Placement	  of	  pigtail	  catheter	  
Source:	  Edwards	  Lifesciences	  
	  
4. Evaluate	   the	   height	   between	   the	   inferior	   aspect	   of	   the	   annulus	   and	   the	  
inferior	   aspects	   of	   the	   lowest	   coronary	   ostium	   for	   subsequent	   prosthetic	  
aortic	  valve	  implantation.	  
5. Set	  the	  stimulation	  parameters,	  test	  pacing	  at	  200	  to	  220	  b/min	  (See	  Edwards	  
Rapid	  Pacing	  Protocol)	  and	  then	  start	  pacing	  on	  demand	  at	  80	  beats/min	  or	  
as	  clinically	  indicated.	  
	  
	  
b) Apical	  access	  and	  native	  valve	  predilatation	   	  
	  
1. Access	   the	  apex	  of	   the	  pericardium	  through	  a	  mini-­‐anterior	   thoracotomy	  at	  
the	  5th	  or	  6th	  intercostal	  space.	  Incise	  the	  pericardium	  to	  expose	  the	  apex	  of	  
the	  left	  ventricle	  (LV).	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Fig.12.	  Transapical	  access	  
	  
Source:	  Edwards	  Lifesciences	  
	  
	  
2. Attach	  epicardial	  pacing	  leads	  to	  left	  ventricle	  and	  plug	  proximal	  end	  of	  leads	  
into	  pacemaker.	  
3. Place	   a	   reinforced	   double	   purse	   string	   on	   the	   LV	   apex	   to	   access	   the	   left	  
ventricle.	   Ensure	   the	   patient	   is	   anticoagulated	   with	   heparin	   to	   obtain	   an	  
activated	  clotting	  time	  (ACT)	  of	  ≥	  250	  seconds.	  
4. Under	   image	   guidance,	   place	   an	   18	   gauge	   (1.2	   mm)	   percutaneous	   needle	  
through	  the	  purse	  string	  into	  the	  LV	  cavity	  and	  advance	  a	  short	  0.035"	  (0.89	  
mm)	  stiff	  guidewire	  through	  the	  needle	  into	  the	  LV.	  Remove	  the	  needle	  and	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place	   an	   7F	   (2.7	   mm)	   introducer	   over	   the	   guidewire;	   then	   remove	   the	  
guidewire.	   Advance	   an	   260	   m	   x	   0.035"	   (0.89	   mm)	   extra-­‐stiff	   guidewire	  
through	   the	   87F	   (2.7	   mm)	   introducer	   and	   the	   native	   valve	   into	   the	  
descending	  aorta	  (Fig13,14,15).	  
	  
Fig.13	  
Source:	  Edwards	  Lifesciences	  
	  
Fig14.	  
Source:	  Edwards	  Lifesciences	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Fig	  15.	  
Source:	  Edwards	  Lifesciences	  
	  
	  
5. Remove	  the	  7F	  (2.7	  mm)	  sheath	  and	  replace	  with	  14F	  (4.7	  mm)	  sheath	  or	  use	  
the	  Ascendra®	  (Edwards	  Lifesciences,	  Irvine,	  CA,	  USA)	  introducer	  sheath	  set,	  
26F	  (8.6	  mm)	  x	  21	  cm.	  (Fig.15,16,17)	  
	  
Fig	  16.	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Source:	  Edwards	  Lifesciences	  
	  
Fig	  17.	  
Source:	  Edwards	  Lifesciences	  
	  
	  
6. Prepare	   a	   20	   mm	   commercially	   available	   balloon	   valvuloplasty	   catheter	  
(BVC),	   or	   the	   Ascendra®	   (Edwards	   Lifesciences,	   Irvine,	   CA,	   USA)	   	   balloon	  
aortic	  valvuloplasty	  catheter.	  
7. Advance	  the	  prepared	  BVC	  through	  the	  sheath	  over	  the	  guidewire,	  cross	  the	  
aortic	  valve,	  and	  position	  the	  balloon.	  (Fig.18)	  
	  
Fig.18	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Source:	  Edwards	  Lifesciences	  
	  
8. Begin	  predilation	  (Fig.19):	  
-­‐ Begin	  rapid	  pacing	  at	  200-­‐220	  bpm	  (beats	  per	  minute);	  once	  arterial	  
blood	  pressure	  has	  decreased	  to	  50	  mmHg	  or	  below,	  balloon	  inflation	  
can	  commence.	  
-­‐ Once	  the	  desired	   implantation	  position	   is	  verified,	  rapidly	   inflate	  the	  
BVC.	  
-­‐ Rapidly	  deflate	  the	  BVC.	  
-­‐ When	  the	  BVC	  has	  been	  completely	  deflated	  the	  pacemaker	  may	  be	  
turned	  off,	  or	  returned	  to	  80	  b/min,	  if	  clinically	  indicated.	  	  
9. Remove	  the	  balloon	  valvuloplasty	  catheter,	  leaving	  the	  guidewire	  in	  place	  in	  




Source:	  Edwards	  Lifesciences	  
	  
10. If	   applicable,	   remove	   14F	   (4.7	   mm)	   sheath	   and	   advance	   the	   Edwards®	  
(Edwards	   Lifesciences,	   Irvine,	   CA,	   USA)	   26F	   (8.6	   mm)	   x	   21	   cm	   introducer	  
sheath	   system	   over	   the	   guidewire.	   Insert	   the	   tip	   of	   the	   introducer	   sheath	  
through	   the	   apex	   of	   the	   LV	   and	   locate	   the	   sheath	   tip	   in	   the	   LV	   outflow	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immediately	  below	  the	  aortic	  valve;	  withdraw	  the	  dilator	  slowly,	  keeping	  the	  
introducer	  sheath	  in	  place.	  Continue	  to	  hold	  the	  guidewire	  centered	  relative	  
to	  the	  introducer	  sheath	  
	  
c)	  Prosthetic	  valve	  delivery	  
1. Advance	   the	   bioprosthesis/balloon	   catheter	   delivery	   assembly	   with	   the	  
loader	  over	  the	  guidewire.	  
2. Insert	   the	   tip	   of	   the	   loader	   into	   the	   introducer	   sheath	   housing	   while	  
maintaining	   a	   firm	   grip.	   The	   loader	   will	   lock	   into	   place	   when	   it	   is	   fully	  
advanced	  into	  the	  housing.	  
3. Tap	   lightly	   on	   the	   introducer	   sheath	   housing	   to	   release	   air	   bubbles	   to	   the	  
proximal	  end	  of	  the	  loader.	  Loosen	  the	  loader	  cap	  to	  release	  the	  air	  bubbles	  
from	   the	   loader,	   then	   tighten	   the	   cap	   until	   the	   loader	   is	   sealed	   but	   the	  
catheter	  can	  be	  moved	  with	  minimal	  resistance.	  (Fig.20)	  
	  
Fig.20	  	  
Source:	  Edwards	  Lifesciences	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4. Cross	  the	  native	  aortic	  valve	  and	  position	  the	  bioprosthesis/balloon	  assembly	  
so	  that	  the	  mid-­‐point	  of	  the	  bioprosthesis	  is	  beside	  the	  calcified	  zone	  of	  the	  
diseased	  valve	  as	  visualized	  on	  fluoroscopy.	  
5. Loosen	   the	   pusher	   nut	   and	   pull	   the	   pusher	   sleeve	   as	   far	   proximal	   as	   possible.	  
Tighten	  the	  pusher	  nut.	  (Fig.21)	  
	  
Fig.21	  
Source:	  Edwards	  Lifesciences	  
	  
6. The	   bioprosthesis/balloon	   assembly	   position	   may	   be	   adjusted	   within	   the	  
annulus	  by	  pulling	  back	  on	  the	  knob	  on	  the	  handle	  to	  deflect	  the	  catheter	  tip.	  
The	  deflection	  occurs	  in	  the	  same	  plane	  as	  the	  knob.	  If	  deflection	  is	  used,	  the	  
knob	  must	  be	  held	  until	  deployment	  of	  the	  bioprosthesis	  is	  complete.	  
	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   113	  
Fig.22	  
Source:	  Edwards	  Lifesciences	  
	  
7. Just	  prior	  to	  bioprosthesis/balloon	  inflation,	  start	  rapid	  pacing	  by	  setting	  the	  
PM	   to	   pace	   at	   200-­‐220	   b/min.	   The	   marked	   decrease	   in	   cardiac	   output	  
induced	   by	   the	   ventricular	   tachycardia	   allows	   for	   a	   more	   stable	   balloon	  
inflation.	  
8. Verify	   the	  correct	   location	  of	   the	  bioprosthesis	  with	   respect	   to	   the	  calcified	  
valve	  using	  image	  guidance.	  (Fig.23,24)	  
	  
Fig.23	  
Source:	  Edwards	  Lifesciences	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Fig.24	  
Source:	  Edwards	  Lifesciences	  
	  
9. Begin	  bioprosthesis	  deployment:	  
a. Begin	  rapid	  pacing	  at	  200-­‐220	  bpm;	  once	  arterial	  blood	  pressure	  has	  
decreased	   to	   50	   mmHg	   or	   below,	   balloon	   inflation	   can	   commence.	  
(Fig.25)	  
b. Rapidly	   inflate	   the	   balloon	   catheter	   with	   the	   entire	   contents	   of	   the	  
inflation	  syringe	  to	  completely	  deploy	  the	  bioprosthesis	   in	  the	  target	  
location.	  (Fig.26)	  
c. Once	  the	  bioprosthesis	  has	  been	  deployed,	  rapidly	  deflate	  the	  balloon	  
catheter.	  
d. When	   the	   balloon	   catheter	   has	   been	   completely	   deflated	   the	  
pacemaker	  may	   be	   turned	   off,	   or	   returned	   to	   80	   b/min,	   if	   clinically	  
indicated.	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Fig.25	  








d)	  Verification	  of	  prosthetic	  valve	  position	  and	  measurements	  
1. Perform	   a	   supra	   aortic	   angiogram	   to	   evaluate	   device	   performance	   and	  
coronary	  patency.	  (Fig.27)	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Fig.27	  
Source:	  Edwards	  Lifesciences	  
	  




Source:	  Edwards	  Lifesciences	  
	  
3. Tie	  the	  apical	  purse	  string	  in	  place	  and	  confirm	  hemostasis.	  
4. Measure	  the	  transvalvular	  pressure	  gradients.	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5. Remove	   all	   catheters	   and	   sheaths	   when	   the	   ACT	   level	   is	   appropriate	   (e.g.,	  
reaches	  <	  150	  sec).	  
6. Apply	  local	  hemostatic	  compression	  on	  the	  catheterization	  puncture	  sites,	  or	  




Source:	  Consorcio	  Hospital	  General	  Universitario	  (Valencia,	  Spain)	  
	  
7. The	   patient	   should	   remain	   on	   clopidogrel	   (75	   mg/day)	   for	   6	   months	   post	  
procedure	   and	   aspirin	   (75-­‐100	   mg/day)	   for	   life.	   Ticlopidine	   may	   be	   used	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• TRANSFEMORAL	  APPROACH	  
	  
a) Baseline	  parameters	  
1. Prepare	   and	   place	   a	   6F	   (2.0	   mm)	   sheath	   into	   each	   femoral	   artery,	   per	  
standard	  technique.	  (Fig.30)	  
2. Prepare	  and	  place	  an	  8F	  (2.7	  mm)	  sheath	  into	  the	  femoral	  vein	  that	  is	  contra-­‐
lateral	  to	  the	  artery	  selected	  for	  bioprosthesis	  implantation.	  
3. In	   the	  same	   leg	  used	   in	  Step	  2,	   introduce	  a	  5F	   (1.67	  mm)	  or	  a	  6F	   (2.0	  mm)	  
pigtail	   catheter	   into	   the	   femoral	   artery	   and	   advance	   the	   catheter	   into	   the	  
aortic	  root	  for	  continuous	  blood	  pressure	  monitoring.	  
4. Advance	   an	   8F	   (2.7	   mm)	   PA	   catheter	   into	   the	   femoral	   vein	   sheath	   to	   the	  
pulmonary	  artery.	  Collect	  required	  measurements.	  
5. If	  no	  diagnostic	  procedure	  has	  been	  performed	  within	  one	  month,	  perform	  
the	  following:	  
a. Through	  the	  femoral	  artery	  sheath,	  sequentially	  advance	  right	  and	  left	  
coronary	  artery	  diagnostic	  catheters,	  and	  perform	  selective	  coronary	  
angiograms.	  
b. Through	  the	  femoral	  artery	  sheath,	  perform	  a	  supra-­‐aortic	  angiogram	  
with	   the	   projection	   of	   the	   native	   aortic	   valve	   perpendicular	   to	   the	  
screen.	  
c. Evaluate	   the	   height	   between	   the	   inferior	   aspect	   of	   the	   annulus	   and	  
the	   inferior	   aspects	   of	   the	   lowest	   coronary	   ostium	   for	   subsequent	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Fig.	  30.	  	  
Source:	  Edwards	  Lifesciences	  
	  
6. Introduce	  a	  5F	  (1.67	  mm)	  to	  7F	  (2.3	  mm)	  pacemaker	  (PM)	   lead	  through	  the	  
8F	  (2.7	  mm)	  sheath	  in	  the	  femoral	  vein	  and	  advance	  the	  pacemaker	  lead	  until	  
its	  distal	  end	  is	  positioned	  in	  the	  right	  ventricle.	  
7. Set	   the	   stimulation	   parameters,	   test	   pacing	   at	   200	   to	   220	   b/min	   and	   then	  
start	  pacing	  on	  demand,	  at	  80	  b/min	  or	  as	  clinically	  indicated.	  	  
	  
	  
b) Native	  Valve	  Predilatation	  
1. Manually	  pre-­‐shape	  the	  tip	  of	  the	  guidewire.	  Through	  the	  6F	  (2.0	  mm)	  sheath	  
in	  the	  femoral	  artery	  selected	  for	  bioprosthesis	  implantation:	  
a. Advance	  a	  pigtail	   catheter	  over	  a	   standard	   	   guidewire	  and	  cross	   the	  
aortic	  valve	  per	  preferred	  technique.	  It	   is	  recommended	  to	  cross	  the	  
valve	   in	   the	   50°	   LAO	   position,	   using	   a	   straight	   guidewire.	   After	   the	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valve	   is	   crossed,	   advance	   the	   selected	   catheter	   over	   the	   guidewire	  
into	  the	  left	  ventricle.	  
b. Remove	   the	   guidewire	   and	   record	   required	   hemodynamic	  
information.	  Measure	  the	  cardiac	  output	  and	  assess	  the	  valve	  area.	  
	  
2. Advance	  a	  260	  cm	  extra-­‐stiff	  guidewire	  through	  the	  catheter	  (pigtail)	  into	  the	  
left	  ventricle.	  
3. Remove	  the	  catheter,	  leaving	  the	  guidewire	  in	  place	  in	  the	  left	  ventricle.	  
4. Over	  this	  guidewire,	  advance	  a	  14F	  (4.7	  mm)	  sheath	  into	  the	  femoral	  artery.	  
5. Advance	  the	  prepared	  balloon	  through	  the	  sheath	  over	  the	  guidewire,	  cross	  
the	  aortic	  valve,	  and	  position	  the	  balloon	  
6. Using	   diluted	   contrast	   medium	   (e.g.,	   15%	   contrast	   medium	   to	   heparinized	  
saline)	  fully	  and	  rapidly	  inflate	  the	  balloon	  with	  a	  hand-­‐held	  syringe	  until	  the	  
desired	  size	  is	  reached.	  In	  case	  of	  balloon	  instability,	  repeat	  balloon	  inflation	  
while	   ensuring	   rapid	   pacing	   (200-­‐220	   b/min)	   of	   the	   right	   ventricle.	   During	  
balloon	   inflation,	   measure	   the	   aortic	   blood	   pressure	   using	   the	   pigtail	  
catheter.	   Once	   the	   blood	   pressure	   has	   decreased	   to	   50	   mmHg	   or	   below,	  
balloon	  inflation	  can	  commence.	  (Fig.31)	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Fig.31	  
Source:	  Edwards	  Lifesciences	  
	  
	  
7. Remove	  the	  BVC,	  leaving	  the	  guidewire	  in	  place	  in	  the	  left	  ventricle.	  
	  
c) Prosthetic	  Valve	  Delivery	  
1. Predilate	  the	  femoro-­‐iliac	  axis	  by	  advancing	  increasing	  sized	  dilators	  over	  the	  
guidewire.	  Advance	  the	  maximum	  possible	  length	  of	  the	  introducer	  over	  the	  
guidewire	   while	   following	   its	   progression	   on	   fluoroscopy.	   Alternatively,	  
create	   an	   arteriotomy	   in	   the	   femoral	   artery	   selected	   for	   bioprosthesis	  
implantation	  to	  allow	  introduction	  of	  the	  sheath.	  Use	  a	  dilator,	   if	  necessary,	  
to	  expand	  the	  puncture	  site.	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2. Pull	   the	   bioprosthesis	   assembly	   into	   the	   delivery	   RetroFlex®	   (Edwards	  
Lifesciences	  Inc.,	  Irvine,	  CA,	  USA)	  or	  CoreValve®	  (Medtronic	  Inc.,	  Minneapolis,	  
MN,	   USA)	   catheter	   until	   the	   proximal	   edge	   of	   the	   bioprosthesis	   butts	   up	  
against	  the	  distal	  end	  of	  the	  delivery	  catheter;	  be	  careful	  to	  fold	  the	  proximal	  
balloon	   to	   allow	   easy	   advancement	   of	   the	   balloon	   out	   of	   the	   delivery	  
catheter.	  Deflect	  the	  delivery	  catheter	  and	  advance	  the	  balloon	  catheter	  out	  
to	  verify	  ease	  of	  advancement.	  (Fig.32)	  
	  
Fig.32	  
Source:	  Edwards	  Lifesciences	  
	  
	  
3. Advance	   the	  bioprosthesis	   assembly	   into	   the	   loader	   and	  position	   the	   tip	  of	  
the	  balloon	  catheter	  at	  the	  tip	  of	  the	  loader.	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4. Push	   the	   RetroFlex	   catheter	   up	   the	   descending	   aorta;	   deflect	   the	   tip	   as	  
needed	   (by	   rotating	   its	   handle	   "clockwise"	   or	   "counter-­‐clockwise")	   to	   track	  
over	  the	  guidewire	  and	  around	  the	  aortic	  arch.	  (Fig.33)	  
5. Cross	  the	  native	  aortic	  valve	  and	  position	  the	  bioprosthesis	  assembly	  so	  that	  
the	   bioprosthesis	   is	   beside	   the	   calcified	   zone	   of	   the	   diseased	   valve	   as	  
visualized	  on	  fluoroscopy.	  (Fig.34)	  
	  
Fig.	  33	  
Source:	  Edwards	  Lifesciences	  
	  
Fig.34	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Source:	  Edwards	  Lifesciences	  
	  
	  
6. Just	   prior	   to	   bioprosthesis	   inflation,	   start	   rapid	   pacing	   by	   setting	   the	  
pacemaker	   catheter	   to	   pace	   at	   200-­‐220	   b/min.	   The	   marked	   decrease	   in	  
cardiac	   output	   induced	   by	   the	   ventricular	   tachycardia	   allows	   for	   additional	  
stable	   balloon	   inflation	   (Not	   necessary	   in	   self-­‐expanding	   nitinol	   valves	   –	  
CoreValve®)	  
7. Re-­‐verify	   the	   correct	   location	   of	   the	   bioprosthesis	   with	   respect	   to	   the	  
calcified	  valve	  using	  fluoroscopy	  guidance.	  (Fig.35)	  
Fig.35	  
Source:	  Edwards	  Lifesciences	  
	  
8. Begin	  bioprosthesis	  deployment:	  
a. Begin	  rapid	  pacing	  at	  200-­‐220	  bpm;	  once	  arterial	  blood	  pressure	  has	  
decreased	  to	  50	  mmHg	  or	  below,	  balloon	  inflation	  can	  commence.	  
b. Once	  the	  desired	   implantation	  position	   is	  verified,	  rapidly	   inflate	  the	  
balloon	   catheter	  with	   the	   entire	   contents	   of	   the	   inflation	   syringe	   to	  
completely	  deploy	  the	  bioprosthesis	  in	  the	  target	  location.	  (Fig.36)	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Fig.36	  
Source:	  Edwards	  Lifesciences	  
	  
c. Once	  the	  bioprosthesis	  has	  been	  deployed,	  rapidly	  deflate	  the	  balloon	  
catheter.	  
d. When	   the	   balloon	   catheter	   has	   been	   completely	   deflated	   the	  
pacemaker	   may	   be	   turned	   off,	   or	   returned	   to	   80	   b/min	   if	   clinically	  
indicated.	  
	  
9.	  For	  Corevalve®	  deployment	  rapid	  pacing	  is	  not	  necessary.	  Start	  releasing	  the	  valve	  
when	  it	  is	  correctly	  positioned.	  
	  
d) Verification	  of	  Prosthetic	  Valve	  Position	  and	  Measurements	  
Measure	   and	   record	   both	   the	   invasive	   and	   non-­‐invasive	   hemodynamic	  
parameters	  required	  by	  the	  protocol.	  (Fig.37)	  
1	   Perform	  a	   supra	   aortic	   angiogram	   to	   evaluate	  device	  performance	   and	   coronary	  
patency.	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Fig.37	  
Source:	  Edwards	  Lifesciences	  
	  
2	  Measure	  and	  record	  the	  transvalvular	  pressure	  gradients.	  
3	  Remove	  all	  catheters	  and	  sheaths	  when	  the	  ACT	  level	  is	  appropriate	  (e.g.,	  reaches	  
<	  150	  sec).	  
4	  Apply	  local	  hemostatic	  compression	  on	  the	  catheterization	  puncture	  sites,	  or	  close	  
surgically	  if	  clinically	  indicated.	  (Fig.38)	  
	   Fig.38	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Source:	  Edwards	  Lifesciences	  
	  
5	   The	   patient	   should	   remain	   on	   clopidogrel	   (75	   mg/day)	   for	   6	   months	   post-­‐
procedure	  and	  aspirin	  




CONVENTIONAL	  AORTIC	  VALVE	  REPLACEMENT	  	   	  
	  
Full	   median	   sternotomy	   is	   the	   usual	   incision	   for	   conventional	   aortic	   valve	  
replacement,	   although	   a	   partial	   upper	   hemisternotomy	   is	   also	   used.	   After	  
heparinization	  (ACT>300	  sec),	  the	  ascending	  aorta	  is	  cannulated	  in	  the	  usual	  fashion,	  
and	   the	   right	   atrium	   is	   cannuated	   with	   a	   two-­‐stage	   single	   venous	   cannula.	  
Anterograde	  cardioplegia	  and	  aortic	  root	  vent	  catheter	  are	  placed	  in	  the	  ascending	  
aorta,	   just	  distal	   to	   the	  proposed	  aortotomy	  site.	  A	  pursestring	  suture	   is	  placed	  on	  
the	   lateral	   side	   of	   the	   right	   atrium	   for	   the	   placement	   of	   a	   retrograde	   cardioplegia	  
cannula	  into	  the	  coronary	  sinus	  if	  needed.	  	  
	  
Cardiopulmonary	  bypass	  is	  instituted	  and	  the	  patient	  is	  systemically	  cooled	  to	  
34ºC.	  For	  patients	  with	  pure	  aortic	  stenosis	  without	  regurgitation,	  cardioplegic	  arrest	  
can	   adequately	   be	   achieved	   in	   an	   anterograde	   fashion.	   In	   those	   with	   a	   grade	   of	  
aortic	  regurgitation	  and	  depending	  on	  its	  severity,	  the	  first	  dose	  of	  cardioplegia	  can	  
be	   given	   directly	   into	   the	   coronary	   ostia	   via	   hand-­‐held	   cannulae	   after	   an	   oblique	  
aortotomy.	  During	  the	  operation,	  cardioplegic	  arrest	  is	  maintained	  with	  intermittent	  
instillation	  of	  cardioplegia	  every	  20	  minutes.	  Blood-­‐based	  cold	  cardioplegia	  at	  4ºC	  is	  
used	  in	  all	  cases,	  as	  well	  as	  topical	  hypothermia.	  
	  
An	   oblique	   aortotomy	   is	   made	   with	   the	   initial	   incision	   2-­‐4	   mm	   above	   the	  
sinotubular	   junction	  and	  4-­‐6	  mm	  above	  the	  origin	  of	  the	  right	  coronary	  artery.	  The	  
incision	  extends	  towards	  the	  non-­‐coronary	  sinus,	  staying	  just	  above	  the	  level	  of	  the	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commissures.	   Sutures	   of	   3/0	   silk	   or	   polyester	   are	   placed	   in	   the	   aortic	   wall	   for	  
retraction	  and	  exposure.	  	  	  
	  
The	  anatomy	  of	   the	  aortic	  valve,	   sinuses,	   sinotubular	   junction,	  and	  anterior	  
leaflet	  of	  the	  mitral	  valve	  is	  assessed.	  The	  diseased	  valve	  is	  sharply	  excised	  without	  
damage	   to	   the	   aortoventricular	   junction	   and	   the	   annulus	   carefully	   debrided	   of	  
calcific	   deposits	   using	   small	   rongeurs.	   Care	   should	   be	   taken	   as	   vigorous	  
decalcification	   may	   result	   in	   aortic	   wall	   injury,	   injury	   to	   the	   anterior	   mitral	   valve	  
leaflet,	   annular	   disruption,	   or	   left	   ventricular	   wall	   injury.	   Small	   calcific	   debris	   is	  




Source:	  Consorcio	  Hospital	  General	  Univeritario	  (Valencia,	  Spain)	  
	  
The	   annulus	   is	   sized	  with	   a	   valve	   sizer	   and	   interrupted	   horizontal	  mattress	  
sutures	  of	  3/0	  with	  Teflon	  pledgets	  are	  placed	  in	  the	  annulus.	  Sutures	  are	  positioned	  
in	  a	  ventricle-­‐to-­‐aorta	  fashion	  for	  supra-­‐valvular	  placement	  of	  the	  prosthesis.	  Care	  is	  
taken	   in	   the	   region	   of	   the	   membranous	   septum,	   located	   inferior	   to	   the	   cupola	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formed	  by	  the	  commissure	  of	  the	  noncoronary	  and	  right	  coronary	  leaflets,	  so	  as	  to	  
avoid	  injury	  to	  the	  bundle	  of	  His.	  	  
	  
The	  sutures	  are	  passed	  through	  the	  sewing	  ring	  of	  the	  valve	  prosthesis.	  The	  
valve	  holder	   is	  removed	  and	  the	  valve	  gently	  pushed	  into	  position.	  The	  sutures	  are	  
tied	  and	  cut	  and	  the	  competency	  of	  the	  valve	  is	  tested.	  (Fig	  40.)	  
Aortotomy	   is	   closed	  using	  a	  4/0	  polypropylene	   continuous	   suture	  placed	   in	  
an	  overlapping	  fashion	  beginning	  from	  the	  level	  of	  the	  sinus	  and	  extending	  upward,	  
while	  the	  patient	  is	  rewarming.	  	  
After	   aortotomy	   closure,	   the	   aortic	   root	   vent	   is	   connected	   to	   suction,	   volume	   is	  
added	   to	   the	   heart,	   lungs	   are	   gently	   ventilated	   and	   the	   left	   ventricle	   is	   gently	  
massaged.	  	  
	  
The	   patient	   is	   placed	   in	   a	   steed	   Trendelemburg’s	   position	   and	   the	   aortic	  
cross-­‐clamp	   is	   removed.	   With	   the	   heart	   ejecting	   the	   aortotomy	   is	   inspected	   for	  
hemostasis.	   Additional	   deairing	   maneuvers	   are	   performed.	   After	   adequate	  
rewarming	   the	   patient	   is	   weaned	   from	   cardiopulmonary	   bypass	   and	   then	  
deccanulated.	   Hemostasis	   and	   sternotomy	   closure	   are	   performed	   in	   the	   usual	  
fashion.	  	  
	  
In	   cases	   of	   combined	   aortic	   valve	   replacement	   and	   coronary	   artery	   bypass	  
grafting,	   the	   distal	   coronary	   anastomoses	   using	   vein	   or	   free	   arterial	   grafts	   are	  
constructed	   first	   before	   the	   valve	   procedure.	   The	   distal	   internal	   mammary	   artery	  
graft	   anastomosis	   is	   performed	   after	   the	   valve	   procedure	   and	   closure	   of	   the	  
aortotomy.	   During	   a	   combined	   valve-­‐coronary	   procedure,	   cardioplegia	   can	   be	  
instilled	  anterograde	  via	  the	  vein	  (or	  free	  arterial)	  grafts	  and	  retrograde	  through	  the	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Fig.40	  
	  




Patients	   are	   closely	  monitored	   in	   the	   intensive	   care	  unit	   postoperatively.	   A	  
pulmonary	  artery	  catheter	  is	  often	  helpful	  in	  assessing	  cardiac	  performance.	  Because	  
they	   experience	   reduced	   left	   ventricular	   afterload,	   the	   majority	   of	   patients	   with	  
aortic	   stenosis	   and	   left	   ventricular	   dysfunction	   have	   dramatic	   improvement	   after	  
aortic	  valve	  replacement.	  Ejection	  fraction	  is	  improved,	  and	  the	  left	  ventricular	  end-­‐
diastolic	   volume	   and	   capillary	   wedge	   pressures	   are	   decreased.	   In	   those	   with	   low	  
transvalvular	   gradients	   preoperatively,	   left	   ventricular	   performance	   may	   not	  
improve	   significantly	  after	  aortic	   valve	   replacement,	  and	   intra-­‐aortic	  balloon	  pump	  
support	  may	  be	  required	  in	  the	  early	  postoperative	  period.	  	  
	  
Although	   myocardial	   function	   generally	   improves	   relatively	   rapidly,	   the	  
hypertrophied	   ventricle	   requires	   and	   elevated	   preload	   to	   function	   normally.	   If	   the	  
residual	  transvalvular	  gradient	  is	  low,	  left	  ventricular	  hypertrophy	  regresses	  over	  the	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ensuing	   months.	   If	   the	   patient	   had	   a	   previous	   significant	   degree	   of	   aortic	  
regurgitation,	   left	   ventricular	   end-­‐diastolic	   pressure	   and	   volume	   decrease	  
immediately	   along	   with	   a	   decrease	   in	   wall	   stress;	   however,	   regression	   of	   left	  
ventricular	  hypertrophy	  and	  dilatation	  is	  gradual.	  Postoperatively,	  adequate	  preload	  
is	   important	   to	   fill	   the	  dilated	   left	   ventricle.	   Inotropic	  or	   intra-­‐aortic	  balloon	  pump	  
may	  be	  required	  early	  postoperatively	  until	  left	  ventricular	  function	  improves.	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5.	  Variables	  in	  the	  study	  
	   	  
The	  main	  variables	  used	  in	  the	  study	  are	  presented	  in	  Table	  3.,	  along	  with	  its	  
continuous	  (CON)	  or	  categorical	  (CAT)	  condition	  and	  its	  definition.	  They	  are	  classified	  
into	  preoperative	  variables,	  preoperative	  rhythm,	  coronary	  disease,	  anatomical	  and	  
morphometric,	   valve	   outcomes,	   primary	   outcomes,	   length	   of	   stay	   and	   discharge	  
rhythm.	  
	  
Table	  3.	  Main	  variables	  in	  the	  study	  
VARIABLES	   TYPE	   DEFINITION	  
	   	   	  
PREOPERATIVE	   	   	  
Age	  (y)	   CON	   Age	  in	  years	  
Gender	  (%male)	   CAT	   Gender	  (male/female)	  
EuroSCORE	   CON	   Additive	  score	  for	  EuroSCORE	  scale	  









Any	   of	   or	   more	   of	   the	   following:	   claudication,	  
carotid	   occlusion	   or	   >50%	   stenosis,	   previous	   or	  
planned	   intervention	   on	   the	   abdominal	   aorta,	  




Neurologic	   dysfunction	   severely	   affecting	  
ambulation	  or	  day-­‐to-­‐day	  functioning	  
Previous	  Cardiac	  Surgery	   CAT	  





Preoperative	  creatinine	  level	  >2.2	  mg/d	  L	  and/or	  
preoperative	  hemodyalisis	  
Active	  Endocarditis	   CAT	  
Patient	   still	   under	   antibiotic	   treatment	   for	  




Any	   one	   or	   more	   of	   the	   following:	   ventricular	  
tachycardia	   or	   fibrillation	   or	   aborted	   sudden	  
death,	   preoperative	   cardiac	   massage,	  
preoperative	   ventilation	   before	   arrival	   in	   the	  
anaesthetic	   room,	   preoperative	   inotropic	  
support,	  intraaortic	  balloon	  counterpulsation,	  or	  
preoperative	   acute	   renal	   failure	   (anuria	   or	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oliguria	  <10	  mL/h)	  
Unstable	  angor	   CAT	  
Rest	  angina	  requiring	  nitrates	  until	  arrival	  in	  the	  
anaesthetic	  room	  
EF	  30/50	  %	   CAT	  
Moderate	   left	  ventricle	  dysfunction	  (30-­‐50%)	  as	  
measured	  by	  echocardiography	  
EF	  <	  30%	   CAT	  
Severe	   left	   ventricle	   dysfunction	   (<30%)	   as	  
measured	  by	  echocardiography	  
Recent	  MI	   CAT	   Myocardial	  infarction	  within	  90	  days	  of	  surgery	  
Severe	  Pulmonary	  
Hypertension	  
CAT	   Systolic	  pulmonary	  artery	  pressure	  >60	  mmHg	  
Emergency	   CAT	  
Suregery	   carried	   out	   on	   referral	   before	   the	  
beggining	  of	  the	  next	  working	  day	  
Other	  than	  CABG	   CAT	  
Major	   cardiac	   procedure	   other	   than	   or	   in	  
addition	  to	  coronary	  artery	  bypass	  graft	  surgery	  
Surgery	  on	  Thoracic	  
Aorta	  
CAT	  
Surgery	   for	   disorder	   of	   the	   ascending,	   arch	   or	  
descending	  aorta.	  	  




Moderate	   or	   severe	   mitral	   valve	   regurgitation	  
(grades	   III	   or	   IV)	   as	   measured	   by	  
echocardiography	  
NYHA	  III/IV	   CAT	  
New	   York	   Heart	   Association	   functional	   class	  
grades	  III	  or	  IV	  
CHF	   CAT	  
Clinical	   or	   radiologic	   signs	   of	   left	   heart	   failure	  
(ortopnea,	  pulmonary	  edema,	  etc)	  
Calcified	  Aorta	   CAT	  
Severe	   calcification	   of	   the	   ascending,	   arch	   or	  
descending	   aorta	   identified	   by	   preoperative	  
image	  studies.	  
Diabetes	  mellitus	   CAT	  
Diabetes	   mellitus	   under	   pharmacologic	   or	  
insulin	  control	  
	   	   	  
RHYTHM	  (PREOP)	   	  
Preoperative	   cardiac	   rhythm	   on	  
electrocardiography	  
sinus	  rhythm	   CAT	   sinus	  rhythm	  
AF	  rhythm	   CAT	   atrial	  fibrillation	  or	  flutter	  rhythms	  
PCM	  rhythm	   CAT	   pacemaker	  rhythm	  
	   	   	  
CORONARY	  DISEASE	   	  
Presence	  of	  ischemic	  coronary	  disease	  identified	  
by	  haemodinamic	  studies	  
PTCA	   CAT	  
Previous	   preoperative	   precutaneous	  
transluminal	  coronary	  angioplasty	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CABG	   CAT	  
One	   or	   more	   coronary	   artery	   bypass	   grafts	   in	  
addition	  to	  aortic	  valve	  replacement	  
No	  vessels	   CON	   Number	  of	  diseased	  coronary	  vessels	  
No	  grafts	   CON	  
Number	   of	   coronary	   artery	   bypass	   grafts	  
performed	  
	   	   	  
ANATOMICAL	  &	  
MORPHOMETRIC	  
	   	  
Weight	  (kg)	   CON	   Wheight	  in	  kilograms	  
Height	  (cm)	   CON	   Height	  in	  centimeters	  
BSA	   CON	   Body	  Surface	  Area	  in	  m2	  
BMI	   CON	   Body	  Mass	  Index	  in	  kg/m2	  
Valve	  area	   CON	  
Aortic	   valve	   area	   by	   planimetry	   on	   ultrasound	  
studies	  (cm2)	  
Mean	  grad	   CON	  
Mean	   transaortic	   valve	   gradient	   on	   ultrasound	  
studies	  (mmHg)	  
Peak	  grad	   CON	  
Peak	   transaortic	   valve	   gradient	   on	   ultrasound	  
studies	  (mmHg)	  
Peak	  vel	   CON	   Peak	  transaortic	  blood	  jet	  flow	  velocity	  (m/s)	  
	   	   	  
VALVE	  OUTCOMES	   	   	  
Success	  implant	  rate	   CAT	   Rate	  of	  successful	  aortic	  valve	  implant	  
Valve	  implant	  size	  (mm)	   CON	   Prosthetic	  implant	  diameter	  in	  mm	  
Biological	  valve	  (%)	   CAT	   Biological	  protsthetic	  implant	  
	   	   	  
PRIMARY	  OUTCOMES	   	   	  
30-­‐d	  mortality	  (%)	   CAT	   Perioperative	  mortality	  at	  30	  days	  after	  surgery	  
MACCE	   CAT	  
Major	  Adverse	  Cardio	  or	  Cerebrovascular	  Event.	  
Composite	  event	  of	  perioperative	  mortality	  (30-­‐
days	   mortality)	   or	   major	   cardiovascular	   or	  
neurological	  complications	  
Mortality	  (cause)	   	   Causes	  of	  perioperative	  mortality	  
cardiac	   CAT	  
Cardiac-­‐related	   death	   (myocardial	   infarction,	  
malignant	  arrhythmia,	  sudden	  death,	  etc)	  
neurological	   CAT	  
Neurological-­‐related	   death	   (stroke,	   coma,	  
vegetative	  status,	  etc)	  
infective	   CAT	  
Death	  related	  to	  a	  non-­‐cardiac	  infective	  process	  
(septic	  shock,	  etc)	  
endocarditis	   CAT	   Death	   related	   to	   an	   early	   prosthetic	   valve	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endocarditis	  
respiratory	   CAT	  
Respiratory-­‐related	  death	   (distress,	   pneumonia,	  
etc)	  
renal	   CAT	   Death	  related	  to	  a	  postoperative	  renal	  failure	  
multiorganic	   CAT	   Death	  related	  to	  a	  multiorganic	  failure	  
unknown	   CAT	   Unknown	  cause	  of	  death	  
Perioperative	  morbidity	  
(all)	  
	   Major	  postoperative	  complications	  
Reintervention	   CAT	  
Major	   bleeding	   or	   pericardial	   tamponade	   that	  
requires	   reintervention	   in	   the	   early	  
postoperative	  period	  
Cardiovascular	   CAT	  
Major	   cardiovascular	   complication	   excluding	  
rhythm	   complication	   (myocardial	   infarction,	  
aortic	  or	  vascular	  injury,	  etc)	  
Respiratory	   CAT	  
Major	   respiratory	   complication	   (respiratory	  
insufficiency,	  distress,	  pneumonia,	  etc)	  
Wound	   CAT	  
Major	   wound	   complication	   (wound	   infection,	  
sternal	  dehiscence,	  mediastinitis,	  etc)	  
Renal	   CAT	  
Major	   renal	   complication	   (acute	   postoperative	  
renal	   failure,	   need	   for	   postoperative	  
haemofiltration	  or	  dyalisis,	  etc)	  
Neurological	   CAT	  
Major	   neurological	   complication	   (postoperative	  
stroke,	  coma,	  transient	  ischemic	  attack,	  etc)	  
Infective	   CAT	   Major	  infective	  complication	  (septic	  shock,	  etc)	  
Other	   CAT	   Other	  major	  complications	  (implant-­‐related,	  etc)	  
	   	   	  
LENGTH	  OF	  STAY	   	   	  
ICU	  LOS	  (days)	   CON	   Intensive	  Care	  Unit	  length	  of	  stay	  in	  days	  
Hospital	  LOS	  (days)	   CON	   Hospital	  length	  of	  stay	  in	  days	  
	   	   	  
RHYTHM	  (DISCHARGE)	   	  
Postoperative	   rhythm	   in	   the	   last	   ECG	   prior	   to	  
discharge	  
sinus	  rhythm	   CAT	   sinus	  rhythm	  
AF	  rhythm	   CAT	   atrial	  fibrillation	  
PCM	  rhythm	   CAT	  
pacemaker	   rhythm	   at	   discharge	   (includes	   pre	  
and	  postoperative	  PCM	  rhythms)	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6.	  Statistical	  analysis	  
	  
Statistical	  software	  package	  SPSS®	  v17.0	   for	  Windows®	  (SPSS	   Inc,	  MN,	  USA)	  
was	   used	   for	   the	   data	   analysis	   throughout	   the	  whole	   study,	   considering	   a	   level	   of	  
significance	  of	  p<0.05.	  The	  details	  for	  the	  group	  configuration	  and	  the	  data	  obtained	  
are	  presented	  as	  follows:	  
	  
a) GROUP	  CONFIGURATION	  
	  
Results	  are	  presented	  as	  ‘Overall’	  when	  referred	  to	  the	  whole	  population	  of	  
the	   study.	   Grouping	   of	   the	   data	   concerns	   the	   ‘TAVI	   (Transcatheter	   Aortic	   Valve	  
Implant)’	   group	   and	   the	   control	   ‘AVR	   (conventional	   Aortic	   Valve	   Replacement)’	  
group	  as	  separate	  and	  independent	  groups,	  according	  to	  the	  selected	  approach	  for	  
the	  surgical	  procedure	  in	  each	  case.	  Direct	  statistical	  comparison	  between	  groups	  is	  
foreseen.	  	  
	  
Subgroup	   analysis	   is	   planned	   in	   the	   design	   of	   the	   present	   study	   and	   it	  
considers	  the	  following	  subgroups:	  	  
• A	   so-­‐called	   ‘High-­‐Risk	   conventional	   Aortic	   Valve	   Replacement	   (HR-­‐
AVR)’	   group	   is	   obtained	   by	   means	   of	   statistical	   propensity	   score	  
matching	  (described	  later	  in	  the	  present	  chapter)	  and	  used	  for	  direct	  
comparison	   against	   the	   TAVI	   group.	   Univariate	   and	   multivariate	  
analysis	  as	  well	  as	  a	  survival	  study	  between	  TAVI	  and	  HR-­‐AVR	  is	  also	  
anticipated	  in	  this	  design.	  	  
	  
• Preoperative	   risk	   profile	   is	   measured	   by	   the	   preoperative	   variable	  
‘Logistic	   EuroSCORE’	   and	   it	   is	   used	   to	   divide	   groups	   with	   patients	  
scoring	   15%	   or	   over	   against	   those	   scoring	   under	   15%	   for	   direct	  
statistical	   comparison	   of	   the	   outcome	   variables	   ’30-­‐days	   mortality’	  
and	  ‘MACCE’.	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• Surgical	   approach	   site:	   transfemoral	   (TF)	   or	   transapical	   (TA)	   are	  
subgroups	  inside	  the	  TAVI	  group.	  Direct	  comparison	  between	  TF	  and	  
TA	  for	  the	  previously	  described	  study	  variables	   is	  performed.	  On	  the	  
other	   hand,	   surgical	   approach	   site	   considering	   median	   sternotomy	  
(MS),	  transfemoral	  approach	  (TF)	  or	  transapical	  approach	  (TA)	  is	  used	  
for	   subgroup	   testing	   in	   univariate	   analysis,	   multivariate	   analysis,	  
survival	  analysis	  and	  heart	  rhythm	  assessment	  between	  TAVI	  and	  HR-­‐
AVR	  groups.	  	  
• Year	  in	  which	  the	  procedure	  is	  performed	  is	  considered	  for	  descriptive	  
statistics	  between	  TAVI	  and	  HR-­‐AVR	  groups,	  as	  well	  as	  in	  multivariate	  
Cox	   regression	  analysis	   for	   long-­‐term	  survival	   to	  assess	   the	  effect	  of	  
the	  learning	  curve	  for	  each	  procedure.	  
	  
• Prostheses	   types	   used	   inside	   the	   TAVI	   group	   are	   presented	   for	  
descriptive	  statistics	  only.	  
	  
	  
b) DESCRIPTIVE	  STATISTICS	  
	  
• Continuous	  variables	  are	  presented	  as:	  mean	  +	  /-­‐	  standard	  deviation	  
or	  median	   (minimum	  –	  maximum)	  values.	   I	   .e.	  Age	   (years)	  71.76	  +/-­‐	  
8.35.	  Student	  t	  statistic	  is	  used	  for	  data	  analysis.	  
• Categorical	  (dichotomic)	  variables	  are	  presented	  as:	  number	  of	  cases	  
(percentage	  over	  total	  of	  the	  group).	   I.e.	  Gender	  (male)	  293	  (62.6%).	  
X2	   statistic	   or	   Fisher’s	   test	   (when	   the	   observed	   number	   of	   cases	   is	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c) PROPENSITY	  SCORE	  MATCHING	  
	  
A	  propensity	  score	   is	  performed	  to	   identify	  and	  match	  appropriate	  controls	  
inside	   the	   AVR	   group,	   by	   building	   a	   binary	   logistic	   regression	   model	   with	   the	  
following	  variables:	  EurosSCORE,	  body	  surface	  area,	  body	  mass	   index,	  age,	  gender,	  
chronic	   pulmonary	   disease,	   extracardiac	   arteropathy,	   neurological	   dysfunction,	  
previous	  cardiac	  surgery,	  preoperative	  renal	  failure,	  left	  ventricular	  ejection	  fraction,	  
pulmonary	  hypertension,	  mitral	   regurgitation,	  NYHA	  class,	   preoperative	   congestive	  
heart	  failure,	  calcified	  aorta,	  diabetes	  and	  presence	  of	  concomitant	  coronary	  lesions.	  	  
	  
The	  predicted	  group	  probability	  returned	  by	  the	  logistic	  regression	  equation,	  
using	   the	  enter	   stepwise	  method,	  was	  saved	  and	  used	   to	   select	  proximity	  controls	  
among	  the	  AVR	  group	  that	  matched	  every	  experimental	  case	   in	  the	  TAVI	  group,	  to	  
conform	   the	   control	  HR-­‐AVR	   group.	  Goodness-­‐of-­‐fit	   of	   the	  model	   is	   assessed	   by	   a	  
Hosmer-­‐Lemeshow’s	   test	   and	   discrimination	   capacity	   by	   building	   a	   receptor-­‐
operator	  characteristics	  (ROC)	  curve,	  to	  contrast	  the	  probability	  of	  belonging	  to	  the	  
TAVI	  group	  (returned	  by	  the	   logistic	  regression	  model)	  versus	  the	  real	  allocation	  to	  
that	  group	  for	  each	  case	  and	  the	  resulting	  area	  under	  the	  curve.	  	  	  
	  
TAVI	   experimental	   group	   is	   tested	   against	   HR-­‐AVR	   control	   group	   for	  
descriptive	  statistics,	  hospital	  length	  of	  stay,	  univariate	  and	  multivariate	  analysis	  for	  
30-­‐days	  mortality	  and	  MACCE	  outcome	  variables,	  long-­‐term	  survival	  analysis	  as	  well	  
as	  for	  the	  new	  preoperative	  discrimination	  score	  build-­‐up.	  
	  
	  
d) UNIVARIATE	  ANALYSIS	  
	   	  
Univariate	   logistic	   regression	   analysis	   between	   TAVI	   and	   HR-­‐AVR	   groups	   is	  
designed	  in	  order	  to	  assess	  significant	  predictors	  for	  the	  primary	  outcome	  variables:	  
30-­‐days	   mortality	   and	   MACCE.	   Results	   are	   obtained	   by	   binary	   logistic	   regression	  
equation	  using	   the	  enter	   stepwise	  method	  and	  expressed	  as	   regression	  coefficient	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(B),	  level	  of	  significance	  for	  the	  regression	  coefficient	  and	  predicted	  odds	  ratio	  with	  
95%	  confidence	  interval	  for	  each	  variable	  subjected	  to	  study.	  	  
	  
	  
e) MULTIVARIATE	  ANALYSIS	  
	  
	   Multivariate	  logistic	  regression	  analysis	  between	  TAVI	  and	  HR-­‐AVR	  groups	  is	  
performed	   to	   identify	   significant	   and	   independent	  predictors	   for	  30-­‐days	  mortality	  
and	  MACCE.	  A	  previously	   level	  of	   significance	  of	  p<0.2	   in	   the	  univariate	  analysis	   is	  
required	   to	   enter	   the	   model.	   Results	   are	   obtained	   by	   binary	   logistic	   regression	  
equation	  using	   the	  enter	   stepwise	  method	  and	  expressed	  as	   regression	  coefficient	  
(B),	  level	  of	  significance	  for	  the	  regression	  coefficient	  and	  predicted	  odds	  ratio	  with	  
95%	  confidence	  interval	  for	  each	  variable	  subjected	  to	  study.	  	  
	  
	  
f) SURVIVAL	  ANALYSIS	  
	  
Kaplan-­‐Meier	  survival	  method	  and	   log-­‐rank	  testing	  are	  set	   to	   find	  statistical	  
differences	   in	   long-­‐term	  survival	  between	  TAVI	   and	  HR-­‐AVR	  groups.	  A	  1-­‐year	  after	  
surgery	  survival	  analysis	  is	  foreseen	  as	  an	  intermediate	  endpoint.	  	  Long-­‐term	  survival	  
data	   was	   retrospectively	   collected	   from	   the	   ABUCASIS	   valencian	   health	   system	  
database.	  
	  
On	   the	  other	  hand,	   planned	   subgroup	  analysis	   considers	   long-­‐term	   survival	  
according	  to	  surgical	  approach	  site:	  median	  sternotomy	  (MS),	  transfemoral	  approach	  
(TF)	  or	  transapical	  approach	  (TA).	  	  
	  
This	  study	  seeks	  to	  ascertain	  the	   influence	  of	  a	   learning	  curve	  effect	  among	  
the	  different	  surgical	  approaches	  on	  survival.	  Multivariate	  Cox	  regression	  analysis	  is	  
designed	  considering	  the	  approach	  site	  (MS,	  TF,	  TA),	  the	  year	  in	  which	  the	  procedure	  
is	  performed	  and	  the	  survival	  status.	  Results	  are	  presented	  as	  regression	  coefficient	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(B),	  level	  of	  significance	  for	  the	  regression	  coefficient	  and	  predicted	  odds	  ratio	  with	  
95%	  confidence	  interval.	  
	  
	  
g) HEART	  RHYTHM	  ASSESSMENT	  	  
	  
	   Direct	   crosstabulation	   between	   preoperative	   and	   postoperative	   heart	  
rhythms	   is	   planned	   for	   TAVI	   and	   HR-­‐AVR	   groups,	   and	   X2	   of	   Fisher’s	   tests	   (if	   any	  
observation	  is	  n	  <	  5)	  are	  performed	  in	  order	  to	  find	  relevant	  differences	  before	  and	  
after	  surgery	  for	  both	  groups.	  Subgroup	  analysis	  considers	  approach	  site	  (MS,	  TF	  or	  
TA)	  and	  direct	  crosstabulation	  and	  X2	  or	  Fisher’s	  tests	  among	  them	  for	  preoperative	  
and	  postoperative	  rhythms.	  	  
	  
	  
h) ´REPLACEMENT	  OR	  TRANS-­‐CATHETER	  IMPLANT	  ODDS’	  SCORE	  
	  
The	  results	  of	  the	  multivariate	  logistic	  regression	  analysis	  between	  TAVI	  and	  HR-­‐
AVR	  groups	  are	  used	  in	  the	  construction	  of	  the	  new	  score.	  The	  non-­‐decimal	  part	  of	  
the	  regression	  coefficients	  (B)	  for	  each	  variable	  are	  considered	  as	  the	  scoring	  point	  
and	  the	  arithmetic	  sum	  of	  them	  if	  the	  total	  score	  for	  every	  patient.	  	  
	  
Discrimination	  capacity	  of	  the	  new	  score	  is	  tested	  in	  the	  case-­‐control	  study	  (TAVI	  
and	   HR-­‐AVR)	   by	   means	   of	   a	   Receptor-­‐Operator	   Characteristics	   (ROC)	   curve	   and	  
compared	  with	  additive	  and	  logistic	  EuroSCORE	  scores.	  The	  results	  are	  presented	  as	  
Area	  Under	  the	  Curve	  (AUC)	  and	  its	  95%	  confidence	  interval.	  	  
	  
After	  scoring	  calculation,	  patients	  are	  conventionally	  classified	  into	  ´Low	  Profile´	  
score	  (between	  0	  and	  2	  points)	  and	  ‘High	  Profile’	  score	  (3	  or	  more	  points).	  These	  two	  
categories	  (Low	  Profile,	  High	  Profile)	  are	  used	  as	  a	  categorical	  variable	  and	  combined	  
with	  the	  categorical	  procedure	  variable	  (TAVI	  or	  conventional	  AVR)	  to	  construct	  the	  
Classification	   and	   Regression	   Tree	   for	   the	   case-­‐control	   study	   (TAVI	   vs.	   HR-­‐AVR)	   in	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order	   to	   assess	   perioperative	   mortality	   for	   every	   different	   arm	   of	   the	   tree:	   Low	  
Profile-­‐TAVI,	  Low	  Profile-­‐HR-­‐AVR,	  High	  Profile-­‐TAVI,	  High	  Profile-­‐HR-­‐AVR.	  	  	  
	  
Internal	  validation	  and	  discrimination	  capacity	  of	  the	  new	  score	  is	  tested	  again	  in	  
the	  Overall	  database	  and	  afterwards	  in	  two	  subgroups:	  logistic	  EuroSCORE	  	  <	  15	  and	  
logistic	  EuroSCORE	  >	  15.	  ROC	  curves	  and	  CRT	  trees	  are	  constructed	  for	  every	  one	  of	  
them	  and	  results	  presented	  in	  the	  same	  fashion	  as	  previously	  described.	  	  
	  
External	   validation	   of	   the	   new	   score	   is	   intended	   by	   modelizing	   a	   ‘dummy’	  
database	  with	  similar	  characteristics	  as	  the	  PARTNER	  cohort	  A	  trial	  (see	  introduction	  
for	   details).	   A	   blank	   database	   is	   constructed	   and	   random	   allocation	   of	   dependent	  
variables	  and	  perioperative	  mortality	  is	  calculated	  for	  each	  case,	  intending	  to	  obtain	  
identical	   overall	   rates	   as	   those	   presented	   in	   the	   PARTNER	   Cohort	   A	   trial	   for	   each	  
variable.	   	   The	   new	   score	   is	   tested	   again	   in	   this	   ‘dummy’	   database	   in	   the	   same	  
fashion:	  ROC	  curves	  are	  constructed	  for	  the	  new	  score	  and	   logistic	  EuroSCORE	  and	  
the	  AUC	  is	  calculated	  and	  presented.	  CRT	  construction	  pretends	  to	  set	  discrimination	  
capacity	  of	   the	  new	  score	   in	   the	   ‘dummy’	  database	   for	  Low	  and	  High	  Risk	  Profiles,	  
the	  procedure	  performed	  (TAVI	  or	  AVR)	  and	  perioperative	  mortality	  rates.	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III.	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This	  retrospective	  study	  presents	  the	  data	  collected	  between	  April	  2007	  and	  
January	   2012,	   and	   includes	   a	   total	   of	   468	   patients	   that	   received	   AVR	   surgery	   in	   a	  
single	   institution	   (Consorcio	   Hospital	   General	   Universitario,	   Valencia,	   Spain).	   The	  
main	  demographic,	  morphometric	  and	  echocardiocraphic	  ultrasound	  characteristics	  
are	  presented	  on	  Table	  1.	  	  
	  
Table	  1.	  Preoperative	  characteristics	  
 
	   Overall	   TAVI	   AVR	   	  
n	   468	   53	   415	   	  
Age	  (y)	   71.76+/-­‐8.35	   80.42+/4.84	   70.65+/-­‐8.05	   p<0.001	  
Gender	  (%male)	   293	  (62.6%)	   26	  (49.1%)	   267	  (64.3%)	   p<0.05	  
Weight	  (kg)	   74.42+/-­‐12.66	   71.65+/-­‐16.51	   74.68+/-­‐12.06	   ns	  
Height	  (cm)	   160.13+/-­‐9.69	   155.72+/-­‐15.06	   160.70+/-­‐8.76	   p<0.05	  
BSA	  (m2)	   1.81+/-­‐0.17	   1.74+/-­‐0.17	   1.82+/-­‐0.17	   ns	  
BMI	  (kg/m2)	   28.93+/-­‐4.67	   28.19+/-­‐4.46	   29.02+/-­‐4.69	   ns	  
Coronary	  lesions	   176	  (37.6%)	   23	  (43.4%)	   153	  (36.9%)	   ns	  
No	  vessels	   0.72+/-­‐1.08	   1.74+/-­‐1.18	   1.95+/-­‐0.84	   ns	  
PTCA	   13	  (2.8%)	   11	  (20.8%)	   2	  (0.5%)	   ns	  
CABG	   142	  (30.3%)	   0	   142	  (34.2%)	   -­‐	  
No	  grafts	   0.63+/-­‐1.14	   0	   1.93+/-­‐1.21	   -­‐	  
Valve	  area	  (cm2)	   0.68+/-­‐0.19	   0.61+/-­‐0.13	   0.72+/-­‐0.21	   ns	  
Mean	  Grad	  (mmHg)	   52.38+/-­‐16.14	   52.25+/-­‐16.50	   53.04+/-­‐14.24	   ns	  
Peak	  Grad	  (mmHg)	   83.85+/-­‐26.25	   84.41+/-­‐27.65	   83.74+/-­‐26.05	   ns	  
Peak	  Vel	  (m/s)	   4.41+/-­‐0.82	   4.44+/-­‐0.72	   4.41+/-­‐0.86	   ns	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• PATIENT	  CHARACTERISTICS	  AND	  DEMOGRAPHICS	  
	  
Mean	  age	  was	  80.42+/-­‐4.84	   in	   the	  TAVI	  group	  and	  70	  +/-­‐8.05	  years	   in	  AVR	  
(p<0.001).	   Gender	   distribution	   was	   49.1%	   and	   64.3%	  male,	   respectively.	   (p<0.05).	  
Morphometric	   features	  were	   analyzed	   by	  weight	   (71.65+/-­‐16.51	   vs.	   74.68+/-­‐12.06	  
Kg,	   ns.),	   height	   (155.72+/-­‐15.06	   vs.	   160.70+/-­‐8.76	   cm,	   p<0.05)	   and	   their	   derivate	  
body	   surface	   area	   (BSA	   1.74+/-­‐0.17	   vs.	   1.82+/-­‐0.17	  m2,	   ns.)	   and	   body	  mass	   index	  
(BMI	  28.19+/-­‐4.46	  vs.	  29.02+/-­‐4.69	  Kg/m2,	  ns.)	  (Table	  1.	  Fig.	  1,2).	  
	  
Fig.1.	  Age	  distribution	  by	  groups	  
	  
BSA:	  Body	   surface	  area.	  BMI:	  body	  mass	   index.	  No.	   vessels:	   number	  of	  diseased	  
coronary	   vessels	   PTCA:	   percutaneous	   transluminal	   coronary	   angioplasty.	   CABG:	  
coronary	   artery	   bypass	   graft.	   No	   grafts:	   number	   of	   grafts.	   Mean	   grad:	   mean	  
transvalvular	  gradient.	  Peak	  grad:	  peak	  transvalvular	  gradient.	  Peak	  vel:	  peak	  jet	  
flow	  velocity.	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A	   total	   of	   313	   isolated	   AVR	   procedures	   and	   155	   ‘mixed’	   or	   ‘aortic	   plus	  
coronary’	   procedures	   were	   recorded,	   as	   long	   as	   they	   presented	   with	   both	   aortic	  
valve	   and	   ischemic	   coronary	   disease.	   Previous	   surgically	   or	   percutaneously	  
revascularized	   patients	   were	   considered	   as	   an	   isolated	   AVR	   in	   a	   REDO	   setting.	  
(methods),	   including	   	   11	   (20.8%)	   previous	   or	   concomitant	   PTCA	   with	   the	   TAVI	  
procedure	  and	  142	  (34.2%)	  concomitant	  CABG	  +	  AVR	  (Table	  1).	  
	  
21	   patients	   (4.48%)	   presented	   in	   a	   REDO	   setting	   (previous	   cardiac	   surgery)	  
regardless	   their	  preceding	  ethiology:	  8	   (15.1%)	   in	   the	  TAVI	   group	  and	  13	   (3.1%)	   in	  
the	  AVR	  group	  (Table	  2).	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All	  patients	   (100%)	  underwent	   surgery	  under	   the	  diagnosis	  of	   severe	  aortic	  
stenosis	  	  (with	  or	  without	  significant	  aortic	  regurgitation)	  of	  degenerative	  ethiology	  
(aortic	   calcific	   disease)	   Rheumatic	   valves,	   pure	   aortic	   regurgitation	   and	   surgery	   of	  
the	   aortic	   root	   were	   excluded	   from	   the	   analysis	   by	   echocardiographic	   ultrasound	  
studies.	  The	  main	  variables	  analyzed	  were	  aortic	  valve	  area	  by	  planimetry	   (0.68+/-­‐
0.19	  cm2),	  mean	  transaortic	  valve	  gradient	  (52.38+/-­‐16.14	  mmHg),	  peak	  transaortic	  
valve	   gradient	   (83.85+/-­‐26.25	  mmHg)	   and	   peak	   transaortic	   blood	   jet	   flow	   velocity	  
(4.41+/-­‐0.82	  m/s)	  (Table	  1).	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• PREOPERATIVE	  SURGICAL	  RISK	  
	  
Global	   median	   additive	   EuroSCORE	   was	   6	   (1-­‐15)	   and	  mean	   logistic	   8.90+/-­‐
8.57.	   By	   groups:	   9	   (4-­‐14)	   vs.	   6	   (1-­‐15),	   p<0.001;	   and	   16.53+/-­‐10.08	   vs.	   7.92+/-­‐7.85,	  
p<0.001	  in	  the	  TAVI	  and	  AVR	  group	  respectively	  (Table	  2,	  Fig.	  3,4,5).	  
	  
Table	  2.	  Preoperative	  surgical	  risk	  and	  clinical	  features.	  
 
	   Overall	   TAVI	   AVR	   	  
n	   468	   53	   415	   	  
EuroSCORE	   6	  (1-­‐15)	   9	  (4-­‐14)	   6	  (1-­‐15)	   p<0.001	  
logEuroSCORE	   8.90+/-­‐8.57	   16.53+/-­‐10.08	   7.92+/-­‐7.85	   p<0.001	  
	   	   	   	   	  
Chronic	  Pulmonary	  
Disease	  
110	  (23.5%)	   21	  (39.6%)	   89	  (21.4%)	   p<0.01	  
Extracardiac	  Arteropathy	   78	  (16.7%)	   9	  (17.0%)	   69	  (16.6%)	   ns	  
Neurological	  dysfunction	   26	  (5.6%)	   7	  (13.2%)	   19	  (4.6%)	   p<0.05	  
Previous	  Cardiac	  Surgery	   21	  (4.5%)	   8	  (15.1%)	   13	  (3.1%)	   p<0.001	  
Preoperative	  Renal	  Failure	   20	  (4.3%)	   4	  (7.5%)	   16	  (3.9%)	   ns	  
Active	  Endocarditis	   0	   0	   0	   -­‐	  
Preoperative	  Critical	  
Status	  
11	  (2.4%)	   0	   11	  (2.7%)	   ns	  
Unstable	  angor	   32	  (6.8%)	   3	  (5.7%)	   29	  (7.0%)	   ns	  
EF	  30/50	  %	   85	  (18.2%)	   8	  (15.1%)	   77	  (18.6%)	   ns	  
EF	  <	  30%	   24	  %5.1%)	   5	  (9.4%)	   19	  (4.6%)	   ns	  
Recent	  MI	   8	  (1.7%)	   0	   8	  (1.9%)	   ns	  
Severe	  Pulmonary	   39	  (8.3%)	   11	  (20.8%)	   28	  (0.7%)	   p<0.01	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Hypertension	  
Emergency	   78	  (16.7%)	   8	  (15.1%)	   70	  (16.9%)	   ns	  
Other	  than	  CABG	   468	  (100%)	   53	  (100%)	   415	  (100%)	   ns	  
Surgery	  on	  Thoracic	  Aorta	   0	   0	   0	   -­‐	  
Post	  MI	  VSD	   0	   0	   0	   -­‐	  
Severe	  Mitral	  
Regurgitation	  
	   5	  (9.4%)	   21	  (5.1%)	   ns	  
NYHA	  III/IV	   380	  (81.2%)	   48	  (90.6%)	   332	  (80%)	   ns	  
CHF	   30	  (6.4%)	   5	  (9.4%)	   25	  (6.0%)	   ns	  
Calcified	  Aorta	   45	  (9.6%)	   10	  (18.9%)	   35	  (8.4%)	   p<0.05	  
Diabetes	  mellitus	   153	  (32.7%)	   20	  (37.7%)	   133	  (32.0%)	   ns	  
Rhythm	  (Preop)	   	   	   	   	  
sinus	   410	  (87.6)	   31	  (58.5%)	   379	  (91.3%)	   	  
AF	   52	  (11.1%)	   35	  (8.4%)	   17	  (32.1%)	   	  












EF:	   ejection	   fraction	   (left	   ventricle).	   MI:	   myocardial	   infarction.	   CABG:	   coronary	  
artery	   bypass	   graft.	   VSD:	   ventricular	   septal	   defect.	   NYHA:	   New	   York	   Heart	  
Association	   functional	   class.	   CHF:	   congestive	   heart	   failure.	   Rhythm	   (preop):	  
Preoperative	   heart	   rhythm.	   Sinus:	   sinus	   rhythm.	   AF.	   Atrial	   fibrillation.	   PCM:	  
pacemaker	  rhythm.	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• CLINICAL	  PREOPERATIVE	  FEATURES	  
	  
Statistically	  significant	  differences	  were	  found	  between	  TAVI	  and	  AVR	  groups	  
for	   the	   following	   clinical	   preoperative	   variables:	   chronic	  pulmonary	  disease	   (39.6%	  
vs.	   21.4%),	   neurological	   dysfunction	   (13.2%	   vs.	   4.6%),	   previous	   cardiac	   surgery	  
(15.1%	  vs.	  3.1%),	  pulmonary	  hypertension	  (20.8%	  vs.	  0.7%)	  calcified	  aorta	  (18.9%	  vs	  
8.4%)	  and	  preoperative	  sinus	  rhythm	  (58.5%	  vs.	  91.3%).	  	  
	  
Fig	  4.	  Additive	  EuroSCORE	  distribution	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Fig.	  5.	  Logistic	  EuroSCORE	  by	  groups.	  
	  
Extracardiac	   arteropathy,	   preoperative	   renal	   failure,	   preoperative	   critical	  
status,	   unstable	   angor,	   left	   ventricular	   ejection	   fraction,	   recent	   myocardial	  
infarction,	  emergency,	  mitral	  regurgitation,	  NYHA	  class	  III/IV,	  congestive	  heart	  failure	  





• PERIOPERATIVE	  MORTALITY	  
	  	  
30-­‐days	   operative	   mortality	   differences	   were	   non-­‐signficant.	   4	   patients	  
(7.5%)	   in	   the	   TAVI	   group:	   1	   cardiac	   (myocardial	   infarction),	   2	   neurological	  
(postoperative	  stroke)	  and	  1	  multiorganic-­‐related;	  vs.	  25	  (6.0%)	  in	  the	  control	  (AVR)	  
group:	  7	  cardiac,	  2	  neurological,	  4	  infective,	  1	  endocarditis,	  3	  respiratory,	  2	  renal,	  2	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multiorganic-­‐related	  and	  4	  of	  unknown	  ethiology.	  Overall	  mortality	  of	  the	  series	  was	  
29/468	  (6.2%)	  (Table	  3,	  Fig.	  7).	  
	  
Fig	  6.	  Preoperative	  features	  by	  group	  
	  
	  
• POSTOPERATIVE	  COMPLICATIONS	  
	  
45.3%	   (24	   cases)	   presented	   a	   major	   postoperative	   complication	   in	   the	  
experimental	   (TAVI	   group,	   vs.	   34.5%	   (143)	   in	   AVR.	  Overall	  morbidity	   by	   any	   cause	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Table	  3.	  Operative	  results.	  Postoperative	  morbidity	  and	  mortality	  
 
	   Overall	   TAVI	   AVR	   	  
n	   468	   53	   415	   	  
Biological	  valve	  (%)	   357	  (71.2%)	   53	  (100%)	   304	  (73,3%)	   ns	  
30-­‐d	  mortality	  (%)	  
log	  EuroSCORE	  <	  15	  













Mortality	  (cause)*	   	   	   	   	  
cardiac	   8	  (1.71%)	   1	  (1.9%)	   7	  (1.7%)	   	  
neurological	   4	  (0.85%)	   2	  (3.8%)	   2	  (0.5%)	   	  
infective	   4	  (0.85%)	   0	   4	  (1.0%)	   	  
endocarditis	   1	  (0.21%)	   0	   1	  (0.2%)	   	  
respiratory	   3	  (0.64%)	   0	   3	  (0.7%)	   	  
renal	   2	  (0.43%)	   0	   2	  (0.5%)	   	  
multiorganic	   2	  (0.43%)	   1	  (1.9%)	   2	  (0.5%)	   	  
Unknown	   4	  (0.85%)	   0	   4	  (1.0%)	   	  
Perioperative	  morbidity	  
(all)*	  
167	  (35.7%)	   24	  (45.3%)	   143	  (34.5%)	   ns	  
Reintervention	   33	  (7.1%)	   3	  (5.7%)	   30	  (5.2%)	   ns	  
Cardiovascular	   6	  (1.3%)	   4	  (7.5%)	   2	  (0.2%)	   p<0.01	  
Respiratory	   35	  (7.5%)	   3	  (5.7%)	   32	  (7.7%)	   ns	  
Wound	   7	  (1.5%)	   3	  (5.7%)	   4	  (1.0%)	   p<0.05	  
Renal	   32	  (6.8%)	   4	  (7.5%)	   28	  (6.7%)	   ns	  
Neurological	   15	  (3.2%)	   5	  (9.4%)	   10	  (2.4%)	   p<0.05	  
Infective	   19	  (4.1%)	   0	   19	  (4.6%)	   ns	  
Other	   22	  (4.71%)	   4	  (7.5%)	   18	  (4.34%)	   ns	  
MACCE	   41	  (8.8%)	   9	  (17.0%)	   32	  (7.7%)	   p<0.05	  
Rhythm	  (discharge)	   	   	   	   	  
sinus	   391	  (83.5%)	   34	  (64.2%)	   357	  (86.0%)	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AF	   64	  (13.7%)	   8	  (15.1%)	   56	  (13.5%)	   	  






Respiratory	   morbidity	   (pleural	   effusion,	   prolonged	   ventilation,	   pneumonia)	  
represented	   the	  main	  and	  most	   frequent	   source	  of	  morbidity:	  7.5%	   (5.7%	  TAVI	  vs.	  
7.7%	  AVR,	  ns.),	   followed	  by	  early	  reintervention	  caused	  by	  excessive	  postoperative	  
bleeding	   or	   cardiac	   tamponade:	   7.1%	   (5.7%	   vs.	   5.2%,	   ns.).	   The	   most	   significant	  
differences	   by	   morbidity	   source	   were:	   cardiovascular	   (postoperative	   myocardial	  
infarction	   or	   major	   vascular	   injury)	   7.5%	   TAVI	   vs.	   0.2	   AVR,	   p<0.05;	   wound	  
complications	   (superficial	   or	   deep	   incision	   site	   infection)	   5.7	   TAVI	   vs.	   1.0%	   AVR,	  
p<0.05;	   and	   neurological	   events	   (permanent	   stroke	   or	   transitory	   ischemic	   attack)	  
9.4%	  TAVI	  vs.	  2.4%	  AVR	  (Table	  3,	  Fig.8).	  	  
	  
Overall	   MACCE	   rate	   (composite	   event	   of	   death,	   cardiovascular	   or	  
neurological	  morbidity)	  was	  8.8%	  (17.0%	  TAVI	  vs.	  7.7%	  AVR,	  p<0.05)	  (Table	  3,	  Fig.	  7).	  
	  
30-­‐d	  mortality:	  thirty-­‐day	  mortality.	  MACCE:	  major	  adverse	  cardio	  or	  cerebral	  events.	  AF:	  
atrial	  fibrillation.	  PCM:	  pacemaker.	  
*	  See	  Annex	  for	  definitions	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Fig.	  7.	  Perioperative	  mortality	  and	  MACCE	  rates	  by	  group.	  
	  
30-­‐d	  mortality:	   thirty-­‐days	  mortality.	  MACCE:	  perioperative	  death	  or	  major	  adverse	  
cardio	  or	  cerebral	  events.	  p=	  ns.	  For	  both	  30-­‐days	  mortality	  and	  MACCE	  analysis	  of	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Statistically	   significant	   differences	   among	   the	   different	   ECG	   rhythms	  
preoperatively	  and	  at	  the	  time	  of	  discharge	  were	  found.	  Rhythm	  rates	  found	  before	  
surgery	  were	   58.5%	   TAVI	   vs.	   91.3%	   AVR	   for	   sinus	   rhythm;	   32.1%	   vs.	   8.4%	   for	   AF;	  
9.4%	   vs.	   0.2%	   for	   PCM	   rhythm	   (p<0.01);	   and	   before	   discharge:	   64.2%	   vs.	   86.0%,	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Rhythm	  (preop):	  Preoperative	  heart	  rhythm.	  Rhythm	  (discharge):	  Postoperative	  heart	  
rhythm	   at	   the	   time	   of	   discharge.	   Sinus:	   sinus	   rhythm.	   AF:	   atrial	   fibrillation.	   PCM:	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Subgroup	   crosstabulation	   analysis	   for	   preoperative	   versus	   postoperative	  
heart	  rhythm	  was	  performed	  for	  TAVI	  and	  AVR	  groups,	  finding	  significant	  changes	  in	  
the	  rhythm	  patterns	  before	  and	  after	  surgery	  in	  the	  experimental	  group	  (rates	  of	  AF	  
rhythm	  of	  32.1%	  vs.	  15.1%	  and	  PCM	  rhythm	  of	  9.4%	  vs.	  20.8%)	  The	  distribution	  of	  
cases	  for	  preoperative	  and	  postoperative	  rhythm	  for	  each	  group	  are	  shown	  on	  Fig.	  
10.	  
	  
Fig.	  10.	  Crosstabulation	  analysis	  of	  heart	   rhythm	  (before	  vs.	  after	  surgery)	   for	  each	  
group.	  
  
AVR: Rhythm (preop) vs. Rhythm (discharge)a 
No. patients 
Rhythm (discharge) 
Total sinus AF PCM 
Rhythm (preop) Sinus 328 49 2 379 
AF 28 7 0 35 
PCM 1 0 0 1 
Total 357 56 2 415 
a. p = ns. 
 
TAVI: Rhythm (preop) vs. Rhythm (discharge)a 
No. patients 
Rhythm (discharge) Total 
sinus AF PCM  
Rhythm (preop) sinus 25 1 5 31 
AF 5 7 5 17 
PCM 4 0 1 5 
Total 34 8 11 53 
a. p< 0.01 
	  
Rhythm	  (preop):	  Preoperative	  heart	  rhythm.	  Rhythm	  (discharge):	  Postoperative	  heart	  
rhythm	   at	   the	   time	   of	   discharge.	   Sinus:	   sinus	   rhythm.	   AF:	   atrial	   fibrillation.	   PCM:	  
pacemaker	  rhythm.	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2.	  Case-­‐control	  analysis	  by	  propensity	  score	  matching	  
	  
A	  propensity	  score	  was	  performed	  to	  identify	  appropriate	  controls	  inside	  the	  
AVR	   group,	   by	   building	   a	   binary	   logistic	   regression	   model	   with	   the	   following	  
variables:	   age,	   gender,	   body	   surface	   area,	   body	   mass	   index,	   logistic	   EuroSCORE,	  
chronic	   pulmonary	   disease,	   extracardiac	   arteropathy,	   neurological	   dysfunction,	  
previous	  cardiac	  surgery,	  preoperative	  renal	  failure,	  left	  ventricular	  ejection	  fraction,	  
severe	   pulmonary	   hypertension,	   severe	   mitral	   regurgitation,	   NYHA	   class,	  
preoperative	   congestive	   heart	   failure,	   calcified	   aorta,	   diabetes	   and	   presence	   of	  
concomitant	   coronary	   lesions.	   The	   predicted	   group	   probability	   returned	   by	   the	  
logistic	  regression	  equation,	  using	  the	  enter	  stepwise	  method,	  was	  saved	  and	  used	  
to	  select	  67	  controls	  among	  the	  AVR	  group	  to	  conform	  the	  so-­‐called	  HR-­‐AVR	  group	  
(High-­‐Risk	  Aortic	  Valve	  Replacement	   group),	   and	  match	   them	  with	   the	  53	   cases	   in	  
the	   TAVI	   group.	   Goodness-­‐of-­‐fit	   was	   assessed	   by	   a	   non-­‐significant	   Hosmer-­‐
Lemeshow’s	  test.	  Discrimination	  capacity	  of	  the	  model	  was	  evaluated	  by	  a	  receptor-­‐
operator	  characteristics	   curve,	   contrasting	   the	  probability	  of	  belonging	   to	   the	  TAVI	  
group	   returned	   by	   the	   logistic	   regression	  model	   versus	   the	   real	   allocation	   to	   that	  
group	  in	  each	  case;	  and	  resulted	  in	  an	  area	  under	  the	  curve	  of	  0.925	  (95%	  CI	  0.893	  –	  
0.957)	  	  (Fig.11).	  
	  
	  Distribution	  of	   cases	  and	   the	   selected	  controls	  according	   to	   the	  year	  when	  




• PREOPERATIVE	  CHARACTERISTICS	  
	  
No	  differences	  in	  terms	  of	  isolated	  valve	  replacement	  or	  combined	  valve	  plus	  
coronary	  procedures	  (43.4%	  TAVI	  vs.	  46.3%	  HR-­‐AVR)	  were	  found.	  Neither	  concerning	  
demographic	   (80.42+/-­‐4.84	   vs.	   79.13+/-­‐4.22	   years;	   49.1%	   vs.	   56.7%	   male)	   or	  
echocardiographic	   features	   (0.61+/-­‐0.13	   vs.	   0.64+/-­‐0.17	   cm2	   valve	   area,	   52.25+/-­‐
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16.50	   vs.	   54.02+/-­‐16.23	   mmHg	  mean	   transaortic	   gradient,	   4.44+/-­‐0.72	   vs.	   4.23+/-­‐
0.74	  m/s	  peak	  jet	  flow	  velocity.	  (Table	  4).	  Age	  distribution	  is	  shown	  on	  Fig.	  13.	  
	  
• RISK	  PROFILE	  
	  
Both	  case	   (TAVI)	  and	  control	   (HR-­‐AVR)	  groups	  were	  statistically	  comparable	  
in	   terms	  of	   preoperative	   risk	  profile:	  Additive	   EuroSCORE	  9	   (4-­‐14)	   vs.	   8	   (3-­‐15)	   and	  
Logistic	  EuroSCORE	  16.53+/-­‐10.08	  vs.	  14.82+/-­‐11.73	  (Fig.14);	  as	  well	  as	  regarding	  the	  
main	   clinical	   preoperative	   variables:	   chronic	   pulmonary	   disease	   39.6%	   vs.	   35.8%,	  
extracardiac	  arteropathy	  17.0%	  vs.	  16.4%,	  neurological	  dysfunction	  13.2%	  vs.	  9.0%,	  
previous	  cardiac	  surgery	  15.1%	  vs.	  10.4%,	  preoperative	  renal	  failure	  7.5%	  vs.	  6.9%	  ,	  
severe	   ventricular	   function	   impairment	   (<30%)	   9.4%	   vs.	   9.0%,	   recent	   myocardial	  
infarction	  0%	  vs.	  3.0%,	  pulmonary	  hypertension	  20.8%	  vs.	  11.9%,	  Emergency	  15.1%	  
vs.	  22.4%,	  NYHA	  class	  III	  or	  IV	  90.6%	  vs.	  92.5%	  ,	  congestive	  left	  heart	  failure	  9.4%	  vs.	  
6.0%	  calcified	  aorta	  18.9%	  vs.	  19.4%	  or	  diabetes	  37.7%	  vs.	  35.8%	  (Fig	  15).	  
	  
Fig.11.	  Receptor-­‐operator	  characteristics	  curve.	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Table	  4.	  	  Main	  preoperative	  charcteristics	  
	   TAVI	   HR-­‐AVR	   	  
N	   53	   67	   	  
Age	  (y)	   80.42+/4.84	   79.13+/-­‐4.22	   ns	  
Gender	  (%male)	   26	  (49.1%)	   38	  (56.7%)	   ns	  
Weight	  (kg)	   71.65+/-­‐16.51	   71.18+/-­‐11.45	   ns	  
Height	  (cm)	   155.72+/-­‐15.06	   157.15+/-­‐8.81	   ns	  
BSA	  (m2)	   1.74+/-­‐0.17	   1.76+/-­‐0.17	   ns	  
BMI	  (kg/m2)	   28.19+/-­‐4.46	   28.77+/-­‐4.69	   ns	  
Coronary	  lesions	   23	  (43.4%)	   31	  (46.3%)	   ns	  
No	  vessels	   1.74+/-­‐1.18	   2.03+/-­‐0.79	   ns	  
PTCA	   11	  (20.8%)	   0	   ns	  
CABG	   0	   27	  (40.3%)	   ns	  
No	  grafts	   0	   1.81+/-­‐1.11	   ns	  
Valve	  area	  (cm2)	   0.61+/-­‐0.13	   0.64+/-­‐0.17	   ns	  
Mean	  Grad	  (mmHg)	   52.25+/-­‐16.50	   54.02+/-­‐16.23	   ns	  
Peak	  Grad	  (mmHg)	   84.41+/-­‐27.65	   81.43+/-­‐27.80	   ns	  
Peak	  Vel	  (m/s)	   4.44+/-­‐0.72	   4.23+/-­‐0.74	   ns	  
 
	  
BSA:	   Body	   surface	   area.	   BMI:	   body	   mass	   index.	   No.	   Vessels:	   numer	   of	   diseased	  
coronary	   vessels.	   PTCA:	   percutaneous	   transluminal	   coronary	   angioplasty.	   CABG:	  
coronary	   artery	   bypass	   graft.	   No	   grafts:	   number	   of	   grafts.	   Mean	   grad:	   mean	  
transvalvular	   gradient.	   Peak	   grad:	   peak	   transvalvular	   gradient.	   Peak	   vel:	   peak	   jet	  
flow	  velocity.	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Fig,13,	  Age	  distribution	  by	  year	  and	  age	  for	  TAVI	  and	  HR-­‐AVR	  groups.	  
	  
	  
However,	   different	   rates	   of	   preoperative	   ECG	   rhythms	   were	   found:	   58.5%	  
sinus,	  32.1%	  AF	  and	  9.4%	  PCM	  rhythm	  for	  TAVI	  vs.	  83.6%,	  14,9%	  and	  1.5%	  for	  HR-­‐
AVR,	  respectively	  (Table	  5.).	  	  
	  
Table	  5.	  Preoperative	  risk	  profile	  and	  clinical	  variables.	  
	   TAVI	   HR-­‐AVR	   	  
n	   53	   67	   	  
EuroSCORE	   9	  (4-­‐14)	   8	  (3-­‐15)	   ns	  
logEuroSCORE	   16.53+/-­‐10.08	   14.82+/-­‐11.73	   ns	  
	   	   	   	  
Chronic	  Pulmonary	  Disease	   21	  (39.6%)	   24	  (35.8%)	   ns	  
Extracardiac	  Arteropathy	   9	  (17.0%)	   11	  (16.4%)	   ns	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Neurological	  dysfunction	   7	  (13.2%)	   6	  (9.0%)	   ns	  
Previous	  Cardiac	  Surgery	   8	  (15.1%)	   7	  (10.4%)	   ns	  
Preoperative	  Renal	  Failure	   4	  (7.5%)	   4	  (6.9%)	   ns	  
Active	  Endocarditis	   0	   0	   ns	  
Preoperative	  Critical	  Status	   0	   3	  (4.5%)	   ns	  
Unstable	  angor	   3	  (5.7%)	   6	  (9.0%)	   ns	  
EF	  30/50	  %	   8	  (15.1%)	   12	  (17.9%)	   ns	  
EF	  <	  30%	   5	  (9.4%)	   6	  (9.0%)	   ns	  
Recent	  MI	   0	   2	  (3.0%)	   ns	  
Severe	  Pulmonary	  
Hypertension	  
11	  (20.8%)	   8	  (11.9%)	   ns	  
Emergency	   8	  (15.1%)	   11	  (22.4%)	   ns	  
Other	  than	  CABG	   53	  (100%)	   67	  (100%)	   ns	  
Surgery	  on	  Thoracic	  Aorta	   0	   0	   ns	  
Post	  MI	  VSD	   0	   0	   ns	  
Severe	  Mitral	  Regurgitation	   5	  (9.4%)	   5	  (7.5%)	   ns	  
NYHA	  III/IV	   48	  (90.6%)	   62	  (92.5%)	   ns	  
CHF	   5	  (9.4%)	   4	  (6.0%)	   ns	  
Calcified	  Aorta	   10	  (18.9%)	   13	  (19.4%)	   ns	  
Diabetes	   20	  (37.7%)	   24	  (35.8%)	   ns	  
Rhythm	  (Preop)	   	   	   	  
sinus	   31	  (58.5%)	   56	  (83.6%)	   	  
AF	   17	  (32.1%)	   10	  (14.9%)	   	  
PCM	   5	  (9.4%)	   1	  (1.5%)	   p<0.05	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EF:	  ejection	  fraction	  (left	  ventricle).	  MI:	  myocardial	  infarction.	  CABG:	  coronary	  artery	  
bypass	   graft.	   VSD:	   ventricular	   septal	   defect.	   NYHA:	   New	   York	   Heart	   Association	  
functional	  class.	  Rhythm	  (preop):	  Preoperative	  heart	  rhythm.	  Sinus:	  sinus	  rhythm.	  AF.	  
Atrial	  fibrillation.	  PCM:	  pacemaker	  rhythm.	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• OPERATIVE	  OUTCOMES	  
	  
Operative	   outcomes	   resulted	   in	   different	   median	   prosthetic	   implant	  
diameters	  26	  (23-­‐29)	  for	  TAVI	  and	  21	  (18-­‐25)	  for	  HR-­‐AVR	  (p<0.01).	  30-­‐days	  mortality	  
(7.5%	   vs.	   4.5%,	   ns)	   and	   global	   perioperative	  morbidity	   (45.3%	   vs.	   32.8%,	   ns)	  were	  
comparable	   (Table	   6).	   Nevertheless,	   a	   significant	   level	   was	   reached	   for	  
cardiovascular	   (7.5%	   TAVI	   vs.	   0%	   HR-­‐AVR)	   and	   neurological	   (9.4%	   vs.	   0%)	   major	  
postoperative	   complications.	   The	   differences	   in	   the	   composite	   event	   MACCE	  
(perioperative	   mortality	   or	   major	   adverse	   cardiac	   or	   cerebral	   events)	   were	   also	  
found	  to	  be	  relevant:	  17.0%	  TAVI	  vs.	  4.5%	  HR-­‐AVR	  Table	  6,	  Figs.	  16-­‐17).	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Table	  6.	  Operative	  outcomes.	  
 
	   TAVI	   HR-­‐AVR	   	  
n	   53	   67	   	  
Biological	  valve	  (%)	   53	  (100%)	   63	  (94.0%)	   ns	  
30-­‐d	  mortality	  (%)	  
LogEuroSCORE	  <	  15	  











Mortality	  (cause)*	   	   	   	  
cardiac	   1	  (1.9%)	   1	  (1.5%)	   	  
neurological	   2	  (3.8%)	   0	   	  
infective	   0	   1	  (1.5%)	   	  
endocarditis	   0	   0	   	  
respiratory	   0	   1	  (1.5%)	   	  
renal	   0	   0	   	  
multiorganic	   1	  (1.9%)	   0	   	  
unknown	   0	   0	   	  
Perioperative	  morbidity	  (all)*	   24	  (45.3%)	   22	  (32.8%)	   ns	  
Reintervention	   3	  (5.7%)	   5	  (7.5%)	   ns	  
Cardiovascular	   4	  (7.5%)	   0	   p<0.05	  
Respiratory	   3	  (5.7%)	   8	  (11.9%)	   ns	  
Wound	   3	  (5.7%)	   0	   ns	  
Renal	   4	  (7.5%)	   8	  (11.9%)	   ns	  
Neurological	   5	  (9.4%)	   0	   p<0.05	  
Infective	   0	   3	  (4.5%)	   ns	  
Other	   4	  (7.5%)	   0	   p<0.05	  
MACCE	   9	  (17.0%)	   3	  (4.5%)	   p<0.05	  
Rhythm	  (discharge)	   	   	   	  
sinus	   34	  (64.2%)	   58	  (86.6%)	   	  
AF	   8	  (15.1%)	   9	  (13.4%)	   	  
PCM	   11	  (20.8%)	   0	   p<0.001	  
 
30-­‐d	   mortality:	   thirty-­‐day	   mortality.	   MACCE:	   death	   or	   major	   adverse	   cardio	   or	  
cerebral	  events.	  AF:	  atrial	  fibrillation.	  PCM:	  pacemaker.	  
*	  See	  Annex	  for	  definitions	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Fig.16.	  30-­‐days	  mortality	  (p=ns)	  and	  MACCE	  rates	  (p<0.05)	  by	  group	  .	  
Fig	  17.	  Main	  postoperative	  morbidity	  by	  group.	  
	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   170	  
	  
Fig.	  18.	  Preoperative	  and	  postoperative	  rhythm	  rates	  by	  group	  
	  
Rhythm	  (preop):	  Preoperative	  heart	  rhythm.	  Rhythm	  (discharge):	  Postoperative	  heart	  






Pearson	   Chi-­‐Square	   test	   returned	   a	   significant	   result	   (p<0.001)	   in	   the	  
Preoperative	   vs.	   Dischargre	   Rhythm	   crosstabulation	   in	   the	   TAVI	   group.	   10	   new	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pacemaker	  implants	  were	  reported	  (5	  in	  previous	  sinus	  rhythm	  and	  5	  in	  previous	  AF)	  
against	  0	  in	  the	  HR-­‐AVR	  group.	  Postoperative	  AF	  was	  15.09%	  (TAVI)	  vs.	  13.43%	  (HR-­‐
AVR),	   although	   there	  was	   only	   1	   new	  AF	   case	   in	   the	   experimental	   group	   versus	   8	  
among	  the	  HR-­‐AVR	  controls;	  and	  discharge	  sinus	  rhythm	  rates	  64.15%	  (34	  cases)	  vs.	  
86.57%	  (58	  cases),	  respectively	  (Fig.18-­‐19).	  	  
	  
Fig.	  19.	  Crosstabulation	  analysis	  of	  heart	   rhythm	  (before	  vs.	  after	  surgery)	   for	  each	  
group.	  
 
TAVI: Rhythm (preop) vs. Rhythm (discharge)a 
No. patients 
Rhythm (discharge) Total 
sinus AF PCM  
Rhythm 
(preop) 
sinus 25 1 5 31 
AF 5 7 5 17 
PCM 4 0 1 5 
Total 34 8 11 53 
a. p< 0.01 
 
 




Total sinus AF 
Rhythm 
(preop) 
sinus 48 8 56 
AF 9 1 10 
PCM 1 0 1 
Total 58 9 67 
a. p= ns. 
	  
Rhythm	  (preop):	  Preoperative	  heart	  rhythm.	  Rhythm	  (discharge):	  Postoperative	  heart	  
rhythm	   at	   the	   time	   of	   discharge.	   Sinus:	   sinus	   rhythm.AF:	   atrial	   fibrillation.	   PCM:	  
pacemaker	  rhythm.	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LENGTH	  OF	  STAY	  
	  
Mean	   intensive	   care	   unit	   (ICU)	   and	   Hospital	   length	   of	   stay	   (LOS)	   were	  
computed	  concluding	  statistical	  evidence	  between	  TAVI	  and	  HR-­‐AVR	  groups	  for	  ICU	  
LOS	   (2.03+/-­‐2.58	   vs.	   3.33+/-­‐1.80)	   but	   not	   for	   total	   in	   hospital	   LOS	   (7.25+/-­‐4.35	   vs.	  
8.00+/-­‐3.10).	  Table	  7.	  Fig.	  20.	  
	  
Table	  7.	  ICU	  and	  Hospital	  length	  of	  stay	  by	  group.	  
	   TAVI	   HR-­‐AVR	   	  
ICU	  LOS	  (days)	  
EuroSCORE	  <	  15	  










Hospital	  LOS	  (days)	  
EuroSCORE	  <	  15	  












ICU	  LOS:	  Intensive	  care	  unit	  length	  of	  stay.	  Hospital	  LOS:	  Total	  hospital	  length	  of	  stay	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Fig.	  20.	  ICU	  and	  Hospital	  length	  of	  stay	  (days)	  by	  group.	  
	  






Univariate	   logistic	   regression	   analysis	   to	   assess	   significant	   predictors	   of	   30-­‐
days	   perioperative	   mortality	   and	   MACCE	   (composite	   event	   of	   death,	   cardio	   or	  
cerebrovascular	  major	  adverse	  events)	  among	  120	  patients	  (53	  TAVI	  and	  67	  HR-­‐AVR)	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Table	  8.	  Univariate	  analysis	  for	  30-­‐days	  mortality	  endopoint.	  
 
30-­‐d	  mortality	   	   	   	  
	   B	   (Sig.)	   OR	  (95%	  CI)	  
TAVI	  procedure	   0.555	   0.481	   1.741	  (0.372-­‐8.144)	  
Surgical	  Approach	   	   	   	  
MS	   n/a	   n/a	   n/a	  
TF	   -­‐0.026	   0.978	   0.974	  (0.156-­‐6.104)	  
TA	   1.335	   0.271	   3.800	  (0.562-­‐25.693)	  
Age	  (y)	   0.141	   0.243	   1.151	  (0.953-­‐1.390)	  
Gender	  (female)	   0.477	   0.570	   1.564	  (0.335-­‐7.310)	  
Coronary	  disease	   0.519	   0.510	   1.680	  (0.359-­‐7.854)	  
Chronic	  Pulmonary	  Disease	   0.237	   0.763	   1.268	  (0.271-­‐5.943)	  
Extracardiac	  Arteropathy	   2.090	   0.010	   8.083	  (1.652-­‐39.545)	  
Neurological	  dysfunction	   0.338	   0.763	   1.403	  (0.155-­‐12.660)	  
Previous	  Cardiac	  Surgery	   -­‐18.564	   0.999	   0	  (0	  -­‐	  )	  
Preoperative	  Renal	  Failure	   0.926	   0.420	   2.524	  (0.266-­‐23.968)	  
Active	  Endocarditis	   n/a	   n/a	   n/a	  
Preoperative	  Critical	  Status	   -­‐18.448	   0.999	   0	  (0	  -­‐	  )	  
Unstable	  angor	   -­‐18.504	   0.999	   0	  (0	  -­‐	  )	  
EF	  30/50	  %	   1.443	   0.074	   4.235	  (0.869-­‐20.630)	  
EF	  <	  30%	   -­‐18.524	   0.999	   0	  (0	  -­‐	  )	  
Recent	  MI	   -­‐18.439	   0.999	   0	  (0	  -­‐	  )	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Severe	  Pulmonary	  
Hypertension	  
1.514	   0.062	   4.547	  (0.929-­‐22.244)	  
Emergency	   1.249	   0.220	   3.487	  (0.723-­‐16.813)	  
Other	  than	  CABG	   n/a	   n/a	   n/a	  
Surgery	  on	  Thoracic	  Aorta	   n/a	   n/a	   n/a	  
Post	  MI	  VSD	   n/a	   n/a	   n/a	  
Severe	  Mitral	  Regurgitation	   -­‐18.514	   0.999	   0	  (0	  -­‐	  )	  
CHF	   -­‐18.504	   0.999	   0	  (0	  -­‐	  )	  
Calcified	  Aorta	   0.561	   0.519	   1.752	  (0.318-­‐9.59)	  
Diabetes	  mellitus	   0.275	   0.727	   1.317	  (0.261-­‐6.176)	  
Rhythm	  (Preop)	   	   	   	  
sinus	   n/a	   n/a	   n/a	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AF	   0.507	   0.571	   1.660	  (0.287-­‐9.603)	  
PCM	   1.423	   0.239	   4.150	  (0.388-­‐44.389)	  
	  
TAVI:	  Transcatheter	  Aortic	  Valve	  Implant	  group..	  MS:	  median	  sternotomy	  approach.	  
TF:	   transfemoral	   approach.	   TA:	   Transapical	   approach.	   EF:	   left	   ventricular	   ejection	  
fraction.	   MI	   myocardial	   infarction.	   CHF.	   Congestive	   heart	   failure.	   .	   sinus:	   sinus	  




Table	  9.	  Univariate	  analysis	  for	  MACCE	  endpoint	  
MACCE	   	   	   	  
	   B	   (Sig.)	   OR	  (95%	  CI)	  
TAVI	  procedure	   1.473	   0.034	   4.364	  (1.118-­‐17.033)	  
Surgical	  Approach	   	   	   	  
MS	   n/a	   n/a	   n/a	  
TF	   1.181	   0.110	   3.257	  (0.765-­‐13.863)	  
TA	   1.846	   0.038	   6.333	  (1.103-­‐36.370)	  
Age	  (y)	   0.215	   0.010	   1.240	  (1.052-­‐1.460)	  
Gender	  (female)	   0.522	   0.397	   1.686	  (0.503-­‐5.645)	  
Coronary	  disease	   -­‐0.545	   0.396	   0.580	  (0.165-­‐2.042)	  
Chronic	  Pulmonary	  Disease	   -­‐0.202	   0.754	   0.817	  (0.231-­‐2.885)	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Extracardiac	  Arteropathy	   1.056	   0.115	   2.875	  (0.774-­‐10.681)	  
Neurological	  dysfunction	   -­‐0.318	   0.770	   0.727	  (0.086-­‐6.140)	  
Previous	  Cardiac	  Surgery	   -­‐19.155	   0.999	   0	  (0-­‐	  )	  
Preoperative	  Renal	  Failure	   0.271	   0.808	   1.312	  (0.147-­‐11.670)	  
Active	  Endocarditis	   n/a	   n/a	   n/a	  
Preoperative	  Critical	  Status	   -­‐19.034	   0.999	   0	  (0-­‐	  )	  
Unstable	  angor	   -­‐19.093	   0.999	   0	  (0-­‐	  )	  
EF	  30/50	  %	   1.056	   0.115	   2.875	  (0.774-­‐10.681)	  
EF	  <	  30%	   -­‐19.113	   0.999	   0	  (0-­‐	  )	  
Recent	  MI	   -­‐19.024	   0.999	   0	  (0-­‐	  )	  
Severe	  Pulmonary	  Hypertension	   1.131	   0.093	   3.100	  (0.830-­‐11.585)	  
Emergency	   0.851	   0.299	   2.342	  (0.639-­‐8.580)	  
Other	  than	  CABG	   n/a	   n/a	   n/a	  
Surgery	  on	  Thoracic	  Aorta	   n/a	   n/a	   n/a	  
Post	  MI	  VSD	   n/a	   n/a	   n/a	  
Severe	  Mitral	  Regurgitation	   -­‐19.103	   0.999	   0	  (0-­‐	  )	  
CHF	   0.128	   0.908	   1.136	  (0.130-­‐9.953)	  
Calcified	  Aorta	   0.383	   0.590	   1.467	  (0.364-­‐5.912)	  
Diabetes	   -­‐0.607	   0.382	   0.545	  (0.139-­‐2.129)	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   178	  
Rhythm	  (Preop)	   	   	   	  
sinus	   n/a	   n/a	   n/a	  
AF	   1.545	   0.018	   4.686	  (1.303-­‐33.683)	  
PCM	   1.188	   0.318	   3.280	  (0.319-­‐33.683)	  
 
TAVI:	  Transcatheter	  Aortic	  Valve	   Implant	  group.	  MS:	  median	  sternotomy	  approach.	  
TF:	   transfemoral	   approach.	   TA:	   Transapical	   approach.	   EF:	   left	   ventricular	   ejection	  
fraction.	  MI	  myocardial	  infarction.	  CHF.	  Congestive	  heart	  failure.	  	  sinus:	  sinus	  rhythm.	  
AF.	  Atrial	  fibrillation.	  PCM:	  pacemaker	  rhythm	  
	  
	  
TAVI	  procedures,	   neither	  when	  as	   a	  whole	  nor	  when	   the	   surgical	   approach	  
(TF	   or	   TA)	   was	   detached	   showed	   a	   significant	   association	   with	   perioperative	  
mortality	  with	   the	   resulting	   odds	   ratios	   (95%	   CI)	   against	   conventional	   aortic	   valve	  
replacement	  (HR-­‐AVR):	  	  1.741	  (0.372-­‐8.144)	  for	  the	  whole	  TAVI	  group,	  0.974	  (0.156-­‐
6.104)	  for	  the	  TF	  approach	  and	  3.800	  (0.562-­‐25.693)	  for	  the	  TA	  approach.	  	  
	  
	  	  	   However,	  these	  results	  reached	  significance	  for	  TAVI	  as	  well	  as	  for	  TA	  when	  
the	  MACCE	  endpoint	  was	  considered,	  but	  not	  for	  the	  TF	  approach	  alone;	  with	  4.364	  
(1.118-­‐17.033),	   6.333	   (1.103-­‐36.370)	   and	   3.257	   (0.765-­‐13.863)	   respective	   odds	  
ratios.	  
	  
	   Other	   predictors	   for	   30-­‐days	   mortality	   endpoint	   were	   (OR,	   95%	   CI):	  
extracardiac	   arteropathy	   (8.803,	   1.652-­‐39.545),	   impaired	   left	   ventricular	   ejection	  
fraction	  or	  EF	  30/50	  (4.235,	  0.869-­‐20.630),	  severe	  pulmonary	  hypertension	  	  (4.547,	  
0.929-­‐22.244)	   and	   urgent	   nature	   of	   the	   intervention	   or	   Emergency	   (3.487,	   0.723-­‐
16.813);	  although	  these	  last	  three	  variables	  were	  in	  the	  limits	  of	  significance.	  	  
	  
	   Back	   to	   the	   MACCE	   endpoint,	   age	   (1.240,	   1.052-­‐1.460),	   as	   well	   as	  
preoperative	   atrial	   fibrillation	   (4.686,	   1.303-­‐16.852),	   were	   also	   found	   to	   be	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significant	  predictors	  of	  an	  event;	  and	  pulmonary	  hypertension	  showed	  a	  strong	  but	  
non-­‐significant	  association	  (3.100,	  0.830-­‐11.585).	  
	  
Univariate	  analysis	   for	  main	  postoperative	  complications	  was	  performed	  for	  
the	  30-­‐days	  mortality	  endpoint	  exclusively:	   cardiovascular	   (22.200,	  2.573-­‐191.554),	  
respiratory	   (9.884,	   1.871-­‐51.803)	   and	   neurological	   postoperative	   complications	  




Table	  10.	  Univariate	  analysis	  for	  postoperative	  complications	  and	  30-­‐days	  mortality	  
endpoint.	  
30-­‐d	  mortality	   	   	   	  
	   B	   (Sig.)	   OR	  (95%	  CI)	  
Perioperative	  morbidity	  (all)*	   	   	   	  
Reintervention	   0.926	   0.420	   2.524	  (0.266-­‐23.968)	  
Cardiovascular	   3.100	   0.005	   22.200	  (2.573-­‐191.554)	  
Respiratory	   2.287	   0.007	   9.884	  (1.871-­‐51.803)	  
Wound	   -­‐18.448	   0.999	   0	  (0	  -­‐	  )	  
Renal	   1.416	   0.116	   4.120	  (0.706-­‐24.035)	  
Neurological	   2.686	   0.009	   14.667	  (1.983-­‐108.493)	  
Infective	   2.225	   0.086	   9.250	  	  (0.732-­‐116.951)	  
Other	   1.810	   0.141	   6.111	  (0.550-­‐67.886)	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MACCE	   n/a	   n/a	   n/a	  
Rhythm	  (discharge)	   	   	   	  
sinus	   n/a	   n/a	   n/a	  
AF	   0.110	   0.921	   0.896	  (0.101-­‐7.950)	  
PCM	   -­‐18.540	   0.999	   0	  (0	  -­‐	  )	  
 
MACCE:	   death	   or	   major	   adverse	   cardio	   or	   cerebrovascular	   events.	   sinus:	   sinus	  
rhythm.	  AF.	  Atrial	  fibrillation.	  PCM:	  pacemaker	  rhythm	  





As	  previously	  stated	  in	  the	  Methods	  section,	  an	  agreed	  level	  of	  significance	  of	  
0.2	   in	   the	   univariate	   analysis	   was	   required	   to	   enter	   the	   multivariate	   logistic	  
regression	  model	   for	  both	  30-­‐days	  mortality	   and	  MACCE	  endpoints.	  Results	  of	   the	  
equation	  computed	  by	  enter	  method	  are	  presented	  on	  Tables	  11-­‐12.	  
	  
Table	  11.	  Multivariate	  analysis	  for	  30-­‐days	  mortality	  endpoint 
 
30-­‐d	  mortality	   	   	   	  
	   B	   (Sig.)	   OR	  (95%	  CI)	  
Extracardiac	  Arteropathy	   2.080	   0.009	   21.766	  (2.189-­‐216.418)	  
EF	  30/50	  %	   1.083	   0.215	   2.953	  (0.534-­‐16.332)	  
Pulmonary	  Hypertension	   1.622	   0.028	   13.766	  (1.318-­‐143.742)	  
	  
EF:	  left	  ventricular	  ejection	  fraction	  
	  
Both	   extracardiac	   arteropathy	   (21.766,	   2.189-­‐216.418)	   and	   pulmonary	  
hypertension	   (13.766,	   1.318-­‐143.742)	   variables	   were	   found	   to	   be	   independent	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predictors	   for	   the	  30-­‐days	  mortality	  endpoint.	  Left	  ventricular	   function	  dysfunction	  
or	  EF	  30/50	  	  (2.953,	  0.534-­‐16.332)	  did	  not	  reach	  enough	  statistical	  power.	  
	  
Table	  12.	  Multivariate	  analysis	  for	  MACCE	  endpoint	  
 
MACCE	   	   	   	  
	   B	   (Sig.)	   OR	  (95%	  CI)	  
Surgical	  Approach	   	   	   	  
MS	   n/a	   n/a	   n/a	  
TF	   1.307	   0.178	   3.694	  (0.551-­‐24.767)	  
TA	   1.182	   0.278	   3.262	  (0.386-­‐27.574)	  
Age	  (y)	   0.182	   0.036	   1.199	  (1.011-­‐1.422)	  
Extracardiac	  Arteropathy	   1.108	   0.231	   3.027	  (0.494-­‐18.534)	  
EF	  30/50	  %	   0.971	   0.259	   2.640	  (0.488-­‐14.274)	  
Pulmonary	  Hypertension	   0.958	   0.253	   2.606	  (0.505-­‐13.446)	  
Rhythm	  (Preop)	   	   	   	  
sinus	   n/a	   n/a	   n/a	  
AF	   0.991	   0.181	   2.695	  (0.630-­‐11.535)	  
PCM	   0.222	   0.873	   1.248	  (0.082-­‐18.907)	  
 
MS:	   median	   sternotomy.	   TF.	   Transfemoral.	   TA:	   transapical.	   EF:	   left	   ventricular	  
ejection	  fraction.	  Sinus:	  sinus	  rhythm.	  AF:	  atrial	  fibrillation.	  PCM:	  pacemaker	  rhythm.	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With	   regard	   to	   the	   MACCE	   endpoint,	   Age	   was	   the	   only	   significant	  
independent	   predictor	   of	   event	   in	   the	  multivariate	   analysis	   although	   presenting	   a	  
weak	   association	   with	   the	   independent	   variable	   (1.199,1.011-­‐1.422).	   Neither	  
extracardiac	   artheropathy	   (3.027,	   0.494-­‐18.534),	   pulmonary	   hypertension	   (2.606,	  
0.505-­‐13.446),	   nor	   previous	  AF	   (2.695,	   0.630-­‐11.535),	   TF	   (3.694,	   0.551-­‐24.767),	   TA	  
approaches	  (3.262,	  0.386-­‐27.574)	  reached	  signification.	  	  
	  
SURVIVAL	  ANALYSIS	  
	   	  
Mean	  long-­‐term	  follow-­‐up	  was	  1.49+/-­‐1.22	  years	  (range	  0-­‐4.66	  years)	  in	  the	  
whole	  120	  cases	  series.	  	  0.99+/-­‐0.75	  years	  (range	  0-­‐3.35	  years)	  in	  the	  TAVI	  group	  and	  
1.90+/-­‐1.38	  years	  (range	  0.02-­‐4.66	  years)	   in	  the	  HR-­‐AVR	  group.	  Cumulative	  survival	  
was	  83.0%	  and	  81.4%	  for	  each	  group,	  respectively	  (global	  survival	  82.1%).	  Log-­‐rank	  
test	  (Mantel-­‐Cox)	  resulted	  non	  significant	  between	  both	  groups	  (Fig	  21.).	  	  
	  
Fig.	  21.	  Long-­‐term	  cumulative	  survival	  by	  groups	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 Chi-Square df Sig. 




We	   also	   performed	   a	   1-­‐year	   after	   surgery	   survival	   as	   an	   intermediate	  
endpoint	  in	  the	  survival	  analysis	  with	  an	  estimated	  overall	  survival	  of	  88.6%	  (95%	  CI	  
82.8-­‐94.4),	  85.5%	  (74.9-­‐96.1)	  for	  TAVI	  and	  90.9%	  (84.1-­‐97.8)	  for	  HR-­‐AVR	  groups,	  with	  
a	  non-­‐relevant	  log-­‐rank	  test	  result	  (Fig.	  22).	  	  
	  
Fig.	  22.	  1-­‐year	  cumulative	  survival	  by	  groups.	  	  
 
 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox)        .029 1 .865 
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Considering	  the	  different	  surgical	  approaches,	  transapical	  presented	  a	  66.7%	  
long-­‐term	  overall	  survival	  (mean	  follow-­‐up	  of	  1.08+/-­‐1.17)	  and	  transfemoral	  a	  87.8%	  
(0.97+/-­‐0.64)	   versus	   the	  81.4%	   for	  median	   sternotomy	   in	   the	  HR-­‐AVR	   (1.90+/-­‐1.38	  
years)	  group.	  Log-­‐rank	  test	  was	  non-­‐significant	  (Fig.	  23).	  
	  
	  
	   In	  order	  to	  assess	  the	  hypothetical	  learning	  curve	  effect	  for	  each	  approach	  in	  
the	  survival	  analysis	  a	  Cox	  multivariate	  logistic	  regression	  test	  was	  performed,	  
including	  long-­‐term	  survival	  as	  an	  independent	  variables;	  and	  the	  surgical	  approach	  
used	  and	  the	  year	  in	  which	  surgery	  was	  performed	  as	  dependent	  variables.	  MS	  and	  
2007	  were	  chosen	  as	  references.	  TA	  showed	  an	  OR	  2.880	  (95%	  CI	  0.733-­‐11.315)	  and	  
TF	  1.361	  (0.367-­‐5.041)	  though	  none	  of	  them	  reached	  a	  significant	  result.	  Year	  in	  
which	  surgery	  was	  performed	  presented	  a	  progressive,	  mild	  non-­‐relevant	  protective	  
effect	  represented	  by	  the	  negative	  regression	  coefficients	  in	  the	  logistic	  regression	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Fig.	  23.	  Long-­‐term	  cumulative	  survival	  by	  surgical	  approach	  
	  
 
 Chi-Square df Sig. 
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Table	  13.	  Multivariate	  Cox	  Regression	  analysis	  for	  long-­‐term	  survival.	  
 
long-­‐term	  survival	   	   	   	  
	   B	   (Sig)	   OR	  (95%	  CI)	  
Surgical	  Approach	   	   	   	  
MS	   n/a	   n/a	   n/a	  
TF	   0.308	   0.645	   1.261	  (0.367-­‐5.041)	  
TA	   1.058	   0.130	   2.880	  (0.733-­‐11.315)	  
year	  of	  surgery	   	   	   	  
2007	   n/a	   n/a	   n/a	  
2008	   -­‐0.313	   0.669	   0.731	  (0.174-­‐3.069)	  
2009	   0.102	   0.888	   1.107	  (0.268-­‐4.577)	  
2010	   -­‐0.886	   0.336	   0.412	  (0.068-­‐2.505)	  
2011	   -­‐0.323	   0.756	   0.724	  (0.094-­‐5.562)	  
2012	   -­‐8.553	   0.998	   0	  (0-­‐	  )	  
 
MS:	  Median	  sternotomy.	  TF:	  transfemoral.	  TA:	  transapical.	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3.	  Transfemoral	  vs.	  Transapical	  approach	  subgroup	  analysis	  
	  
	  
Subgroup	   analysis	   as	   foreseen	   in	   the	  Methods	   section	   sets	   the	   descriptive	  
statistics	   (Table	   14-­‐15),	   operative	   outcomes	   (Table	   16)	   and	   heart	   rhythm	   analysis	  
(Fig.24)	  of	  TF	  vs.	  TA	  subgroups.	  	  
	  
	   No	  differences	   in	  preoperative	  demographics	  or	  risk	  data	  were	  found,	  apart	  
from	  a	  higher	  rate	  of	  extracardiac	  arteropathy	  in	  the	  TA	  group	  (50%	  vs	  7.3%	  p<0.01).	  
Operative	   outcomes	   differences	   were	   also	   non-­‐significant,	   although	   a	   higher	  
incidence	  of	  renal	  failure	  for	  the	  TA	  approach	  (33.3%	  vs.	  0%).	  	  
	  
Table	  14.	  Descriptive	  statistics	  for	  TF	  and	  TA	  subgroups	  
	   TF	   TA	   	  
n	   41	   12	   	  
Age	  (y)	   80.71+/-­‐4.70	   79.42+/-­‐5.40	   ns	  
Gender	  (%male)	   20	  (48.8%)	   6	  (50.0%)	   ns	  
Weight	  (kg)	   72.16+/-­‐17.84	   69.94+/-­‐11.27	   ns	  
Height	  (cm)	   154.82+/-­‐16.13	   158.78+/-­‐10.75	   ns	  
BSA	  (m2)	   1.74+/-­‐0.17	   1.75+/-­‐0.19	   ns	  
BMI	  (kg/m2)	   28.33+/-­‐4.71	   27.71+/-­‐3.59	   ns	  
Coronary	  disease	   18	  (43.9%)	   5	  (41.7%)	   ns	  
No	  vessels	   0.71+/-­‐1.10	   0.92+/-­‐1.38	   ns	  
PTCA	   8	  (19.5%)	   3	  (25.0%)	   ns	  
CABG	   0	   0	   -­‐	  
No	  grafts	   0	   0	   -­‐	  
Valve	  area	  (cm2)	   0.59+/-­‐0.10	   0.69+/-­‐0.18	   ns	  
Mean	  Grad	  (mmHg)	   54.62+/-­‐14.25	   47.85+/-­‐13.55	   ns	  
Peak	  Grad	  (mmHg)	   80.33+/-­‐38.56	   85.71+/-­‐23.91	   ns	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Peak	  Vel	  (m/s)	   4.46+/-­‐0.78	   4.27+/-­‐0.11	   ns	  
 
 
BSA:	   Body	   surface	   area.	   BMI:	   body	   mass	   index.	   No.	   Vessels:	   numer	   of	   diseased	  
coronary	   vessels.	   PTCA:	   percutaneous	   transluminal	   coronary	   angioplasty.	   CABG:	  
coronary	   artery	   bypass	   graft.	   No	   grafts:	   number	   of	   grafts.	   Mean	   grad:	   mean	  




Table	  15.	  Preoperative	  features	  for	  TF	  and	  TA	  subgroups.	  
 
	   TF	   TA	   	  
n	   41	   12	   	  
EuroSCORE	   9	  (4-­‐14)	   10	  (6-­‐13)	   ns	  
logEuroSCORE	   15.76+/-­‐10.10	   19.20+/-­‐10.00	   ns	  
	   	   	   	  
Chronic	  Pulmonary	  Disease	   17	  (41.5%)	   4	  (33.3%)	   ns	  
Extracardiac	  Arteropathy	   3	  (7.3%)	   6	  (50.0%)	   p<0.01	  
Neurological	  dysfunction	   5	  (12.2%)	   2	  (16.7%)	   ns	  
Previous	  Cardiac	  Surgery	   5	  (12.2%)	   3	  (25.0%)	   ns	  
Preoperative	  Renal	  Failure	   4	  (9.8%)	   0	   ns	  
Active	  Endocarditis	   0	   0	   -­‐	  
Preoperative	  Critical	  Status	   0	   0	   -­‐	  
Unstable	  angor	   2	  (4.9%)	   1	  (8.3%)	   ns	  
EF	  30/50	  %	   5	  (12.2%)	   3	  (25.0%)	   ns	  
EF	  <	  30%	   5	  (12.2%)	   0	   ns	  
Recent	  MI	   0	   0	   -­‐	  
Pulmonary	  Hypertension	   8	  (19.5%)	   3	  (25.0%)	   ns	  
Emergency	   5	  (12.2%)	   3	  (25.0%)	   ns	  
Other	  than	  CABG	   41	  (100%)	   12	  (100%)	   ns	  
Surgery	  on	  Thoracic	  Aorta	   0	   0	   -­‐	  
Post	  MI	  VSD	   0	   0	   -­‐	  
Mitral	  Regurgitation	   5	  (12.2%)	   0	   ns	  
NYHA	  III/IV	   37	  (90.2%)	   11	  (91.7%)	   ns
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CHF	   5	  (12.2%)	   0	   ns	  
Calcified	  Aorta	   6	  (14.6%)	   4	  (33.3%)	   ns	  
Diabetes	   15	  (36.6%)	   5	  (41.7%)	   ns	  
Rhythm	  (Preop)	   	   	   	  
sinus	   24	  (58.5%)	   7	  (58.3%)	   	  
AF	   12	  (29.3%)	   5	  (41.7%)	   	  
PCM	   5	  (12.2%)	   0	   ns	  
 
 
EF:	  ejection	  fraction	  (left	  ventricle).	  MI:	  myocardial	  infarction.	  CABG:	  coronary	  artery	  
bypass	   graft.	   VSD:	   ventricular	   septal	   defect.	   NYHA:	   New	   York	   Heart	   Association	  
functional	  class.	  Rhythm	  (preop):	  Preoperative	  heart	  rhythm.	  Sinus:	  sinus	  rhythm.	  AF.	  
Atrial	  fibrillation.	  PCM:	  pacemaker	  rhythm.	  
 
 
Table	  16.	  Operative	  outcomes	  for	  TF	  and	  TA	  subgroups	  
 
	   TF	   TA	   	  
n	   41	   12	   	  
Valve	  implant	  size	  (mm)	   26	  (23-­‐29)	   26	  (23-­‐29)	   ns	  
Biological	  valve	  (%)	   41	  (100%)	   12(100%)	   ns	  
30-­‐d	  mortality	  (%)	   2	  (4.9%)	   2	  (16.7%)	   ns	  
Mortality	  (cause)*	   	   	   	  
cardiac	   1	  (2.4%)	   0	   	  
neurological	   1	  (2.4%)	   1	  (8.3%)	   	  
infective	   0	   0	   	  
endocarditis	   0	   0	   	  
respiratory	   0	   0	   	  
renal	   0	   0	   	  
multiorganic	   0	   1	  (8.3%)	   	  
unknown	   0	   0	   	  
Perioperative	  morbidity	  (all)*	   18	  (43.9%)	   6	  (50.0%)	   ns	  
Reintervention	   2	  (4.9%)	   1	  (8.3%)	   ns	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Cardiovascular	   4	  (9.8%)	   0	   ns	  
Respiratory	   1	  (2.4%)	   2	  (16.7%)	   ns	  
Wound	   3	  (7.3%)	   0	   ns	  
Renal	   0	   4	  (33.3%)	   p<0.01	  
Neurological	   3	  (7.3%)	   2	  (16.7%)	   ns	  
Infective	   0	   0	   -­‐	  
Other	   4	  (9.8%)	   0	   ns	  
MACCE	   6	  (14.6%)	   3	  (25.0%)	   ns	  
Rhythm	  (discharge)	   	   	   	  
sinus	   27	  (65.9%)	   7	  (58.3%)	   	  
AF	   4	  (9.8%)	   4	  (33.3%)	   	  
PCM	   10	  (24.4%)	   1	  (8.3%)	   ns	  
	   	   	   	  
ICU	  LOS	  (days)	   1.97+/-­‐2.76	   2.33+/-­‐1.37	   ns	  
Hospital	  LOS	  (days)	   7.36+/-­‐4.59	   6.71+/-­‐3.25	   ns	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30-­‐d	   mortality:	   thirty-­‐day	   mortality.	   MACCE:	   death	   or	   major	   adverse	   cardio	   or	  
cerebral	  events.	  AF:	  atrial	  fibrillation.	  PCM:	  pacemaker.	   ICU	  LOS:	   intensive	  care	  unit	  
length	  of	  stay.	  Hospital	  LOS:	  Hospital	  length	  of	  stay	  
*	  See	  Annex	  for	  definitions	  
	  
	  
Differences	  in	  ICU	  and	  hospital	  length	  of	  stay	  (1.97+/-­‐2.76	  vs.	  2.33+/-­‐1.37	  and	  
7.36+/-­‐4.59	  vs.	  6.71+/-­‐3.25	  days	  for	  TF	  and	  TA	  approaches	  respectively)	  as	  well	  as	  




Fig.	  24.	  	  Pacemaker	  (PCM)	  rhythm	  at	  discharge	  by	  surgical	  approach	  (p=ns)	  
	  
Surgical approach vs. PCM Rhythm Crosstabulation 
 
PCM 
Total No  Yes 
approach MS  67 0 67 
 100.0% .0% 100.0% 
TF  31 10 41 
 75.6% 24.4% 100.0% 
TA  11 1 12 
 91.7% 8.3% 100.0% 
Total  109 11 120 
 90.8% 9.2% 100.0% 
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4.	  ‘Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds’.	  A	  new	  
discrimination	  score	  for	  preoperative	  assessment	  in	  high-­‐risk	  
aortic	  valve	  replacement	  surgery.	  	  
	  
	  
CONSTRUCTION	  OF	  THE	  NEW	  SCORE	  
	  
The	   first	   step	   to	   construct	   a	   new	   scoring	   system	   for	   the	   preoperative	  
discrimination	  of	  the	  best	  aortic	  valve	  surgery	  procedure	  in	  high-­‐risk	  patients	  was	  to	  
select	   the	  multivariate	   logistic	   regression	   analysis	   dependent	   variables	   for	   the	   30-­‐
days	  mortality	  endpoint	  (Table	  17.).	  	  
	  
Table	  17.	  Multivariate	  logistic	  regression	  analysis	  for	  30-­‐days	  mortality	  endpoint.	  
	  
30-­‐d	  mortality	   	   	   	  
	   B	   (Sig.)	   OR	  (95%	  CI)	  
Extracardiac	  Arteropathy	   2.080	   0.009	   21.766	  (2.189-­‐216.418)	  
EF	  30/50	  %	   1.083	   0.215	   2.953	  (0.534-­‐16.332)	  
Pulmonary	  Hypertension	   1.622	   0.028	   13.766	  (1.318-­‐143.742)	  
	  
	  
Secondly,	   the	  round	  number	   for	   the	  regression	  coefficient	   for	  each	  variable	  
was	   chosen	   as	   the	   punctuation	   score	   and	   the	   additive	   punctuation	   of	   all	   three	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Table	  18.	  
	   	  
	   points	  
Extracardiac	  Arteropathy	   2	  
EF	  30/50	  %	   1	  
Pulmonary	  Hypertension	   1	  
	  
	  
Subsequently	   a	   consensus	   two	  different	   scoring	   profiles	  were	   created:	   Low	  
profile	   (total	   sum	   between	   0	   and	   2	   points),	   and	   High	   profile	   (scoring	   3	   or	   more	  
points).	   The	  descriptive	   results	  of	   the	  punctuation	  and	   the	  distribution	  of	   the	  new	  
score	  profile	  groups	  are	  shown	  on	  Table	  19.	  
	  
Table	  19.	  	  
Score	   Overall	   TAVI	   HR-­‐AVR	  
N	   120	   53	   67	  
risk	  groups	   	   	   	  
Low	  profile	  
102	  (85.0%)	  
44	  (83.02%)	   58	  (86.57%)	  
High	  profile	  
18	  (15.0%)	  
9	  (16.98%)	   9	  (13.43%)	  	  
	  
	  
30-­‐days	   mortality	   discrimination	   capacity	   of	   the	   score	   was	   tested	   against	  
additive	   EuroSCORE	   and	   logistic	   EuroSCORE	   in	   the	   120	   cases	   group	   by	   the	  
construction	   of	   specific	   receptor-­‐operator	   curves	   (ROC	   curve)	   for	   each	   scoring	  
punctuation	  system	  and	  assessing	  the	  area	  under	  the	  curve	  (AUC)	  for	  every	  one	  of	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them	  (0.835	  for	  the	  New	  Score,	  0.702	  for	  additive	  EuroSCORE	  and	  0.660	  for	  logistic	  
EuroSCORE).	  
	  
Fig.	   25.	   Receptor-­‐operator	   carachteristics	   curve	   for	   perioperative	   mortality	   by	  












Area Under the Curve 
Test Result 
Variable(s) Area Std. Errora 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
new score .835 .091 .638 1.000 
EuroSCORE .702 .111 .485 .920 
LogEuroSCORE .660 .116 .432 .888 
 
a. a. standard error 
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And	   finally,	   a	   discrimination	   tree	   by	   the	   Classification	   and	   Regression	   Tree	  
(CRT)	  method	  was	  constructed	  using	  the	  categorical	  classification	  of	  the	  new	  scoring	  
system	   (low-­‐profile	   versus	   high-­‐profile),	   the	   procedure	   to	   select	   (TAVI	   versus	  
conventional	  AVR)	  when	  considering	  30-­‐days	  mortality	  as	  the	  dependent	  (outcome)	  
variable	  in	  the	  120	  patients	  ‘high-­‐risk’	  group.	  (Fig.	  26)	  	  
	  
Discrimination	   Tree	   shows	   a	   2.9%	   perioperative	   mortality	   in	   the	   ´Low	  
Profile´group	   and	   a	   22.2%	   in	   the	   ´High	   Profile´	   group.	   Differences	   between	   both	  
procedures	  were	   found:	   in	   the	   ´Low	  Profile´group,	   30-­‐days	  mortality	  was	   6.8%	   for	  
TAVI,	  higher	  than	  the	  0%	  for	  conventional	  AVR;	  whether	  in	  the	  ´High	  Profile´	  group	  





	   We	   sought	   to	   assess	   internal	   validation	   of	   the	   new	   scoring	   system	   by	  
applying	  the	  punctuation	  to	  the	  overall	  468	  patients’	  database	  and	  subsequently	  to	  
the	  logistic	  EuroSCORE	  <	  15	  and	  over	  15	  subgroups.	  Construction	  of	  ROC	  curves	  for	  
the	   new	   score,	   additive	   and	   logistic	   EuroSCORE	   as	   well	   as	   Classification	   and	  
Regression	  Trees	   (CRT)	   for	   the	  new	  score	  were	  calculated	   for	   the	  overall	  database	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Fig	   26.	   Classification	   and	   Regression	   Tree	   for	   30-­‐days	   mortality	   for	   Low	   and	   High	  
Profile	  groups	  and	   the	  procedure	   (TAVI	  or	   conventional	  AVR)	  performed	   in	   the	  120	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Fig.	  27	  Receptor-­‐operator	  characteristics	  curve	  for	  perioperative	  mortality	  by	  the	  new	  















Area Under the Curve 
Test Result 
Variable(s) Area Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
new score .625 .061 .505 .745 
EuroSCORE .651 .050 .554 .749 
LogEuroSCORE .640 .049 .544 .736 
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Fig.	   28.	  Classification	   and	   Regression	   Tree	   for	   30-­‐days	  mortality	   for	   Low	   and	   High	  
Profile	  groups	  and	   the	  procedure	   (TAVI	  or	   conventional	  AVR)	  performed	   in	   the	  468	  
patients	  overall	  database	  
	  
	  
	   ROC	  curve	  returned	  0.625,	  0651	  and	  0.640	  AUC	  for	   the	  new	  score,	  additive	  
EuroSCORE	  and	  logistic	  EuroSCORE	  respectively.	  CRT	  was	  able	  to	  discriminate	  in	  the	  
high-­‐risk	  profile	  group	  (showing	  50%	  perioperative	  mortality	  for	  TAVI	  and	  23.5%	  for	  
conventional	  AVR)	  but	  not	  in	  the	  Low	  Profile	  group	  (Fig	  27-­‐28).	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   When	  considering	  the	  logistic	  EuroSCORE	  <	  15	  subgroup,	  ROC	  curve	  returned	  
0.544,0.603	   and	   0.584	   AUC	   for	   the	   new	   score,	   additive	   EuroSCORE	   and	   logistic	  
EuroSCORE	  respectively.	  CRT	  was	  unable	  to	  discriminate	  by	  procedure	  neither	  in	  the	  
Low	  Profile	  (5.1%	  perioperative	  mortality)	  nor	   in	  the	  High	  Profile	  (0%	  perioperative	  
mortality)	  (Fig.	  29-­‐30).	  	  
	  
Fig.	  29	  Receptor-­‐operator	  characteristics	  curve	  for	  perioperative	  mortality	  by	  the	  new	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Fig.	   30	   Classification	   and	   Regression	   Tree	   for	   30-­‐days	   mortality	   for	   Low	   and	   High	  
Profile	   groups	   and	   the	   procedure	   (TAVI	   or	   conventional	   AVR)	   performed	   in	   logistic	  




	   	  
	  
Area Under the Curve 
Test Result 
Variable(s) Area Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
new score .544 .072 .403 .685 
EuroSCORE .603 .054 .497 .708 
LogEuroSCORE .584 .049 .488 .680 
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   In	  the	  same	  fashion,	  ROC	  curves	  and	  CRT	  were	  tested	  for	  the	  EuroSCORE	  >	  15	  
subgroup.	   Returned	  AUC	  were	   0.752,	   0.638	   and	  0.631	   for	   the	   new	   score,	   additive	  
EuroSCORE	  and	  logistic	  EuroSCORE	  respectively.	  CRT	  was	  able	  to	  discriminate	  in	  both	  
Low	  and	  High	  Profile,	   showing	  a	  perioperative	  mortality	  of	   100%	   (1	   case)	   for	   TAVi	  
and	  33.3%	  for	  conventional	  AVR	  in	  the	  first	  and	  8.3%	  for	  TAVI	  vs.	  5.9%	  for	  AVR	  in	  the	  
second	  one	  (Fig.	  31-­‐32).	  	  
	  
Fig.	   31.	   Receptor-­‐operator	   characteristics	   curve	   for	   the	   new	   score,	   additive	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Area Under the Curve 
Test Result 
Variable(s) Area Std. Error 
 95%Confidence Interval 
Lower Bound Upper Bound 
new score .752 .095 .566 .938 
EuroSCORE .638 .092 .458 .818 
LogEuroSCORE .631 .083 .468 .794 
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Fig.	   31	   Classification	   and	   Regression	   Tree	   for	   30-­‐days	   mortality	   for	   Low	   and	   High	  
Profile	   groups	   and	   the	   procedure	   (TAVI	   or	   conventional	   AVR)	   performed	   in	   logistic	  






	   As	   described	   in	   the	  Methods	   section,	   external	   validation	  was	  modelized	  by	  
constructing	   a	   ´dummy´	   database	   with	   similar	   characteristics	   as	   those	   presented	  
with	   Cohort	   A	   in	   the	   PARTNER	   trial.	   	   The	   variables	   and	   data	   used	   for	   building	   the	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´dummy	  database´	  are	  presented	  again	   in	   figure	  32.	  ROC	  curves	   for	   the	  new	  score	  
and	  logistic	  EuroSCORE	  	  (Fig.	  33)	  and	  CRT	  for	  perioperative	  mortality	  (Fig.	  34)	  were	  
tested	  in	  this	  ´dummy´database.	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Fig.	   33.	   Receptor-­‐operator	   characteristics	   curve	   for	   perioperative	   mortality	   by	   the	  














Area Under the Curve 
Test Result 
Variable(s) Area Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
new score .778 .038 .705 .852 
logistic EuroScore .508 .052 .407 .610 
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Fig.	   34.	  Classification	   and	   Regression	   Tree	   for	   30-­‐days	  mortality	   for	   Low	   and	   High	  
Profile	   groups	   and	   the	   procedure	   (TAVI	   or	   conventional	   AVR)	   performed	   in	   the	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ROC	   curve	   was	   tested	   for	   the	   new	   score	   and	   logistic	   EuroSCORE	   in	   the	  
PARTNER	   cohort	   A	   ´dummy´database,	   obtaining	   0.778	  AUC	   for	   the	   new	   score	   and	  
0.508	   for	   logistic	   EuroSCORE.	   CRT	   showed	   discrimination	   in	   the	   High	   Profile	   arm	  
(6.1%	  30-­‐days	  mortality	  for	  TAVI	  vs.	  14.8%	  for	  AVR)	  exclusively.	  
	  
	  
	   	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   208	  
	   	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  

















IV.	  DISCUSSION	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1.	  Impact	  of	  new	  technology	  	  
	  
	  
Aortic	   stenosis	   (AS)	   is	   the	   most	   common	   valvular	   heart	   disease	   in	   adults	  
(112).	   The	   disorder	   is	   becoming	   more	   frequent	   as	   the	   age	   of	   the	   population	  
increases,	  representing	  a	  growing	  public	  health	  issue.	  Severe	  AS	  is	  universally	  fatal	  if	  
left	   untreated,	   with	   three-­‐quarters	   of	   patients	   dying	   within	   3	   years	   of	   symptom	  
onset.	  No	  medical	  treatment	  improves	  survival	  in	  chronic	  disease,	  as	  the	  obstruction	  
to	  outflow	  tract	  requires	  mechanical	  relief.	  Mortality	  rates	  are	  significantly	  reduced	  
in	  symptomatic	  patients	  with	  AS	  by	  aortic	  valve	   replacement	   (AVR).	  Thus,	  AVR	  can	  
be	  withheld	  in	  such	  patients	  only	  when	  compelling	  contraindications	  exist.	  A	  recent	  
prospective	   survey	   of	   patients	   with	   valvular	   heart	   disease	   throughout	   Europe	  
suggests	  that	  almost	  one-­‐third	  of	  patients	  over	  the	  age	  of	  75	  with	  severe	  AS	  do	  not	  
undergo	  AVR,	  due	  to	  risks	  arising	  from	  age	  and	  comorbidities	  (112).	  These	  findings	  
have	   stimulated	   tremendous	   interest	   in	   reducing	   patient	   morbidity	   and	   mortality	  
and	  motivated	   the	  development	  of	   a	   less-­‐invasive	   transcatheter	   aortic	   valve	   (TAV)	  
procedure	  (92).	  
	  
The	   emergence	   of	   new	   technologies	   for	   the	   treatment	   of	   aortic	   valve	  
disorders	   has	   brought	   with	   it	   a	   host	   of	   medical	   and	   ethical	   challenges	   regarding	  
patient	   selection	   and	   choice	   of	   treatment.	   Because	   of	   the	   uncertainty	   around	   the	  
safety	   of	   new	   transcatheter	   aortic	   valve	   implantation	   (TAVI)	   technologies,	   early	  
device	  trials	  have	  focused	  on	  enrolling	  and	  treating	  patients	  at	  high	  surgical	  risk	  who	  
are	   ‘‘non-­‐operative’’	   candidates.	   Although	   outcomes	   for	   open	   surgical	   repair	   of	  
critical	   aortic	   stenosis	   are	   improving,	   early	   results	   with	   TAVI	   are	   encouraging	   and	  
have	  led	  to	  expanded	  patient	  selection	  criteria.	  
	  
Consequently,	   transformational	   technology	   is	   defined	   as	   one	   that	   when	  
introduced	   radically	   changes	  markets,	   creates	   wholly	   new	  markets,	   or	   could	   even	  
eliminate	  existing	  markets	  for	  older	  technology.	  The	  field	  of	  medicine	  is	  replete	  with	  
examples	   of	   such	   therapies	   that	   have	   radically	   altered	   the	   treatment	   of	   disease,	  
including	   sterile	   techniques	   in	   surgery,	   vaccines	   to	   cure	   polio,	   penicillin	   and	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sulfamide	   drugs	   for	   infectious	   diseases,	   and	   cortisone.	   Physicians,	   scientists,	   and	  
industry	  partners	  have	  developed	  all	  these	  therapies	  in	  concert.	  
	  
Catheter-­‐based	   therapies	   present	   new	   and	   potentially	   transformational	  
technology	  for	  valvular	  and	  structural	  heart	  disease	  (117).	  The	  associated	  issues	  are	  
complex,	  with	  multiple	  actors:	  first	  and	  foremost,	  the	  patients	  receiving	  this	  therapy,	  
but	   also	   including	   clinicians,	   inventors,	   industry,	   regulatory	   agencies,	   governments	  
and	  professional	  societies.	  
	  
Several	  issues	  emerge	  with	  the	  introduction	  of	  this	  new	  technology.	  
	  
1. How	  will	  this	  technology	  be	  regulated	  and	  by	  whom?	  
2. Will	  the	  technology	  be	  available	  in	  all	  centers	  by	  all	  physicians	  or	  only	  
in	   selected	   regional	   centers;	   if	   the	   latter,	   how	  will	   those	   centers	   be	  
selected?	  
3. How	  will	   training	   of	   physicians	   and	   centers	   be	   accomplished?	  What	  
will	   the	   training	  paradigms	  be	   and	  what	   experience	   is	   necessary	   for	  
credentialing	  to	  be	  deemed	  proficient?	  Will	  the	  training	  be	  the	  same	  
for	  cardiologists	  and	  surgeons?	  
4. Will	   clinical	   databases	   be	   linked	   to	   administrative	   databases	  
facilitating	  long-­‐term	  outcome	  assessment,	  comparative	  effectiveness	  
research,	   and	   cost-­‐effectiveness	   analysis?	   Will	   data	   collection	   be	  
required	  using	  standardized	  definitions	  in	  harmonized	  national	  clinical	  
and	  administrative	  databases	  and	  registries,	  and	  if	  so,	  from	  where	  will	  
the	   resources	   come	   to	   accomplish	   this?	   Can	   these	   standardized	  
registries	  be	  used	  worldwide?	  
5. What	   will	   be	   the	   rational	   diffusion	   of	   the	   new	   technology	   to	   other	  
patient	  groups	  not	  originally	  studied	  in	  randomized	  clinical	  trials?	  
6. How	  will	  patient	  cohorts	  be	   identified	  that	  will	  benefit	  the	  most	  and	  
provide	  the	  most	  cost-­‐effective	  and	  clinically	  effective	  treatment?	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Transcatheter	   valve	   therapy	   is	   a	   transformational	   technology	   with	   the	  
potential	   to	   significantly	   impact	   the	   clinical	  management	   of	   patients	  with	   valvular	  
heart	  disease	   in	  a	   less	   invasive	  manner.	  Although	   the	   initial	   experience	   is	  positive,	  
evidence	  exists	  from	  only	  1	  randomized	  clinical	  trial	  in	  patients	  with	  aortic	  stenosis.	  
In	   order	   to	   address	   the	   challenges	   ahead	   for	   the	   responsible	   diffusion	   of	   this	  
innovative	   transformational	   technology,	   it	   is	   critical	   that	   the	  professional	   societies,	  
industry,	  payers,	  and	  regulatory	  agencies	  work	  together	  to	  optimize	  benefits	  for	  the	  
patient	  and	  society	  (118,119).	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2.	  Current	  state	  of	  the	  evidence	  
	  
• REGISTRY	  EXPERIENCE	  
	  
Registry	  data	  provide	   important	   information	   for	  assessing	   the	   role	  of	  TAVI	   in	  a	  
large	   number	   of	   patients	   who	   are	   not	   eligible	   for	   randomized	   controlled	   trials	  
because	  of	  strict	  selection	  criteria.	  Several	  multicenter	  registries,	  including	  Edwards	  
Lifesciences	  and	  Medtronic	  CoreValve	  (tables	  1	  and	  2),	  have	  reported	  early	  and	  late	  
outcomes	   with	   TAVI.	   However,	   patient	   selection	   criteria	   varied	   amongst	   the	  
different	   registries;	   standardized	   definitions	   for	   clinical	   events	  were	   not	   used;	   and	  
endpoints	   were	   not	   prospectively	   adjudicated	   using	   a	   blinded	   clinical	   event	  
committee.	   This	   study	   is	   not	   an	   exception	   and	   data	  was	   retrospectively	   collected.	  
Selection	  criteria	  have	  been	  widely	  explained	  in	  previous	  sections,	  but	  basically	  were	  
based	  upon	  experts	  committee	  criteria.	  	  
	  
CoreValve	  system	  real-­‐world	  clinical	  experience	  to	  date	  is	  comprised	  of	  multiple	  
registries	   from	   several	   participating	   national	   sites	   (97,120–126).	   These	   study	   sizes	  
range	  from	  61	  to	  663	  patients,	  with	  a	  combined	  clinical	  patient	  experience	  of	  nearly	  
2,350	  patients	  that	  includes	  follow-­‐up	  of	  up	  to	  2	  years	  (Table	  2).	  Our	  study	  comprises	  
a	  single-­‐center	  experience	  of	  468	  patients	  eligible	  for	  aortic	  valve	  replacement,	  out	  
of	  whom	  53	  underwent	  a	  TAVI	  procedure	  and	  the	  rest	  a	  conventional	  AVR.	  
	  
The	  early	  and	  late	  major	  outcomes	  with	  Sapien	  and	  CoreValve	  registries	  are	  
summarized	   in	   Tables	   1	   and	   2	   respectively.	   The	   early	   morbidity	   of	   TAVI	   includes	  
stroke,	   coronary	   occlusion,	   pacemaker	   implantation,	   vascular	   complications,	   renal	  
failure,	  cardiac	  rupture	  and	  tamponade,	  bleeding,	  aortic	  dissection,	  and	  death.	  The	  
overall	  risk	  of	  any	  30-­‐day	  major	  complication	  ranges	  from	  20%	  to	  over	  40%,	  whereas	  
we	  present	  a	  45.3%	  for	  overall	  perioperative	  mortality	  in	  TAVI	  and	  32.8%	  in	  the	  HR-­‐
AVR	  group.	  Early	  mortality	  ranges	  from	  an	  in-­‐hospital	  rate	  of	  5%	  to	  8%	  and	  a	  30-­‐day	  
mortality	  rate	  from	  8%	  to	  10%,	  similar	  to	  the	  7.5%	  for	  TAVI	  presented	  in	  this	  study	  
but	  somewhat	  higher	  than	  for	  HR-­‐AVR	  (4.5%)	  although	  these	  differences	  were	  non-­‐
significant.	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In	   the	   SOURCE	   registry,	   the	   incidence	   of	   a	   major	   bleeding	   event	   was	  
significantly	  greater	  among	  patients	  undergoing	  transapical	  versus	  transfemoral	  TAVI	  
(3.9%	  vs.	  2.3%),	  whereas	  the	  incidence	  of	  vascular	  access	  related	  complications	  was	  
significantly	   higher	   among	   patients	   having	   transfemoral	   TAVI	   (major—11.3%	   vs.	  
2.0%;	   minor—10.4%	   vs.	   1.0%)	   (125,127–129).	   In	   our	   results	   reintervention	   for	  
bleeding	  in	  TA	  group	  is	  increased	  almost	  by	  two-­‐fold	  when	  compared	  to	  TF	  (8.3%	  vs.	  
4.9%).	   In	  consonance,	  vascular	   related	  complications	  were	  absent	   in	  TA	   (0%)	  while	  
9.8%	  in	  TF.	  This	  has	  an	  important	  impact	  in	  the	  overall	  TAVI	  cardiovascular	  morbidity	  
in	  our	  study,	  which	  results	  significantly	  higher	  than	  in	  HR-­‐AVR	  (7.5%	  vs.	  0%,	  p<0.05).	  
Likewise	  stroke	  rates	  differ	  between	  7.3%	  for	  TA	  and	  16.7%	  for	  TF,	  causing	  an	  overall	  
TAVI	  neurological	  complications	  rate	  of	  9.4%,	  between	  two	  and	  tree-­‐fold	  higher	   to	  
those	   reported	   in	   the	  main	   registries	   and	   statistically	   significant	   different	   than	   for	  
the	  HR-­‐AVR	  group	  (0%).	  	  
	  
Permanent	  pacemaker	  placement	  is	  reported	  in	  between	  1.8%	  up	  to	  8.5%	  of	  
patients	  with	  Sapien	  and	  19.1%	  to	  42.5%	  with	  the	  CoreValve	  (90,125).	  Our	  study	  did	  
not	   differenciate	   between	   prosthetic	   implant	   type,	   but	   TF	   pacemaker	   rhythm	   at	  
discharge	   was	   24.4%	   whereas	   in	   the	   TA	   group	   only	   8.3%	   (p=ns).	   In	   the	   same	  




• RESULTS	  OF	  CLINICAL	  TRIALS	  
	  
A	  robust	  knowledge	  of	  the	  current	  scientific	  literature	  is	  mandatory	  to	  place	  this	  
technology	  in	  perspective.	  Data	  from	  multiple	  single-­‐center	  series,	  and	  national	  and	  
commercial	   registries	   are	   available	   for	   both	   transcatheter	   aortic	   and	   mitral	  
procedures.	  Randomized	  clinical	  trials	  represent	  the	  highest	  form	  of	  evidence-­‐based	  
medicine	  and	  form	  the	  backbone	  of	  regulatory	  approval	  and	  instructions	  for	  use.	  Up	  
to	  the	  present	  date,	  only	  the	  results	  of	  one	  trial	  of	  transcatheter	  aortic	  valves	  have	  
been	   published:	   the	   PARTNER	   trial	   has	   received	   a	   great	   deal	   of	   interest.	   Specific	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details	  about	  patient	  selection,	  protocols	  used,	  endpoints,	  and	  statistical	  evaluation	  
are	  crucial.	  
	  
Table	  1.	  Main	  registries	  for	  Sapien	  Valve.	  
	  
	  




The	  PARTNER	  trial	  was	  basically	  2	  parallel	  trials	  that	  enrolled	  the	  highest-­‐risk	  
patients	  ever	   seen	   in	  any	  cardiovascular	   trial	  by	  virtue	  of	   their	  age	  and	  severity	  of	  
comorbid	   conditions:	   1)	   PARTNER	   Cohort	   A,	   which	   randomized	   high-­‐risk	   surgical	  
patients	   to	   either	   traditional	   aortic	   valve	   replacement	   or	   to	   TAVI	   by	   either	   a	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transfemoral	   or	   transapical	   approach;	   and	   2)	   PARTNER	  Cohort	   B	   in	  which	   patients	  
who	  were	  inoperable	  were	  randomized	  to	  either	  a	  TAVI	  by	  a	  transfemoral	  approach	  
or	   to	   conventional	   medical	   therapy,	   which	   typically	   con-­‐	   sisted	   of	   balloon	   aortic	  
valvuloplasty.	  Screening	  required	  an	  evaluation	  by	  2	  experienced	  cardiac	  surgeons	  to	  
agree	  on	   the	   surgical	   risk	   using	   the	   STS	   Predicted	  Risk	   of	  Mortality	   score	   (20)	   and	  
was	   rigorous,	   with	   approximately	   one	   quarter	   to	   one	   third	   of	   screened	   patients	  
subsequently	  enrolled.	  The	  primary	  endpoint	  was	  death	  from	  any	  cause	  at	  1	  year.	  
	  
The	   results	   of	   PARTNER	   Cohort	   B	   have	   recently	   been	   published	   (9)	   and	  
included	  358	  patients	  deemed	  unsuitable	  for	  conventional	  aortic	  valve	  replacement	  
because	  of	  predicted	  probability	  of	  >50%	  mortality	  or	  at	  risk	  for	  a	  serious	  irreversible	  
complication	  by	  30	  days.	  At	  1	  year,	  all-­‐cause	  mortality	  with	  TAVI	  was	  30.7%	  versus	  
50.7%	   with	   medical	   therapy	   (hazard	   ratio:	   0.55,	   95%	   confidence	   interval:	   0.40	   to	  
0.74).	   Despite	   the	  marked	   improvement	   in	   survival	   and	   event-­‐free	   survival,	   there	  
were	  some	  significant	  safety	  hazards,	  particularly	  a	  higher	  incidence	  of	  major	  strokes	  
(5.0%	  versus	  1.1%)	  as	  well	  as	  increased	  major	  vascular	  complications	  (16.2%	  versus	  
1.1%)	   with	   TAVI,	   both	   of	   which	   may	   impact	   early	   and	   longer-­‐term	   outcome	  
adversely.	  
	  
The	  preliminary	   results	  of	   the	  PARTNER	  Cohort	  A	   trial	  were	  presented	  and,	  
the	   primary	   endpoint	   of	   the	   trial	   was	  met,	   with	   TAVI	   found	   to	   be	   non-­‐inferior	   to	  
aortic	   valve	   replacement	   for	   all-­‐cause	  mortality	   at	  1	   year	   (TAVI	   versus	  aortic	   valve	  
replacement,	   24.2%	  versus	   26.8%,	   respectively,	   p<0.001	   for	   non-­‐inferiority).	  Death	  
at	  30	  days	  was	  lower	  than	  expected	  in	  both	  arms	  of	  the	  trial:	  TAVI	  mortality	  (3.4%)	  
was	  the	  lowest	  reported	  in	  any	  series,	  despite	  an	  early	  generation	  device	  and	  limited	  
previous	  operator	  experience.	  Aortic	  valve	  replacement	  mortality	  (6.5%)	  was	   lower	  
than	  the	  expected	  operative	  mortality	  (11.8%).	  	  
	  
In	  our	  study,	  mean	  long-­‐term	  follow-­‐up	  was	  1.49+/-­‐1.22	  years	  (range	  0-­‐4.66	  
years)	   in	  the	  whole	  120	  cases	  series.	   	  0.99+/-­‐0.75	  years	   (range	  0-­‐3.35	  years)	   in	  the	  
TAVI	   group	   and	   1.90+/-­‐1.38	   years	   (range	   0.02-­‐4.66	   years)	   in	   the	   HR-­‐AVR	   group.	  
Cumulative	   survival	   was	   83.0%	   and	   81.4%	   for	   each	   group,	   respectively	   (global	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survival	   82.1%).	   Log-­‐rank	   test	   resulted	   non	   significant	   between	   both	   groups.	  
Intermediate	  1-­‐year	  survival	  analysis	  was	  also	  performed	  with	  an	  estimated	  overall	  
survival	   of	   88.6%	   (95%	   CI	   82.8-­‐94.4),	   85.5%	   (74.9-­‐96.1)	   for	   TAVI	   and	   90.9%	   (84.1-­‐
97.8)	  for	  HR-­‐AVR	  groups,	  with	  a	  non-­‐relevant	  log-­‐rank	  test	  result	  and	  in	  consonance	  
with	  the	  PARTNER	  results.	  
	  
Furthermore,	   in	  PARTNER	  Cohort	  A	  both	  TAVI	  and	  aortic	  valve	  replacement	  
were	  associated	  with	  important	  but	  different	  periprocedural	  hazards:	  major	  strokes	  
at	   30	  days	   (3.8%	  versus	  2.1%,	  p=0.20)	   and	  1	   year	   (5.1%	  versus	  2.4%,	  p=0.07),	   and	  
major	   vascular	   complications	   were	   more	   frequent	   with	   TAVI	   (11.0%	   versus	   3.2%,	  
p<0.001).	   Major	   bleeding	   (9.3%	   versus	   19.5%,	   p<0.001)	   and	   new	   onset	   atrial	  
fibrillation	   (8.6%	   versus	   16.0%,	   p<0.001)	   were	   more	   frequent	   with	   aortic	   valve	  
replacement.	   We	   present	   a	   relatively	   high	   30-­‐days	   stroke	   rate	   in	   TAVI	   of	   9.4%	  
significantly	  higher	  than	  0%	  for	  selected	  matched	  controls	  (HR-­‐AVR).	  Reintervention	  
for	  major	  bleeding	  rates	  and	  atrial	   fibrillation	  rhythms	  on	  discharge	  were	  similar	   in	  
our	  TAVI	  and	  HR-­‐AVR	  series	  (5.7%	  vs.	  7.5%	  and	  15.1%	  vs.	  13.4%	  respectively).	  
	  
The	   30-­‐day	  mortality	   in	   PARTNER	   Cohort	   A	   (3.4%)	   and	   PARTNER	   Cohort	   B	  
(5.2%)	  is	  better	  than	  published	  European	  registry	  mortality	  (8.5%)	  (21–23)	  as	  well	  as	  
for	   our	   series	   (7.5%	   for	   TAVI).	   This	   raises	   questions	   about	   the	   “generalizability”	   of	  
these	   trial	   results	  after	   commercialization.	  Responsible	  diffusion	  of	   this	   technology	  
with	   close	   monitoring	   of	   outcomes	   after	   commercialization	   will	   be	   critical	   to	  
maintain	  these	  results.	  The	  incidence	  of	  neurologic	  events	  (5.5%	  at	  30	  days,	  8.3%	  at	  
1	   year)	   and	  major	   vascular	   complications	   (11%)	   that	   occur	   in	   patients	   undergoing	  
TAVI	  also	  needs	  to	  be	  addressed.	  The	  results	  presented	  in	  this	  work	  also	  support	  this	  
evidence.	  	  
	  
In	  conclusion,	   the	  approval	  of	  TAVI	  represents	  a	  fundamental	  change	   in	  the	  
management	  of	  aortic	  valvular	  heart	  disease	  by	  offering	  an	  alternative	  to	  traditional	  
surgical	   aortic	   valve	   replacement	   in	   carefully	   selected	  patients.	   The	  penetration	  of	  
this	  technology	  in	  the	  broad	  group	  of	  patients	  with	  AS	  remains	  to	  be	  determined	  and	  
will	  depend	  on	  the	  continued	  evolution	  of	  the	  technology	  and	  the	  results	  of	  clinical	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trials	   conducted	   in	   these	   patients.	   At	   the	   present	   time,	   several	   observations	   and	  
recommendations	  can	  be	  extracted	  from	  the	  review	  of	  the	  current	  literature	  (Table	  
3)	  (119).	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3.	  Health	  care	  costs	  and	  effectiveness	  
	  
	  
With	   the	   population	   aging,	   AS	   is	   becoming	   a	  more	   prevalent	   public	   health	  
issue.	  Medical	  therapy	  is	  unlikely	  to	  modify	  the	  course	  of	  the	  disease,	  especially	  once	  
symptoms	   or	   left	   ventricular	   dysfunction	   become	  manifest.	   Percutaneous	   balloon	  
aortic	  valvuloplasty	  has	  only	  a	  limited	  role	  in	  the	  treatment	  of	  AS,	  as	  the	  results	  are	  
not	   durable.	   Surgical	   AVR	   remains	   the	  mainstay	   of	   definitive	   treatment.	   Although	  
surgical	   therapy	   is	   effective,	   it	   entails	   the	   risks	   and	   morbidity	   associated	   with	  
cardiopulmonary	   bypass	   and	  median	   sternotomy.	  When	   a	   frail	   and	   elderly	   patient	  
with	  significant	  comorbidities	  presents	  with	  severe	  AS,	  he	  or	  she	  may	  be	  precluded	  
from	  surgical	  AVR	  due	  to	  potentially	  high	  operative	  risks.	  TAV	  implantation	  with	  its	  
less	  invasive	  nature	  is	  believed	  to	  offer	  a	  safer	  treatment	  solution	  for	  these	  patients.	  
	  
According	  to	  the	  2010	  EACTS	  Database	  Report,	  over	  40.000	  isolated	  AVR	  and	  
over	   25.000	   combined	   AVR	   plus	   coronary	   surgery	   procedures	   were	   performed	  
during	   2008	   in	   the	   Europe.	   Heart	   valve	   replacement	   has	   long	   been	   proven	   to	   be	  
clinically	   effective	   in	   extending	   life	   expectancy	   and	   improving	   quality	   of	   life.	   It	   is	  
increasingly	  performed	  in	  older	  patients,	  including	  those	  aged	  more	  than	  80	  years	  or	  
even	  more	  than	  90	  years.	  The	  clinical	  effectiveness	  of	  this	  technique	  has	  been	  well	  
documented,	   but	   only	   few	   studies	   focus	   on	   cost-­‐effectiveness,	   especially	   when	  
considering	   the	   modern	   TAVI	   techniques.	   	   New	   technologies	   are	   often	   cited	   as	   a	  
major	  contributor	  to	  increasing	  healthcare	  costs.	  Before	  a	  new	  technology	  or	  clinical	  
strategy	   is	  widely	  adopted,	   it	   is	   therefore	   important	   to	  understand	   the	  clinical	  and	  
economic	   benefits	   that	   any	   increased	   upfront	   expenditures	   may	   yield.	   Given	   the	  
advanced	  age	  and	  multiple	  comorbid	  conditions	  that	  characterize	  patients	  with	  high	  
surgical	   risk	   for	   surgical	   valve	   replacement,	   the	   question	   of	   whether	   TAVI	   can	  
provide	   meaningful	   health	   benefits	   to	   the	   population	   at	   an	   acceptable	   cost	   is	  
particularly	  appropriate.	  
	  
	   Cost-­‐effective	  analysis	  has	   long	  been	  used	   to	  compare	  2	   treatments	  on	   the	  
basis	  of	   their	  economic	  and	  clinical	  outcomes	   (130).	  The	   results	  of	  a	   cost-­‐effective	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analysis	   are	   summarized	   as	   a	   cost-­‐effective	   ratio	   (CER),	   of	  which	   the	  numerator	   is	  
the	  difference	  of	  the	  costs	  of	  the	  2	  treatments	  and	  the	  denominator	  is	  the	  difference	  
of	   the	   Quality	   Adjusted	   Life	   Years	   (QALYs).	   Thus,	   the	   CER	   provides	   the	   cost	   for	  
gaining	   1	   additional	  QALY	   and	   is	   commonly	   used	   to	   judge	  whether	   a	   treatment	   is	  
worth	   its	   costs	   compared	   with	   an	   alternative	   treatment.	   Wu	   and	   colleagues	  
published	  that	  concerning	  conventional	  AVR,	  the	  CER	  increased	  according	  to	  age	  at	  
surgery.	  Still,	  the	  CER	  was	  less	  than	  €16,000	  per	  QALY	  for	  all	  but	  the	  nonagenarians,	  
and	  it	  was	  only	  €21,000	  per	  QALY	  for	  them.	  There	  are	  generally	  accepted	  thresholds:	  
A	   treatment	   costing	   less	   than	   €15,000/QALY	   is	   considered	   very	   cost-­‐	   effective,	  
between	  €15,000	  and	  €75,000/QALY	  is	  acceptable,	  and	  more	  than	  €75,000/QALY	  is	  
not	  cost-­‐effective	  (131).	  Despite	  the	  limitations,	  this	  is	  well	  within	  generally	  accepted	  
thresholds,	  making	  AVR	  very	  cost-­‐effective(130).	  
	  
	   Reynolds	  and	  colleagues	  (132)	  have	  set	  the	  CER	  for	  TAVI	  versus	  standard	  care	  
of	  €38,500	  per	  year	  of	   life	  gained.	  The	  cost-­‐effectiveness	  of	  TAVI	   for	  patients	  with	  
inoperable	   aortic	   stenosis	   is	   also	   well	   within	   the	   range	   of	   other	   cardiovascular	  
technologies	   commonly	   used	   (133),	   including	   implantable	   defibrillators	   for	   the	  
primary	   prevention	   of	   sudden	   cardiac	   death	   (134,135)	   and	   catheter	   ablation	   for	  
atrial	   fibrillation	   (136),	   and	   far	  below	   recent	  estimates	  of	   the	   cost-­‐effectiveness	  of	  
percutaneous	  coronary	  intervention	  versus	  medical	  therapy	  for	  patients	  with	  stable	  
coronary	  artery	  disease	  (137)	  or	  left	  ventricular	  assist	  devices	  (138).	  	  
	   Despite	  providing	   substantial	   cost	  offsets	  during	   the	   first	   year	  of	   follow-­‐up,	  
among	  the	  highly	  complex,	  inoperable	  patients	  enrolled	  in	  the	  PARTNER	  trial	  (Cohort	  
B),	   TAVI	   did	   not	   result	   in	   long-­‐term	   cost	   savings.	   In	   fact,	   empirically	   derived	  
projections	   (132)	   suggest	   that	   the	   cost	   difference	   between	   TAVI	   and	   standard	  
therapy	   actually	   increased	   beyond	   the	   first	   year	   of	   follow-­‐up	   as	   a	   result	   of	   the	  
greater	   life-­‐expectancy	   for	   the	   TAVI	   group	   coupled	   with	   the	   high	   cost	   of	   ongoing	  
medical	   care	   even	   after	   successful	   valve	   replacement	   in	   this	   patient	   population.	  
Given	   the	   very	   large	   survival	   benefit	   observed	   in	   the	   PARTNER	   trial	   (cohort	   B),	   it	  
appears	  unlikely	  that	  such	  a	  study	  will	  be	  repeated,	  and	  the	  control	  group	  from	  our	  
study	  will	  remain	  the	  benchmark	  for	  future	  clinical	  and	  economic	  evaluations	  of	  this	  
technique	  among	  inoperable	  patients.	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4.	  Rationale	  of	  indication	  and	  discrimination	  for	  TAVI	  
	  
	  
The	  evolution	  of	   transcatheter	  valve	   therapy	   raises	   important	  questions	   for	  
practitioners,	   patients,	   and	   government	   agencies	   on	   the	   appropriate	   treatment	  
strategy	   for	  patients	  who	  could	  be	  eligible	   for	   this	  procedure	  or	  whether	   it	   results	  
inappropriate	  or	  futile.	  
	  
Therapeutic	   futility	   may	   be	   determined	   based	   upon:	   1)	   lack	   of	   medical	  
efficacy,	  as	  judged	  by	  the	  patient’s	  physician;	  or	  2)	  lack	  of	  a	  meaningful	  survival,	  as	  
judged	  by	   the	  personal	   values	  of	   the	  patient.	  Although	   therapeutic	   futility	  may	  be	  
invoked	  to	  justify	  denial,	  limitation,	  or	  withdrawal	  of	  care,	  the	  threshold	  for	  defining	  
it	   is	  unclear,	  controversial,	  and	  often	  viewed	  differently	  among	   interested	  parts.	   In	  
the	   PARTNER	   trial,	   the	   criterion	   for	   inoperability—used	   as	   a	   surrogate	   for	   futility	  
with	   regards	   to	   surgical	   intervention—was	   an	   estimate	   of	   probability	   of	   death	   or	  
serious,	   irreversible	   morbidity	   >50%	   by	   a	   cardiologist	   and	   2	   experienced	  
cardiothoracic	   surgeons	   (7).	   Despite	   successful	   correction	   of	   AS	   leading	   to	   an	  
absolute	  20%	  survival	  advantage,	  there	  was	  still	  30%	  mortality	  in	  the	  TAVI	  treatment	  
arm	  at	  1	  year,	  mainly	  due	  to	  non-­‐cardiac	  causes.	  The	  key	  to	  treatment	  in	  this	  group	  
of	  “inoperable”	  patients	  is	  to	  define	  the	  “futility	  versus	  utility”	  treatment	  paradigm.	  
Clearer	   definition	   of	   comorbid	   conditions	   that	   adversely	   affect	   survival	   despite	  
successful	   valve	   implementation	   as	   well	   as	   quality	   of	   life	   and	   health	   economic	  
assessment	   in	   those	   “inoperable”	   patients	   is	   crucial	   so	   that	   this	   therapy	   is	  
appropriately	  used	  in	  patients	  likely	  to	  benefit	  (utility)	  compared	  with	  those	  unlikely	  
to	  benefit	  despite	  successful	  therapy	  (futility).	  Although	  some	  might	  argue	  that	  it	  is	  
inappropriate	   and	   misleading	   to	   say	   that	   treatment	   is	   futile	   simply	   because	   the	  
probability	  that	  it	  will	  succeed	  is	  small,	  especially	  given	  the	  substantial	  uncertainty	  in	  
our	   ability	   to	   prognosticate	   in	   individual	   patients	   and	   lack	   of	   validated	   tools	   that	  
universally	  discriminate	  survivors	  from	  non-­‐survivors,	  it	  is	  nonetheless	  important	  to	  
define	  meaningful	  cutoff	  points.	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   Ethical	  frameworks	  can	  offer	  a	  different	  point	  of	  view:	  it	  would	  look	  simply	  at	  
the	   patient	   and	   the	   feasibility	   of	   implanting	   a	   percutaneous	   aortic	   valve.	   If	   the	  
patient	   were	   deemed	   a	   suitable	   candidate,	   he	   or	   she	   would	   be	   offered	   this	  
intervention.	  If	  the	  patient	  is	  an	  appropriate	  candidate	  for	  TAVI,	  it	  should	  be	  offered	  
to	  the	  patient	  to	  improve	  his	  or	  her	  quality	  of	  life	  and	  to	  relieve	  suffering.	  A	  majority	  
of	  clinicians	  would	  follow	  this	  principle	  of	  justice	  (139).	  	  
	  
However,	  as	  previously	  described,	  In	  terms	  of	  the	  possibility	  of	  rationing	  TAVI	  
procedures,	   the	   costs	   of	   this	   procedure	   need	   to	   be	   compared	  with	   other	   existing	  
technologies	   and	   treatments.	   Wu	   and	   colleagues	   (130)	   have	   looked	   at	   the	   cost-­‐
effective	  ratio	  (CER	  or	  monetarily	  costs	  per	  life	  year	  gained)	  of	  standard	  aortic	  valve	  
replacement	  and	  shown	  that	   for	  a	  75-­‐year-­‐old	  patient	   the	  average	  CER	   is	  €13,000.	  
This	  is	  compared	  with	  a	  CER	  of	  €38,500	  for	  TAVI	  procedures	  (132).	  These	  costs	  take	  
into	   consideration	   the	   quality	   of	   life,	   hospital	   costs,	   and	   need	   for	   extended	   care.	  
Although	   this	   difference	   is	   substantial,	   TAVI	   has	   already	  proven	   to	   be	   a	   successful	  
and	  useful	  technology	  for	  high-­‐risk	  surgical	  patients	  with	  critical	  aortic	  stenosis.	  The	  
increased	  procedural	  and	  device	  costs	  of	  TAVI	  compared	  with	  a	  surgical	  aortic	  valve	  
prosthesis	   and	   replacement	   surgery	   put	   TAVI	   procedures	   at	   risk	   for	   future	   health	  
care	  rationing	  as	  part	  of	  health	  care	  reform	  to	  minimize	  growing	  health	  care	  costs	  in	  
the	   western	   world.	   Nevertheless,	   it	   needs	   to	   be	   considered	   that	   the	   CER	   of	   TAVI	  
procedures	   is	   in	   line	   with	   other	   existing	   technologies	   (like	   hemodialysis)	   and	  
therefore	   should	   not	   be	   singled	   out	   as	   an	   ‘expensive’’	   new	   technology.	   The	  
principles	   of	   justice	   in	   health	   care	   rationing	   also	   support	   continued	   use	   of	   TAVI	  
procedures	  in	  high-­‐risk	  patients.	  
	  
The	  real	  world	  experience	  shows	  that	  uncontrolled	  diffusion	  of	  new	  medical	  
technology	  has	  been	  a	  major	  source	  of	  the	  current	  crisis	  in	  funding	  for	  medical	  care.	  
Given	  the	  growing	  elderly	  population	  in	  this	  country	  and	  the	  incidence	  of	  aortic	  valve	  
sclerosis	  in	  this	  aging	  population,	  there	  is	  a	  significant	  likelihood	  that	  use	  of	  TAVI	  for	  
all	   elderly	   patients	   with	   aortic	   valve	   disease	   could	   add	   significantly	   to	   the	   health	  
expenditures	  for	  cardiovascular	  disease.	  
	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   224	  
It	   is	   important	   to	   differenciate	   between	   efficacy	   and	   effectiveness,	   indeed.	  
The	  efficacy	  assessment	   is	   typically	  based	  on	  randomized	  clinical	   trials,	  such	  as	  the	  
PARTNER	   trial,	   in	   carefully	   defined	   clinical	   populations.	   Effectiveness	   has	   been	  
described	   as	   the	   outcome	   when	   this	   same	   device	   is	   deployed	   in	   the	   general	  
population	  by	  the	  medical	  profession.	  The	  assessments	  of	  effectiveness	  involve	  the	  
medical	   profession’s	   obligations	   to	   society	   to	   self-­‐regulate	   and	   to	   wisely	   allocate	  
what	   is	   now	   becoming	   a	   scarce	   societal	   resource.	   Mayer	   and	   others	   (140)	   have	  
argued	  that	   if	  the	  medical	  profession	  does	  not	  actively	  engage	   in	  this	  effectiveness	  
assessment,	  then	  major	  resource	  allocation	  decisions	  will	  be	  made	  by	  those	  who	  o	  
not	   take	   care	   of	   patients,	   and	   then	   the	  medical	   profession	   will	   have	   forfeited	   an	  
important	   role	   and	   responsibility	   in	   society.	   If	   physicians	   and	   surgeons	  
indiscriminately	   apply	   a	   new	   and	   expensive	   technology	   to	   any	   patient	   who	  might	  
benefit,	  even	  if	   it	  will	  minimally	  prolong	  life	  or	  marginally	  reduce	  suffering,	  can	  the	  
medical	   profession	   argue	   that	   there	   has	   been	   a	  wise	   use	   of	   society’s	   health	   care?	  	  
(141,142).	  	  	  
	  
The	  current	  direction	  in	  the	  study	  of	  TAVI	  moves	  towards	  providing	  directions	  
to	   cardiologists	   and	   surgeons	   involved	   in	   this	   therapy	   to	   identify	   subgroups	   of	  
patients	   for	  whom	  this	   therapy	  will	  provide	  superior	  or	   little	  benefit;	  or	  whether	   it	  
could	  result	   in	  significant	  harm.	  In	  our	  study	  we	  identified	  preoperative	  risk	  factors	  
that	  act	  as	  independent	  predictors	  for	  perioperative	  mortality	  by	  multivariate	  logistic	  
regression	   analysis:	   extracardiac	   arteropathy,	   left	   ventricular	   impairment	   and	  
significant	   pulmonary	   hypertension.	  We	   demonstrated	   that	   these	   factors	   not	   only	  
play	  an	  important	  role	  on	  30-­‐days	  outcome,	  but	  also	  that	  its	  relative	  impact	  for	  each	  
procedure	   group	   (TAVI	   or	   conventional	   AVR)	   is	   different.	   Hence	   our	   new	   scoring	  
system	  acts	  as	  an	  easy	  preoperative	  clinical	  decision	  making	  tool,	  by	  discriminating	  
high-­‐risk	   considered	   patients	   candidates	   for	   either	   TAVI	   or	   conventional	   AVR.	   By	  
classifying	   them	   in	   the	   ´Low	   Profile´	   or	   ´High	   Profile´	   score	   groups	   one	   can	   easy	  
decide	  towards	  TAVI	  or	  conventional	  AVR,	  as	  our	  Classification	  and	  Regression	  Trees	  
(CRT)	   show	   important	   differences	   in	   perioperative	   mortality	   between	   them	   (see	  
Results	  section	  for	  details).	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Internal	  validation	  of	  the	  new	  score	  was	  tested.	  Discrimination	  capacity	  was	  
addressed	  by	  means	  of	  ROC	  curve	  analysis	  and	  CRT	  construction.	  As	  expected,	   the	  
performance	  and	  discrimination	  of	  the	  new	  score	  was	  better	  than	  EuroSCORE	  when	  
high-­‐risk	   profile	   patients	   (EuroSCORE	   >	   15	   or	   HR-­‐AVR	   matched	   controls)	   were	  
considered,	   but	   not	   when	   the	   overall	   database	   neither	   when	   the	   low-­‐risk	   profile	  
(logistic	   EuroSCORE	   <	   15)	   group	   were	   evaulated.	   	   This	   brings	   up	   an	   important	  
consideration,	   which	   is	   that	   the	   score	   seems	   only	   applicable	   to	   high-­‐risk	   patients	  
whereas	   low-­‐risk	   patients	   would	   probably	   be	   straightforwardly	   be	   addressed	  
towards	   conventional	   AVR,	   the	   current	   gold-­‐standard.	   On	   the	   other	   hand,	   clearly	  
inoperable	   patients	   as	   described	   in	   PARTNER	   Cohort	   B	   are	  widely	   accepted	   to	   be	  
directly	  addressed	  for	  TAVI.	  In	  the	  in-­‐between	  PARTNER	  cohort	  B	  and	  low-­‐risk	  profile	  
patients	   lays	  a	  huge	   ´grey	  zone´	  of	  elderly,	  high-­‐risk	  considered,	  comorbid	  patients	  
with	  aortic	  stenosis,	  were	  our	  score	  seems	  to	  appropriately	  discriminate	  and	  hence	  it	  
should	  be	  used.	  
	  
External	   validation	   is	   a	   crucial	   issue	   that	   still	   needs	   to	   be	   addressed.	   We	  
hypothesized	  by	  modeling	  a	  random	  ´dummy´	  database	  with	  identical	  preoperative	  
and	  outcome	  characteristics	  as	   in	  PARTNER	  Cohort	  A	  trial,	  by	  random	  allocation	  of	  
variables	   for	   699	   ´dummy´	  patients	   in	   the	  database.	   Therefore	  our	  new	   score	  was	  
tested	  and	  CRT	  showed	  discrimination	  capacity	  for	  High-­‐Profile	  group,	  favoring	  TAVI	  
by	   two-­‐fold,	   but	   was	   non-­‐discriminant	   in	   the	   ‘Low-­‐Profile’	   arm	   of	   the	   tree.	   ROC	  
curves	   also	   returned	   a	   better	   performance	   of	   the	   new	   score	   when	   compared	   to	  
logistic	   EuroSCORE	   (see	   Results	   section	   for	   details).	   These	   results	   are	   based	   upon	  
statistical	  modeling,	  but	  if	  they	  are	  confirmed	  in	  further	  studies	  they	  will	  provide	  an	  
important	   step	   forward	   preoperative	   management	   of	   a	   especially	   controversial	  
group	  of	  patients,	  and	  perhaps	  help	  in	  better	  decision-­‐making	  to	  improve	  outcomes	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5.	  Conclusions	  
	  
TAVI	   represents	   a	   milestone	   in	   the	   treatment	   of	   calcific	   aortic	   stenosis	   and	  
probably	   the	  most	   important	   advance	   in	   cardiac	   surgery	   in	   the	   last	   decade.	   It	   has	  
transformed	   the	   general	   overview	   of	   valve	   disease	   and	   forced	   surgeons,	  
interventional	   and	   clinical	   cardiologists	   to	   closely	  work	   together	   for	   the	   benefit	   of	  
the	   patient.	   Up	   to	   the	   present	   date,	   no	   objective	   discrimination	   tool	   has	   been	  
described	   for	   preoperative	   decision-­‐making	   in	   high-­‐risk	   aortic	   valve	   replacement	  
surgery,	  causing	  heterogeneous	  eligibility	  and	  selection	  criteria	  among	  the	  different	  
studies	  published	  in	  medical	  literature,	  that	  are	  mainly	  based	  upon	  expert	  consensus	  
or	  commercial	  recommendations.	  
	  
This	   work	   proposes	   for	   the	   first	   time	   in	   medical	   literature	   a	   clinical	   tool	   for	  
preoperative	   decision-­‐making	   in	   high-­‐risk	   aortic	   valve	   replacement	   candidates	   for	  
TAVI	   or	   conventional	   AVR,	   based	   in	   commonly	   known	   and	   easily	   determined	  
preoperative	   variables.	   Primary	   and	   secondary	   endpoints	   (as	   described	   in	   the	  
Methods	   section)	  were	   achieved	   and	   our	  work	   hypothesis	   confirmated,	   for	  which	  
the	  following	  conclusions	  can	  be	  extracted:	  
	  
1. The	   current	   direction	   in	   the	   study	   of	   TAVI	   moves	   towards	   providing	  
guidelines	   to	   cardiologists	   and	   surgeons	   involved	   in	   this	   therapy	   to	   identify	  
subgroups	   of	   patients	   for	   whom	   this	   therapy	  will	   provide	   superior	   or	   little	  
benefit;	   or	   whether	   it	   could	   result	   in	   significant	   harm.	   In	   our	   study	   we	  
identified	   preoperative	   risk	   factors	   that	   act	   as	   independent	   predictors	   for	  
perioperative	   mortality	   by	   multivariate	   logistic	   regression	   analysis:	  
extracardiac	   arteropathy,	   left	   ventricular	   impairment	   and	   significant	  
pulmonary	  hypertension.	  We	  demonstrated	  that	  these	  factors	  not	  only	  play	  
an	  important	  role	  on	  30-­‐days	  outcome,	  but	  also	  that	  the	  relative	  impact	  for	  
each	  procedure	  group	  (TAVI	  or	  conventional	  AVR)	  is	  different.	  	  
	  
2. Extracardiac	  arteropathy,	  severe	  pulmonary	  hypertension	  and	  left	  ventricular	  
dysfunction	   were	   identified	   as	   independent	   predictors	   for	   perioperative	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mortality	   in	   the	   multivariate	   logistic	   regression	   analysis	   (B	   regression	  
coefficients	  of	  2.080,	  1.662	  and	  1.083	  respectively).	  Patients	  were	  classified	  
into	  Low	  Profile	  or	  High	  Profile	  according	  to	  the	  presence	  or	  absence	  of	  these	  
variables	   and	   a	   Classification	   and	  Regression	   Tree	  was	  built	   to	   discriminate	  
between	  TAVI	   and	  AVR	   for	   30-­‐days	  mortality	   in	   each	   group.	   TAVI	  mortality	  
was	  significantly	  lower	  than	  AVR	  in	  the	  High	  Profile	  group	  (11.1%	  vs.	  33.3%)	  
whereas	  it	  was	  higher	  in	  the	  Low	  Profile	  group	  (6.8%	  vs.	  0%),	  evidencing	  the	  
discrimination	   capacity	   of	   the	   model.	   Returned	   receptor-­‐operator	  
characteristics	  area	  under	  the	  curve	  was	  0.835	  (0.638-­‐1.000).	  Hence	  our	  new	  
scoring	   system	   acts	   as	   an	   easy	   preoperative	   clinical	   decision	   making	   tool,	  
discriminating	   high-­‐risk	   considered	   patients	   candidates	   for	   either	   TAVI	   or	  
conventional	  AVR.	  By	  means	  of	  classifying	  them	  in	  the	  ´Low	  Profile´	  or	  ´High	  
Profile´	  score	  groups	  one	  can	  easy	  decide	  towards	  TAVI	  or	  conventional	  AVR.	  
	  
3. Internal	   validation	  of	   the	  new	  score	  was	   tested	   in	   the	  overall	   468	  patients’	  
series	   and	   in	   the	   logistic	   EuroSCORE	   <15	   and	   >	   15	   subgroups.	   Acceptable	  
discrimination	   was	   achieved	   in	   the	   high-­‐risk	   subgroup	   (logistic	  
EuroSCORE>15)	   exclusively,	   whereas	   in	   the	   low-­‐risk	   subgroup	   (logistic	  
EuroSCORE	  <	  15)	  or	   in	   the	  overall	   series	   it	   resulted	   to	  be	  non-­‐discriminant.	  
Consequently	   its	   application	   seems	   to	   be	   limited	   to	   the	   operable	   high-­‐risk	  
profile	  group	  of	  patients	  that	  could	  be	  suitable	  for	  both	  techniques	  (TAVI	  or	  
conventional	  AVR)	  where	  decision-­‐making	  is	  still	  controversial.	  	  
	  
4. External	   validation	   of	   the	   new	   score	   needs	   to	   be	   properly	   addressed.	   We	  
statistically	   modelized	   a	   random	   ‘dummy’	   database	   with	   similar	  
characteristics	  in	  terms	  of	  preoperative	  risk,	  comorbidities	  and	  perioperative	  
mortality	  than	  in	  the	  PARTNER	  Cohort	  A	  series,	  and	  tested	  the	  new	  score	  in	  
it,	  with	  acceptable	  discrimination	  capacity.	  However,	  it	  needs	  to	  be	  tested	  in	  
larger	   and	  different	   series	   in	   the	   real	  world	   yet.	  Weighting	  of	   the	   variables	  
included	  might	   change	   as	   well	   as	   different	   new	   variables	  might	   come	   into	  
scene	  with	  its	  application.	  It	  should	  be	  a	  dynamic	  tool	  that	  would	  need	  to	  be	  
periodically	  reviewed	  and	  updated.	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5. According	   to	   our	   results,	   TAVI	   seems	   non-­‐inferior	   to	   conventional	   AVR	   for	  
operable	   high-­‐risk	   patients,	   although	   stroke	   and	   postoperative	   pacemaker	  
rates	   (specially	   for	   TF	   approach)	   and	   learning	   curve	   effect	   (specially	   for	   TA	  
approach)	  are	  still	  crucial	  issues	  for	  this	  novel	  procedure.	  
	  
6. No	   differences	   in	   terms	   of	   preoperative	   risk	   variables	   or	   comorbidities	   nor	  
perioperative	  mortality	   and	   long-­‐term	   survival	   between	   TAVI	   and	  matched	  
HR-­‐AVR	  groups	  were	   found.	  MACCE	  was	   significantly	  higher	   in	   TAVI	   (17.0%	  
vs.	  4.5%,	  p<0.05)	   than	   in	  matched	  HR-­‐AVR	  as	  well	   as	  pacemaker	   rhythm	  at	  
patients’	   discharge	   (20.8%	   vs.	   0%,	   p<0.001).	   Relevant	   intensive	   care	   unit	  
length-­‐of-­‐stay	   differences	   in	   TAVI	   (2.03+/-­‐2.58	   days)	   vs.	   matched	   HR-­‐AVR	  
(3.33+/-­‐1.80	   days)	   were	   appreciable,	   although	   these	   disappeared	   when	   a	  
subgroup	   analysis	   using	   a	   logistic	   EuroSCORE	   cutoff	   value	   of	   15%	   was	  
performed.	  	  	  
	  
7. In	   the	   same	   direction,	  we	   found	   that	   additive	   EuroSCORE	   seems	   to	   have	   a	  
better	  correlation	  with	  perioperative	  mortality	  in	  the	  high-­‐risk	  series	  whereas	  
logistic	  EuroSCORE	  has	  similarities	  with	  MACCE.	  However,	   this	  hypothesis	   is	  
out	   of	   the	   purpose	   of	   the	   present	   study	   and	   it	   should	   be	   addressed	  
separately.	  	  
	  
8. Extracardiac	   arteropathy	   (OR	   8.083,	   95%	  CI	   1.652-­‐39.545)	  was	   found	   to	   be	  
the	   only	   predictor	   of	   30-­‐days	   mortality	   after	   univariate	   logistic	   regression	  
analysis	   in	   the	   TAVI	   vs.	   matched	   HR-­‐AVR	   high-­‐risk	   series.	   Interestingly,	  
different	   variables	   resulted	   significant	   predictors	   for	   MACCE	   composite	  
event:	   TAVI	   approach	   (OR	   4.364,	   95%	   CI	   1.118-­‐17.033),	   especially	   TA	  
approach	   (OR	   6.333,	   95%	   CI	   1.103-­‐36.370),	   age	   (OR	   1.240,	   95%	   CI	   1.052-­‐
1.460)	  and	  preoperative	  AF	  (OR	  4.686,	  95%	  CI	  1.303-­‐33.683).	  
	  
9. Multivariate	  Cox	  regression	  analysis	  was	  performed	  in	  order	  to	  ascertain	  the	  
impact	   of	   the	   different	   approaches	   (MS,	   TF	   or	   TA)	   and	   the	   year	   in	   which	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surgery	  was	  performed	  in	   long-­‐term	  survival.	  No	  statistical	  differences	  were	  
found	  among	  those	  variables,	  although	  negative	  B	  regression	  coefficients	   in	  
the	  year	  timeline	  advocate	  a	  ‘protective’	  effect	  and	  evidence	  a	  certain	  degree	  
of	   learning	   curve	  effect	   in	  mortality.	   To	   sum	  up,	  non-­‐significant	  odds	   ratios	  
for	  the	  different	  approaches	  suggest	  that	  the	  worse	  performance	  of	  TA	  when	  
compared	  to	  TF	  or	  MS	  is	  not	  attributable	  to	  the	  technique	  itself.	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6.	  Limitations	  of	  the	  study	  
	  
	  
This	  study	  is	  based	  on	  non-­‐randomized	  retrospective	  data	  from	  a	  single	   institution.	  
Although	   it	   addresses	   important	   issues	   for	   the	   first	   time	   (like	   objective	   clinical	  
preoperative	   decision-­‐making),	   it	   is	   provides	   limited	   number	   of	   observations	   and	  
their	  results	  might	  non	  be	  applicable	  to	  different	  populations	  than	  the	  one	  intended.	  	  
	  
In	  the	  same	  direction,	  external	  validation	  of	  the	  results	  provided	  by	  the	  new	  
scoring	  system,	  although	  it	  has	  been	  satistically	  modellized,	  it	  has	  not	  been	  tested	  in	  
the	   real	   world	   yet.	   Furthermore,	   applying	   the	   score	   to	   larger	   and	   different	  
populations	  may	   result	   in	   changes	   in	   the	   current	   score	   variables	   and	   proportions.	  
Like	  in	  the	  Heisenberg’s	  uncertainty	  principle	  for	  quantum	  physics,	  application	  of	  the	  
score	  can	  result	  in	  group	  reclassification	  and	  therefore	  different	  risk	  variables	  might	  
appear	  and	  be	  added	  or	  modified	   to	   the	   score.	   Subsequently	   it	   certainly	  will	  need	  
frequent	  review	  and	  update.	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Annex	  
	  
Annex	  1.	  Variable	  definitions	  
	  	   
VARIABLES	   DEFINITION	  
	   	  
PREOPERATIVE	   	  
Age	  (y)	   Age	  in	  years	  
Gender	  (%male)	   Gender	  (male/female)	  
EuroSCORE	   Additive	  score	  for	  EuroSCORE	  scale	  
logEuroSCORE	   Logistic	  score	  for	  EuroSCORE	  scale	  
Chronic	  Pulmonary	  Disease	   Long	  term	  use	  of	  bronchodilators	  or	  steroids	  for	  lung	  disease	  
Extracardiac	  Arteropathy	   Any	  of	  or	  more	  of	  the	  following:	  claudication,	  carotid	  
occlusion	  or	  >50%	  stenosis,	  previous	  or	  planned	  intervention	  
on	  the	  abdominal	  aorta,	  limb	  arteries	  or	  carotids.	  
Neurological	  dysfunction	   Neurologic	  dysfunction	  severely	  affecting	  ambulation	  or	  day-­‐
to-­‐day	  functioning	  
Previous	  Cardiac	  Surgery	   Cardiac	  surgery	  in	  the	  past	  requiring	  opening	  of	  the	  
pericardium	  
Preoperative	  Renal	  Failure	   Preoperative	  creatinine	  level	  >2.2	  mg/dL	  
Active	  Endocarditis	   Patient	  still	  under	  antibiotic	  treatment	  for	  endocarditis	  at	  the	  
time	  of	  surgery	  
Preoperative	  Critical	  Status	   Any	  one	  or	  more	  of	  the	  following:	  ventricular	  tachycardia	  or	  
fibrillation	  or	  aborted	  sudden	  death,	  preoperative	  cardiac	  
massage,	  preoperative	  ventilation	  before	  arrival	  in	  the	  
anaesthetic	  room,	  preoperative	  inotropic	  support,	  intraaortic	  
balloon	  counterpulsation,	  or	  preoperative	  acute	  renal	  failure	  
(anuria	  or	  oliguria	  <10	  mL/h)	  
Unstable	  angor	   Rest	  angina	  requiring	  nitrates	  until	  arrival	  in	  the	  anaesthetic	  
room	  
EF	  30/50	  %	   Moderate	  left	  ventricle	  dysfunction	  (30-­‐50%)	  as	  measured	  by	  
echocardiography	  
EF	  <	  30%	   Severe	  left	  ventricle	  dysfunction	  (<30%)	  as	  measured	  by	  
echocardiography	  
Recent	  MI	   Myocardial	  infarction	  within	  90	  days	  of	  surgery	  
Pulmonary	  Hypertension	   Systolic	  pulmonary	  artery	  pressure	  >60	  mmHg	  
Emergency	   Suregery	  carried	  out	  on	  referral	  before	  the	  beggining	  of	  the	  
next	  working	  day	  
Other	  than	  CABG	   Major	  cardiac	  procedure	  other	  than	  or	  in	  addition	  to	  coronary	  
artery	  bypass	  graft	  surgery	  
Surgery	  on	  Thoracic	  Aorta	   Surgery	  for	  disorder	  of	  the	  ascending,	  arch	  or	  descending	  
aorta.	  	  
Post	  MI	  VSD	   Post	  infarction	  ventricular	  septal	  defect.	  
Mitral	  Reguritation	   Moderate	  or	  severe	  mitral	  valve	  regurgitation	  (grades	  III	  or	  IV)	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as	  measured	  by	  echocardiography	  
NYHA	  III/IV	   New	  York	  Heart	  Association	  functional	  class	  grades	  III	  or	  IV	  
CHF	   Clinical	  or	  radiologic	  signs	  of	  left	  heart	  failure	  (ortopnea,	  
pulmonary	  edema,	  etc)	  
Calcified	  Aorta	   Severe	  calcification	  of	  the	  ascending,	  arch	  or	  descending	  aorta	  
identified	  by	  preoperative	  image	  studies.	  
Diabetes	   Diabetes	  mellitus	  under	  pharmacologic	  or	  insulin	  control	  
	   	  
RHYTHM	  (PREOP)	   Preoperative	  cardiac	  rhythm	  on	  electrocardiography	  
sinus	  rhythm	   sinus	  rhythm	  
AF	  rhythm	   atrial	  fibrillation	  
PCM	  rhythm	   pacemaker	  rhythm	  
	   	  
CORONARY	  DISEASE	   Presence	  of	  ischemic	  coronary	  disease	  identified	  by	  
haemodinamic	  studies	  
PTCA	   Previous	  preoperative	  precutaneous	  transluminal	  coronary	  
angioplasty	  
CABG	   One	  or	  more	  coronary	  artery	  bypass	  grafts	  in	  addition	  to	  
aortic	  valve	  replacement	  
No	  vessels	   Number	  of	  diseased	  coronary	  vessels	  
No	  grafts	   Number	  of	  coronary	  artery	  bypass	  grafts	  performed	  
	   	  
ANATOMICAL	  &	  
MORPHOMETRIC	   	  
Weight	  (kg)	   Wheight	  in	  kilograms	  
Height	  (cm)	   Height	  in	  centimeters	  
BSA	   Body	  Surface	  Area	  in	  m2	  
BMI	   Body	  Mass	  Index	  in	  kg/m2	  
Valve	  area	   Aortic	  valve	  area	  by	  planimetry	  on	  ultrasound	  studies	  (cm2)	  
Mean	  grad	   Mean	  transaortic	  valve	  gradient	  on	  ultrasound	  studies	  
(mmHg)	  
Peak	  grad	   Peak	  transaortic	  valve	  gradient	  on	  ultrasound	  studies	  (mmHg)	  





VALVE	  OUTCOMES	   	  
Succes	  implant	  rate	   Rate	  of	  successful	  aortic	  valve	  implant	  
Valve	  implant	  size	  (mm)	   Prosthetic	  implant	  diameter	  in	  mm	  
Biological	  valve	  (%)	   Biological	  protsthetic	  implant	  
	   	  
PRIMARY	  OUTCOMES	   	  
30-­‐d	  mortality	  (%)	   Perioperative	  mortality	  at	  30	  days	  after	  surgery	  
MACCE	   Major	  Adverse	  Cardio	  or	  Cerebrovascular	  Event.	  Composite	  
event	  of	  perioperative	  mortality	  (30-­‐days	  mortality	  )	  or	  major	  
Replacement	  Or	  trans-­‐Catheter	  Implant	  Odds	   	   A.	  Vázquez	  
	   247	  
cardio	  or	  neurological	  complications	  
Mortality	  (cause)	   Causes	  of	  perioperative	  mortality	  
cardiac	   Cardiac-­‐related	  death	  (myocardial	  infarction,	  malignant	  
arrhythmia,	  sudden	  death,	  etc)	  
neurological	   Neurological-­‐related	  death	  (stroke,	  coma,	  vegetative	  status,	  
etc)	  
infective	   Death	  related	  to	  a	  non-­‐cardiac	  infective	  process	  (septic	  shock,	  
etc)	  
endocarditis	   Death	  related	  to	  an	  early	  prosthetic	  valve	  endocarditis	  
respiratory	   Respiratory-­‐related	  death	  (distress,	  pneumonia,	  etc)	  
renal	   Death	  related	  to	  a	  postoperative	  renal	  failure	  
multiorganic	   Death	  related	  to	  a	  multiorganic	  failure	  
unknown	   Unknown	  cause	  of	  death	  
Perioperative	  morbidity	  
(all)	   Major	  postoperative	  complications	  
Reintervention	   Major	  bleeding	  or	  pericardial	  tamponade	  that	  requires	  
reintervention	  in	  the	  early	  postoperative	  period	  
Cardiovascular	   Major	  cardiovascular	  complication	  excluding	  rhythm	  
complication	  (myocardial	  infarction,	  aortic	  or	  vascular	  injury,	  
etc)	  
Respiratory	   Major	  respiratory	  complication	  (respiratory	  insufficiency,	  
distress,	  pneumonia,	  etc)	  
Wound	   Major	  wound	  complication	  (wound	  infection,	  sternal	  
dehiscence,	  mediastinitis,	  etc)	  
Renal	   Major	  renal	  complication	  (acute	  postoperative	  renal	  failure,	  
need	  for	  postoperative	  haemofiltration	  or	  dyalisis,	  etc)	  
Neurological	   Major	  neurological	  complication	  (postoperative	  stroke,	  coma,	  
transient	  ischemic	  attack,	  etc)	  
Infective	   Major	  infective	  complication	  (septic	  shock,	  etc)	  
Other	   Other	  major	  complications	  (implant-­‐related,	  etc)	  
	   	  
LENGTH	  OF	  STAY	   	  
ICU	  LOS	  (days)	   Intensive	  Care	  Unit	  length	  of	  stay	  in	  days	  
Hospital	  LOS	  (days)	   Hospital	  length	  of	  stay	  in	  days	  
	   	  
RHYTHM	  (DISCHARGE)	   Postoperative	  rhythm	  in	  the	  last	  ECG	  prior	  to	  discharge	  
sinus	  rhythm	   sinus	  rhythm	  
AF	  rhythm	   atrial	  fibrillation	  
PCM	  rhythm	   pacemaker	  rhythm	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Annex	  2.	  List	  of	  abbreviations	  
	  
 
AF	   Atrial	  Fibrillation	  
AR	   aortic	  regurgitation	  
AS	   aortic	  stenosis	  
AUC	   Area	  under	  the	  curve	  
AVA	   aortic	  valve	  area	  
AVR	   Aortic	  Valve	  Replacement	  
BMI	   Body	  Mass	  Index	  (kg/m2)	  
BSA	   Body	  Surface	  Area	  (m2)	  
CABG	   Coronary	  Artery	  Bypass	  Graft	  
CAD	   coronary	  artery	  disease	  
CHF	   congestive	  heart	  failure	  
CRT	   Classification	  and	  Regression	  Tree	  
ECG	   Electrocardiography	  
EF	   ejection	  fraction	  (left	  ventricle)	  
LV	   left	  ventricle	  
LVH	   left	  ventricular	  hypertrophy	  
LVOT	   left	  ventricular	  outflow	  tract	  
MACC
E	  
combined	  event	  of	  perioperative	  death	  or	  Major	  Adverse	  Cardio	  or	  
Cerebrovascular	  Events	  
MR	   mitral	  regurgitation	  
MS	   median	  sternotomy	  approach	  
n/a	   non	  applicable	  
ns	   non	  significant	  
PCM	   pacemaker	  
PH	   pulmonary	  hypertension	  
PTCA	   Percutaneous	  Transluminal	  Coronary	  Angioplasty	  
REDO	   Previous	  Cardiac	  Surgery	  
ROC	  	   Receptor-­‐operator	  characteristics	  
RV	   right	  ventricle	  
TA	   transapical	  approach	  
TAVI	   transcatheter	  aortic	  valve	  implant	  
TEE	   transesophageal	  echocardiography	  
TF	   transfemoral	  approach	  
THV	   trancatheter	  heart	  valve	  
TR	   tricuspid	  regurgitation	  
US	   ultrasound	  (echocardiographic)	  
VSD	   ventricular	  septal	  defect	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